"Brand Name","Generic Name","Therapeutic Area","Recommendation Type","Project Status","Date Submission Received","Date Recommendation Issued","Project Number",Manufacturer
Abraxane,Nab-paclitaxel,"Metastatic Pancreatic Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 14, 2014","Sep 23, 2014",PC0037-000,"Celgene Inc."
Adcetris,"Brentuximab Vedotin","Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 30, 2020","Dec 3, 2020",PC0213-000,"Seattle Genetics, Inc."
Adcetris,"Brentuximab vedotin","Systemic Anaplastic Large Cell Lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Mar 15, 2013","Dec 5, 2013",PC0021-000,"Seattle Genetics, Inc."
Adcetris,"Brentuximab vedotin",,,Withdrawn,"Apr 5, 2016",,PC0086-000,"Seattle Genetics Inc."
Adcetris,"Brentuximab Vedotin","peripheral T-cell lymphoma (PTCL)",Reimburse,Complete,"Oct 8, 2019","Jun 4, 2020",PC0199-000,"Seattle Genetics, Inc."
Adcetris,"Brentuximab vedotin","Hodgkin Lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Mar 14, 2013","Aug 29, 2013",PC0020-000,"Seattle Genetics, Inc."
Adcetris,"Brentuximab Vedotin","HL at high risk of relapse or progression post-ASCT","Reimburse with clinical criteria and/or conditions",Complete,"Aug 10, 2017","Feb 21, 2018",PC0116-000,"Seattle Genetics, Inc."
Adcetris,"Brentuximab Vedotin","Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 2, 2020","Dec 3, 2020",PC0214-000,"Seattle Genetics, Inc."
"Adcetris (Resubmission)","Brentuximab Vedotin","Hodgkin lymphoma (HL)","Do not reimburse",Complete,"Aug 27, 2018","Mar 7, 2019",PC0145-000,"Seattle Genetics, Inc."
Afinitor,Everolimus,"Advanced Breast Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Sep 5, 2012","Mar 25, 2013",PC0014-000,"Novartis Pharmaceuticals Canada Inc."
Afinitor,Everolimus,"Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin","Reimburse with clinical criteria and/or conditions",Complete,"May 30, 2016","Dec 1, 2016",PC0083-000,"Novartis Pharmaceuticals Canada Inc."
Afinitor,Everolimus,"Pancreatic Neuroendocrine Tumour","Reimburse with clinical criteria and/or conditions",Complete,"Feb 27, 2012","Aug 30, 2012",PC0007-000,"Novartis Pharmaceuticals Canada Inc."
Alecensaro,Alectinib,"Locally advanced or metastatic ALK+ NSCLC (first line)","Reimburse with clinical criteria and/or conditions",Complete,"Jan 15, 2018","Jul 25, 2018",PC0125-000,"Hoffmann-La Roche Limited"
Alecensaro,Alectinib,"Non-Small Cell Lung Cancer","Do not reimburse",Complete,"Oct 3, 2016","May 4, 2017",PC0092-000,"Hoffmann-La Roche Limited"
Alecensaro,Alectinib,"Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Aug 18, 2017","Mar 29, 2018",PC0114-000,"Hoffmann-La Roche Limited"
Alimta,Pemetrexed,"Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"May 31, 2013","Nov 19, 2013",PC0027-000,"Eli Lilly Canada"
Alunbrig,Brigatinib,NSCLC,"Do not reimburse",Complete,"Dec 5, 2018","Aug 1, 2019",PC0167-000,"Takeda Canada Inc."
Alunbrig,Brigatinib,"(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 30, 2020","Apr 21, 2021",PC0230-000,"Takeda Canada Inc."
Arzerra,Ofatumumab,"Chronic Lymphocytic Leukemia","Do not reimburse",Complete,"Apr 14, 2014","Jan 29, 2015",PC0038-000,"GlaxoSmithKline Inc."
Atriance,Nelarabine,,,Cancelled,,,PC0170-000,"Novartis Pharmaceuticals Canada Inc."
Avastin,Bevacizumab,"Cervical Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 27, 2014","Mar 23, 2015",PC0045-000,"Hoffmann-La Roche Limited"
Avastin,Bevacizumab,"Ovarian Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Nov 28, 2014","Jun 4, 2015",PC0047-000,"Hoffmann-La Roche Limited"
Avastin,Bevacizumab,,,Withdrawn,"Dec 16, 2016",,PC0100-000,"Hoffmann-La Roche Limited"
Avastin,Bevacizumab,"Platinum Resistant Ovarian Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 29, 2015","May 5, 2016",PC0066-000,"Hoffmann-La -Roche Limited"
"Avastin (with capecitabine)",Bevacizumab,"Metastatic Colorectal Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 18, 2015","Jul 21, 2015",PC0055-000,"Hoffmann-La Roche Limited"
Bavencio,Avelumab,"metastatic Merkel Cell Carcinoma (mMCC)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 10, 2017","Mar 21, 2018",PC0124-000,"EMD Serono - Pfizer Alliance"
Bavencio,Avelumab,"Urothelial Carcinoma (UC)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 18, 2020","Mar 23, 2021",PC0225-000,"EMD Serono - Pfizer Alliance"
Beleodaq,Belinostat,,,Withdrawn,"Jun 29, 2018",,PC0139-000,"Servier Canada Inc."
Besponsa,"Inotuzumab Ozogamicin","Acute Lymphoblastic Leukemia (ALL)","Reimburse with clinical criteria and/or conditions",Complete,"Nov 13, 2017","Jul 6, 2018",PC0121-000,"Pfizer Canada Inc."
Blincyto,Blinatumomab,"Acute Lymphoblastic Leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Aug 24, 2015","Apr 1, 2016",PC0064-000,"Amgen Canada Inc."
Blincyto,Blinatumomab,,,Withdrawn,"Jun 29, 2018",,PC0143-000,"Amgen Canada Inc."
Blincyto,Blinatumomab,"MRD+ ALL Resubmission","Reimburse with clinical criteria and/or conditions",Complete,"Jan 20, 2020","Oct 29, 2020",PC0204-000,"Amgen Canada Inc"
Blincyto,Blinatumomab,"Acute Lymphoblastic Leukemia (pediatric)","Reimburse with clinical criteria and/or conditions",Complete,"Feb 24, 2017","Aug 23, 2017","PC0099 -000","Amgen Canada Inc."
Blincyto,Blinatumomab,"Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)","Reimburse with clinical criteria and/or conditions",Complete,"Aug 31, 2018","Apr 4, 2019",PC0146-000,"Amgen Canada Inc."
"Blincyto (Resubmission)",Blinatumomab,"Acute Lymphoblastic Leukemia (ALL)","Reimburse with clinical criteria and/or conditions",Complete,"Feb 24, 2017","Aug 31, 2017",PC0097-000,"Amgen Canada Inc."
Bosulif,Bosutinib,"Chronic Myeloid Leukemia","Reimburse with clinical criteria and/or conditions",Complete,"May 30, 2014","Apr 21, 2015",PC0039-000,"Pfizer Canada Inc."
"Bosulif (RFA)",Bosutinib,"Chronic Myeloid Leukemia",N/A,Complete,"Apr 8, 2019",,PA0002-000,"Pfizer Canada Inc."
Cabometyx,Cabozantinib,HCC,"Reimburse with clinical criteria and/or conditions",Complete,"Oct 16, 2019","Apr 22, 2020",PC0186-000,"Ipsen Biopharmaceuticals Canada Inc."
Cabometyx,Cabozantinib,"Renal Cell Carcinoma (RCC)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 17, 2018","Feb 20, 2019",PC0163-000,"Ipsen Biopharmaceuticals Canada Inc."
Calquence,Acalabrutinib,"Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 7, 2020","Jan 8, 2021",PC0210-000,"AstraZeneca Canada Inc."
Caprelsa,Vandetanib,"Medullary Thyroid Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Aug 15, 2016","Mar 30, 2017",PC0090-000,"Sanofi Genzyme"
Cotellic,Cobimetinib,"Metastatic melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 11, 2015","Jun 30, 2016",PC0070-000,"Hoffmann-la Roche Ltd."
Cyramza,Ramucirumab,"Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Apr 15, 2015","Oct 29, 2015",PC0059-000,"Eli Lilly Canada Inc."
Cyramza,Ramucirumab,,,Cancelled,,,PC0078-000,"Eli Lilly Canada Inc."
Darzalex,Daratumumab,"BMP for Multiple Myeloma (newly diagnosed)","Reimburse with clinical criteria and/or conditions",Complete,"Jan 4, 2019","Aug 29, 2019",PC0148-000,"Janssen Inc."
Darzalex,Daratumumab,"Multiple Myeloma (second-line)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 3, 2017","Oct 5, 2017",PC0104-000,"Janssen Inc."
Darzalex,Daratumumab,"Multiple Myeloma","Do not reimburse",Complete,"Apr 21, 2016","Dec 1, 2016",PC0079-000,"Janssen Canada Inc."
Darzalex,Daratumumab,"Rd for MM","Reimburse with clinical criteria and/or conditions",Complete,"Jul 17, 2019","Mar 5, 2020",PC0189-000,"Janssen Inc."
Daurismo,Glasdegib,"Acute Myeloid Leukemia (AML)","Do not reimburse",Complete,"May 6, 2020","Jan 8, 2021",PC0207-000,"Pfizer Canada ULC"
Erbitux,Cetuximab,"Metastatic Colorectal Cancer","Do not reimburse",Complete,"Jun 10, 2013","Jan 10, 2014",PC0031-000,"Bristol-Myers Squibb Canada"
Erbitux,Cetuximab,,,Cancelled,,,PC0128-000,"Eli Lilly Canada Inc."
Erivedge,Vismodegib,"Basal Cell Carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Jun 14, 2013","Jan 10, 2014",PC0015-000,"Hoffmann-La Roche Limited"
Erleada,Apalutamide,"non-metastatic castrate resistant prostate cancer (nm-CRPC)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 16, 2018","Nov 1, 2018",PC0133-000,"Janssen Inc."
Erleada,Apalutamide,"metastatic castration-sensitive prostate cancer (mCSPC)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 15, 2019","Apr 22, 2020",PC0200-000,"Janssen Inc."
Faslodex,Fulvestrant,"Locally advanced or metastatic breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jul 17, 2017","Feb 1, 2018",PC0110-000,"AstraZeneca Canada Inc."
Folotyn,Pralatrexate,"Peripheral T-Cell Lymphoma (PTCL)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 1, 2018","Apr 4, 2019",PC0138-000,"Servier Canada Inc."
Gazyva,Obinutuzumab,"Follicular Lymphoma (previously untreated)","Do not reimburse",Complete,"Mar 15, 2018","Nov 1, 2018",PC0126-000,"Hoffmann-La Roche Limited"
Gazyva,Obinutuzumab,"Follicular Lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Nov 4, 2016","Jun 2, 2017",PC0091-000,"Hoffmann-La Roche Limited"
Gazyva,Obinutuzumab,"Chronic Lymphocytic Leukemia",Reimburse,Complete,"Aug 11, 2014","Jan 27, 2015",PC0041-000,"Hoffmann-La Roche Limited"
Giotrif,Afatinib,"Advanced or Metastatic Non-Small Cell Lung Cancer",Reimburse,Complete,"Jun 7, 2013","May 2, 2014",PC0032-000,"Boehringer Ingelheim Canada Ltd."
Halaven,"Eribulin Mesylate","Metastatic Breast Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 9, 2012","Aug 2, 2012",PC0005-000,"Eisai Ltd."
Ibrance,Palbociclib,,,Withdrawn,"Nov 11, 2015",,PC0068-000,"Pfizer Canada Inc."
"Ibrance (with Faslodex)","Palbociclib (with Fulvestrant)","Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Sep 28, 2018","May 3, 2019",PC0150-000,"Pfizer Canada Inc."
"Ibrance Resubmission",Palbociclib,"Advanced breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jun 10, 2016","Nov 21, 2016",PC0093-000,"Pfizer Canada Inc."
Iclusig,Ponatinib,"Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Mar 13, 2015","Oct 1, 2015","PC0056 -000","ARIAD Pharmaceuticals, Inc."
Idhifa,Enasidenib,"Acute myeloid leukemia (AML)","Do not reimburse",Complete,"Apr 5, 2019","Oct 31, 2019",PC0144-000,"Celgene Inc."
Imbruvica,Ibrutinib,"Mantle Cell Lymphoma (relapsed/refractory)","Reimburse with clinical criteria and/or conditions",Complete,"Jan 29, 2016","Jul 19, 2016",PC0073-000,"Janssen Inc."
Imbruvica,Ibrutinib,"Chronic Lymphocytic Leukemia (previously untreated)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 20, 2016","Nov 3, 2016",PC0085-000,"Janssen Canada Inc."
Imbruvica,Ibrutinib,"Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 15, 2014","Mar 5, 2015",PC0043-000,"Janssen Inc."
Imbruvica,Ibrutinib,"Waldenstrom's Macroglobulinemia","Do not reimburse",Complete,"Apr 21, 2016","Nov 3, 2016",PC0082-000,"Janssen Canada Inc."
Imfinzi,Durvalumab,"Unresectable Non-Small Cell Lung Cancer (NSCLC)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 21, 2018","May 3, 2019",PC0131-000,"AstraZeneca Canada"
Inlyta,Axitinib,"Metastatic Renal Cell Carcinoma",Reimburse,Complete,"Aug 16, 2012","Mar 7, 2013",PC0013-000,"Pfizer Canada Inc."
"Inlyta (RFA)",Axitinib,"Metastatic Renal Cell Carcinoma",N/A,Complete,"Apr 18, 2017",,PA0001-000,"Pfizer Canada Inc."
Inqovi,Decitabine-Cedazuridine,"Myelodysplastic Syndromes (MDS)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 9, 2020","Sep 22, 2021",PC0228-000,"Taiho Pharma Canada, Inc."
Istodax,Romidepsin,"Peripheral T-Cell Lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 1, 2014","May 19, 2015",PC0048-000,"Celgene Inc."
Jakavi,Ruxolitinib,Myelofibrosis,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 25, 2012","Jan 14, 2013",PC0012-000,"Novartis Pharmaceuticals Canada Inc."
Jakavi,Ruxolitinib,"Polycythemia vera","Reimburse with clinical criteria and/or conditions",Complete,"Aug 27, 2015","Mar 3, 2016",PC0065-000,"Novartis Pharmaceuticals Canada Inc."
Kadcyla,"Trastuzumab Emtansine","Early Breast Cancer (EBC)",Reimburse,Complete,"Jul 2, 2019","Jan 22, 2020",PC0182-000,"Hoffmann-La Roche Limited"
Kadcyla,"Trastuzumab emtansine","Advanced or Metastatic Breast Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 15, 2013","Jan 10, 2014",PC0024-000,"Hoffman-La Roche Ltd."
Keytruda,Pembrolizumab,"classical Hodgkin Lymphoma (cHL)","Reimburse with clinical criteria and/or conditions",Complete,"Jul 7, 2017","Jan 5, 2018",PC0109-000,"Merck Canada Inc."
Keytruda,Pembrolizumab,"Non-Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Apr 21, 2016","Nov 3, 2016",PC0077-000,"Merck Canada Inc."
Keytruda,Pembrolizumab,"Squamous NSCLC","Reimburse with clinical criteria and/or conditions",Complete,"Feb 8, 2019","Jan 3, 2020",PC0176-000,"Merck Canada"
Keytruda,Pembrolizumab,"Advanced non-small cell lung carcinoma (first line)","Reimburse with clinical criteria and/or conditions",Complete,"Dec 12, 2016","Aug 23, 2017",PC0101-000,"Merck Canada Inc."
Keytruda,Pembrolizumab,"head and neck squamous cell carcinoma (HNSCC)","Reimburse with clinical criteria and/or conditions",Complete,"May 1, 2020","Dec 22, 2020",PC0216-000,"Merck Canada"
Keytruda,Pembrolizumab,"Nonsquamous NSCLC","Reimburse with clinical criteria and/or conditions",Complete,"Sep 14, 2018","May 31, 2019",PC0153-000,"Merck Canada"
Keytruda,Pembrolizumab,"MUC First line","Do not reimburse",Complete,"Feb 20, 2019","Oct 3, 2019",PC0177-000,"Merck Canada"
Keytruda,Pembrolizumab,"Melanoma Adjuvant Treatment","Reimburse with clinical criteria and/or conditions",Complete,"Dec 13, 2018","Aug 1, 2019",PC0168-000,"Merck Canada"
Keytruda,Pembrolizumab,"Metastatic Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Apr 16, 2015","Nov 16, 2015",PC0058-000,"Merck Canada Inc."
Keytruda,Pembrolizumab,"For locally advanced or metastatic urothelial carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Jul 24, 2017","Mar 2, 2018",PC0117-000,"Merck Canada Inc."
Keytruda,Pembrolizumab,"Renal Cell Carcinoma (RCC)","Reimburse with clinical criteria and/or conditions",Complete,"Aug 2, 2019","Apr 2, 2020",PC0185-000,"Merck Canada"
Kisqali,Ribociclib,"Advanced or Metastatic Breast Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 17, 2017","Apr 18, 2018",PC0112-000,"Novartis Pharmaceuticals Canada Inc."
Kisqali,Ribociclib,"HR+, HER2- advanced or metastatic breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Aug 26, 2019","Jun 4, 2020",PC0194-000,"Novartis Pharmaceuticals Canada Inc."
Kisqali,"Ribociclib with Fulvestrant","+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Aug 26, 2019","Apr 22, 2020",PC0195-000,"Novartis Pharmaceuticals Canada Inc."
Kyprolis,Carfilzomib,"Multiple Myeloma (relapsed)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 9, 2016","Mar 30, 2017",PC0084-000,"Amgen Canada Inc."
"Kyprolis (with lenalidomide)","Carfilzomib (with lenalidomide)","Multiple Myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 11, 2015","Jun 21, 2016",PC0067-000,"Amgen Canada Inc."
Lartruvo,Olaratumab,"Advanced Soft Tissue Sarcoma","Reimburse with clinical criteria and/or conditions",Complete,"Oct 26, 2017","Apr 18, 2018",PC0111-000,"Eli Lilly Canada Inc."
Lenvima,Lenvatinib,"Differentiated Thyroid Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Apr 18, 2016","Sep 20, 2016",PC0080-000,"Eisai Limited"
Lenvima,Lenvatinib,"Hepatocellular Carcinoma (HCC)","Reimburse with clinical criteria and/or conditions",Complete,"Feb 8, 2019","Jul 24, 2019",PC0175-000,"Eisai Limited"
Lenvima,Lenvatinib,"Renal Cell Carcinoma (RCC)","Do not reimburse",Complete,"Jun 8, 2018","Jan 4, 2019","PC0140 -000","Eisai Limited"
Libtayo,Cemiplimab,"Advanced Cutaneous Squamous Cell Carcinoma (CSCC)","Reimburse with clinical criteria and/or conditions",Complete,"Jul 9, 2019","Jan 22, 2020",PC0187-000,"Sanofi Genzyme"
Lonsurf,"Trifluridine and Tipiracil","mCRC Resubmission","Do not reimburse",Complete,"Jan 21, 2019","Aug 29, 2019",PC0173-000,"Taiho Pharma Canada, Inc."
Lonsurf,Trifluridine-Tipiracil,"Gastric Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Sep 3, 2019","Mar 24, 2020",PC0197-000,"Taiho Pharma Canada, Inc."
Lonsurf,"Trifluridine and Tipiracil","Metastatic Colorectal Cancer","Do not reimburse",Complete,"Nov 6, 2017","Jul 6, 2018",PC0122-000,"Taiho Pharma Canada, Inc."
Lorbrena,Lorlatinib,"Non-Small Cell Lung Cancer (NSCLC)","Do not reimburse",Complete,"Jun 11, 2019","Jan 30, 2020",PC0183-000,"Pfizer Canada ULC"
Lutathera,"Lutetium Lu 177 dotatate","Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","Reimburse with clinical criteria and/or conditions",Complete,"Jul 30, 2018","Aug 1, 2019",PC0142-000,"Advanced Accelerator Applications"
Lynparza,Olaparib,"metastatic castration-resistant prostate cancer (mCRPC)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 22, 2020","Apr 21, 2021",PC0223-000,"AstraZeneca Canada Inc."
Lynparza,Olaparib,"Ovarian Cancer","Do not reimburse",Complete,"Apr 1, 2016","Sep 29, 2016",PC0081-000,"Astra Zeneca Canada Inc"
Lynparza,Olaparib,"Newly Diagnosed OC","Reimburse with clinical criteria and/or conditions",Complete,"Apr 18, 2019","Dec 5, 2019",PC0174-000,"AstraZeneca Canada"
"Lynparza (Resubmission)",Olaparib,"Ovarian Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 17, 2017","Sep 20, 2017",PC0103-000,"AstraZeneca Canada Inc."
Mekinist,Trametinib,"Metastatic Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"May 6, 2013","Oct 22, 2013",PC0030-000,GlaxoSmithKline
Mvasi,Bevacizumab,"mCRC NSCLC Biosimilar",N/A,Complete,"Oct 3, 2018",,PC0158-000,"Amgen Canada Inc."
Mylotarg,"Gemtuzumab Ozogamicin","Acute Myeloid Leukemia (AML)",Reimburse,Complete,"Aug 9, 2019","Apr 2, 2020",PC0190-000,"Pfizer Canada ULC"
Nerlynx,Neratinib,"ERBB2-positive breast cancer","Do not reimburse",Complete,"Apr 18, 2019","Dec 5, 2019",PC0172-000,"Knight Therapeutics Inc."
Nexavar,Sorafenib,"Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)","Do not reimburse",Complete,"Dec 19, 2014","Jul 16, 2015",PC0049-000,"Bayer Inc."
Ninlaro,Ixazomib,"Multiple Myeloma (2nd-beyond)","Do not reimburse",Complete,"Nov 30, 2018","Jul 5, 2019",PC0164-000,"Takeda Canada Inc."
Ninlaro,Ixazomib,"Multiple Myeloma","Do not reimburse",Complete,"Dec 16, 2016","Jun 29, 2017",PC0088-000,"Takeda Pharmaceutical Company Limited"
Nubeqa,Darolutamide,"non-metastatic castration resistant prostate cancer (nmCRPC)","Reimburse with clinical criteria and/or conditions",Complete,"Aug 27, 2019","Apr 22, 2020",PC0196-000,"Bayer Inc."
Odomzo,Sonidegib,"Basal Cell Carcinoma","Do not reimburse",Complete,"Jun 19, 2020","Apr 29, 2021",PC0215-000,"Sun Pharma Canada Inc."
Ogivri,Trastuzumab,,,Withdrawn,"Dec 18, 2018",,PC0169-000,"BGP Pharma ULC"
Onivyde,"Nanoliposomal Irinotecan",,,Cancelled,,,PC0096-000,"Baxalta Canada Corporation"
Onivyde,"Irinotecan Liposome","Metastatic Pancreatic Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Apr 27, 2017","Jan 5, 2018",PC0107-000,"Shire Canada"
Opdivo,Nivolumab,"Squamous Cell Carcinoma of Head and Neck (SCCHN)","Reimburse with clinical criteria and/or conditions",Complete,"Jan 31, 2017","Aug 31, 2017",PC0095-000,"Bristol-Myers Squibb Canada"
Opdivo,Nivolumab,"Metastatic Hepatocellular Carcinoma (HCC)","Do not reimburse",Complete,"May 8, 2018","Nov 29, 2018",PC0134-000,"Bristol-Myers Squibb Canada"
Opdivo,Nivolumab,"Melanoma Adjuvant Therapy","Reimburse with clinical criteria and/or conditions",Complete,"Aug 27, 2018","Mar 7, 2019",PC0147-000,"Bristol-Myers Squibb Canada"
Opdivo,Nivolumab,"Metastatic non small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 29, 2015","Jun 3, 2016",PC0069-000,"Bristol-Myers Squibb Canada"
Opdivo,Nivolumab,"classical Hodgkin Lymphoma (cHL) after failure of ASCT","Reimburse with clinical criteria and/or conditions",Complete,"Sep 29, 2017","May 3, 2018",PC0120-000,"Bristol-Myers Squibb"
Opdivo,Nivolumab,"Metastatic Renal Cell Carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Feb 24, 2016","Sep 1, 2016",PC0074-000,"Bristol Myers-Squibb Canada"
Opdivo,Nivolumab,"Metastatic Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 13, 2015","Apr 1, 2016",PC0063-000,"Bristol-Myers Squibb Canada"
"Opdivo & Yervoy in combo","Nivolumab & Ipilimumab in combo","Metastatic Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Nov 30, 2016","Nov 30, 2017",PC0098-000,"Bristol-Myers Squibb Canada"
"Opdivo in combination with Yervoy","Nivolumab in combination with Ipilimumab","Advanced or Metastatic Renal Cell Carcinoma (RCC).","Reimburse with clinical criteria and/or conditions",Complete,"Apr 26, 2018","Nov 1, 2018",PC0132-000,"Bristol-Myers Squibb"
"Opdivo in combination with Yervoy","Nivolumab in combination with Ipilimumab",NSCLC,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 23, 2020","Mar 4, 2021",PC0218-000,"Bristol-Myers Squibb"
"Perjeta Herceptin Combo Pack",Pertuzumab,"Metastatic Breast Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Nov 2, 2012","Aug 1, 2013",PC0018-000,"Hoffmann-La Roche Limited"
"Perjeta or Perjeta-Herceptin Combo Pack",Pertuzumab,"Neoadjuvant Breast Cancer","Do not reimburse",Complete,"Dec 19, 2014","Jul 16, 2015",PC0050-000,"Hoffmann-La Roche Limited"
"Perjeta-Herceptin Combo Pack","Pertuzumab-Trastuzumab Combo Pack","Early Breast Cancer","Do not reimburse",Complete,"Apr 9, 2018","Nov 29, 2018",PC0127-000,"Hoffmann-La Roche Limited"
Polivy,"Polatuzumab Vedotin","Diffuse large B-cell lymphoma (DLBCL)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 29, 2020","Apr 21, 2021",PC0227-000,"Hoffmann-La Roche Limited"
Pomalyst,Pomalidomide,"Multiple Myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Jan 13, 2014","Jul 31, 2014",PC0036-000,"Celgene Inc."
Pomalyst,Pomalidomide,"Multiple Myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Mar 15, 2019","Sep 18, 2019",PC0165-000,"Celgene Inc."
Proleukin,"Aldesleukin (IL-2)","In-transit Melanoma",Reimburse,Complete,"Jan 30, 2015","Jun 22, 2015",PC0051-000,"Novartis Pharmaceuticals Canada Inc."
Revlimid,Lenalidomide,"Multiple Myeloma (as maintenance therapy)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 5, 2013","Oct 22, 2013",PC0029-000,"Celgene Inc."
Revlimid,Lenalidomide,"Multiple Myeloma (+bortezomib+dex)","Reimburse with clinical criteria and/or conditions",Complete,"Dec 21, 2018","Jun 19, 2019",PC0141-000,"Celgene Inc."
Revlimid,Lenalidomide,"Multiple Myeloma, newly diagnosed","Reimburse with clinical criteria and/or conditions",Complete,"May 4, 2015","Dec 3, 2015",PC0061-000,"Celgene Inc."
Rituxan,Rituximab,"Acute Lymphoblastic Leukemia","Do not reimburse",Complete,"Feb 13, 2017","Aug 31, 2017",PC0102-000,"Hoffmann-La Roche Limited"
Rozlytrek,Entrectinib,"ROS1-positive NSCLC","Reimburse with clinical criteria and/or conditions",Complete,"Jan 8, 2020","Jan 27, 2021",PC0206-000,"Hoffmann-La Roche Ltd."
Rydapt,Midostaurin,"Systemic Mastocytosis","Do not reimburse",Complete,"Aug 13, 2019","Apr 2, 2020",PC0193-000,"Novartis Pharmaceuticals Canada Inc."
Rydapt,Midostaurin,"Acute Myeloid Leukemia",Reimburse,Complete,"Jun 12, 2017","Dec 19, 2017",PC0108-000,"Novartis Pharmaceuticals Canada Inc."
Sarclisa,Isatuximab,"Multiple Myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 17, 2020","Apr 1, 2021",PC0220-000,"Sanofi Genzyme"
Stivarga,Regorafenib,"Unresectable Hepatocellular Carcinoma (HCC)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 12, 2017","Apr 18, 2018",PC0119-000,"Bayer Inc."
"Stivarga (CRC)",Regorafenib,"Metastatic Colorectal Cancer","Do not reimburse",Complete,"Mar 22, 2013","Nov 15, 2013",PC0026-000,"Bayer Inc."
"Stivarga (GIST)",Regorafenib,"Gastrointestinal Stromal Tumour","Reimburse with clinical criteria and/or conditions",Complete,"Oct 11, 2013","May 2, 2014",PC0034-000,"Bayer Inc."
"Stivarga Resubmission (CRC)",Regorafenib,"Metastatic Colorectal Cancer","Do not reimburse",Complete,"Dec 19, 2014","Jul 16, 2015",PC0046-000,"Bayer Inc."
Sutent,"Sunitinib malate","Pancreatic Neuroendocrine Tumour","Reimburse with clinical criteria and/or conditions",Complete,"Nov 7, 2011","May 3, 2012",PC0004-000,"Pfizer Canada Inc."
Sylvant,Siltuximab,"Multicentric Castleman's disease (MCD)","Reimburse with clinical criteria and/or conditions",Complete,"Jan 30, 2015","Jun 22, 2015",PC0052-000,"Janssen Inc."
Tafinlar,Dabrafenib,"Metastatic Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Mar 18, 2013","Dec 5, 2013",PC0025-000,GlaxoSmithKline
"Tafinlar & Mekinist in combo","Dabrafenib & Trametinib in combo","Metastatic Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Feb 13, 2015","Jul 21, 2015",PC0053-000,"GlaxoSmithKline Inc."
"Tafinlar & Mekinist in combo","Dabrafenib & Trametinib in combo","Non-Small Cell Lung Cancer","Do not reimburse",Complete,"Mar 31, 2017","Nov 2, 2017",PC0106-000,"Novartis Pharmaceuticals Canada Inc."
"Tafinlar & Mekinist in combo","Dabrafenib & Trametinib in combo","Melanoma Adjuvant Therapy","Reimburse with clinical criteria and/or conditions",Complete,"Sep 21, 2018","May 3, 2019",PC0152-000,"Novartis Pharmaceuticals Canada Inc."
"Tafinlar and Mekinist","Dabrafenib and Trametinib","NSCLC BRAF V600","Reimburse with clinical criteria and/or conditions",Complete,"Oct 1, 2020","May 28, 2021",PC0226-000,"Novartis Pharmaceuticals Canada Inc."
Tagrisso,Osimertinib,"Non-Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Apr 1, 2016","May 4, 2017",PC0076-000,"Astra Zeneca Canada Inc"
Tagrisso,Osimertinib,"Non-Small Cell Lung Cancer (NSCLC) (first line)","Reimburse with clinical criteria and/or conditions",Complete,"May 16, 2018","Jan 4, 2019",PC0137-000,"AstraZeneca Canada Inc."
TBD,Bevacizumab,,,Cancelled,"Mar 14, 2019",,PC0178-000,"Pfizer Canada Inc."
TBD,Trastuzumab,,,Cancelled,,,PC0160-000,"Pfizer Canada Inc."
TBD,Rituximab,,,Cancelled,,,PC0180-000,"Sandoz Canada"
TBD,Entrectinib,,,Withdrawn,"Jul 29, 2019",,PC0157-000,"Hoffmann-La Roche Limited"
TBD,Cabozantinib,,,Withdrawn,"Oct 6, 2017",,PC0123-000,"Ipsen Biopharmaceuticals Canada Inc."
Tecentriq,Atezolizumab,,,Withdrawn,"Oct 2, 2019",,PC0171-000,"Hoffmann-La Roche Limited"
Tecentriq,Atezolizumab,"Small Cell Lung Cancer (SCLC)","Do not reimburse",Complete,"Mar 4, 2019","Jan 30, 2020",PC0156-000,"Hoffmann-La Roche Limited"
Tecentriq,Atezolizumab,"Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","Reimburse with clinical criteria and/or conditions",Complete,"Dec 15, 2017","Jun 20, 2018",PC0115-000,"Hoffmann-La Roche Limited"
"Tecentriq & Avastin","Atezolizumab & Bevacizumab",NSQ-NSCLC,"Do not reimburse",Complete,"Nov 18, 2019","Jul 3, 2020",PC0155-000,"Hoffmann-La Roche Limited"
"Tecentriq & Avastin","Atezolizumab & Bevacizumab","Hepatocellular Carcinoma (HCC)","Reimburse with clinical criteria and/or conditions",Complete,"May 21, 2020","Nov 17, 2020",PC0217-000,"Hoffmann-La Roche Limited"
Treanda,"Bendamustine hydrochloride","Non-Hodgkin Lymphoma  and Mantle Cell Lymphoma",Reimburse,Complete,"Apr 24, 2012","Nov 29, 2012",PC0010-000,"Lundbeck Canada Inc."
Treanda,"Bendamustine hydrochloride","Chronic Lymphocytic Leukemia (relapsed/refractory)","Do not reimburse",Complete,"Apr 24, 2012","Nov 29, 2012",PC0011-000,"Lundbeck Canada Inc."
Treanda,"Bendamustine hydrochloride","Chronic Lymphocytic Leukemia (first-line)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 24, 2012","Feb 19, 2013",PC0011-000,"Lundbeck Canada Inc."
"Treanda (in combination with rituximab)","Bendamustine hydrochloride","Chronic Lymphocytic Leukemia",,Withdrawn,"Jun 27, 2014",,PC0040-000,"Lundbeck Canada Inc."
Trisenox,"Arsenic Trioxide","Acute Promyelocytic Leukemia",Reimburse,Complete,"Aug 30, 2013","Feb 18, 2014",PC0033-000,"Lundbeck Canada Inc."
Truxima,Rituximab,,,Cancelled,,,PC0184-000,"Teva Canada Innovation"
"Tykerb (in combination with Letrozole)",Lapatinib,"Metastatic Breast Cancer","Do not reimburse",Complete,"Dec 14, 2012","Jul 5, 2013",PC0019-000,GlaxoSmithKline
Unituxin,Dinutuximab,Neuroblastoma,"Reimburse with clinical criteria and/or conditions",Complete,"Oct 1, 2018","Mar 26, 2019",PC0154-000,"United Therapeutics Corp."
Vectibix,Panitumumab,"Left Sided Metastatic Colorectal Cancer (mCRC)","Do not reimburse",Complete,"Sep 8, 2017","Mar 29, 2018",PC0118-000,"Amgen Canada Inc."
Vectibix,Panitumumab,"Metastatic Colorectal Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Apr 15, 2015","Dec 3, 2015",PC0060-000,"Amgen Canada Inc."
Velcade,Bortezomib,"Multiple Myeloma",Reimburse,Complete,"Oct 29, 2012","Mar 25, 2013",PC0016-000,Janssen
Venclexta,Venetoclax,,,Withdrawn,"Jul 8, 2016",,PC0087-000,"AbbVie Corporation"
Venclexta,"Venetoclax Obinutuzumab","Obinutuzumab for CLL","Reimburse with clinical criteria and/or conditions",Complete,"Apr 17, 2020","Nov 17, 2020",PC0212-000,"AbbVie Corporation"
Venclexta,Venetoclax,"Chronic Lymphocytic Leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Jul 10, 2017","Mar 2, 2018",PC0105-000,"AbbVie Corporation"
"Venclexta in combo Rituximab",Venetoclax,"Chronic Lymphocytic Leukemia (CLL)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 24, 2018","May 31, 2019",PC0162-000,"AbbVie Corporation"
Verzenio,Abemaciclib,"Metastatic Breast Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Dec 3, 2018","Jul 5, 2019",PC0161-000,"Eli Lilly Canada Inc."
Vitrakvi,Larotrectinib,"NTRKplus solid tumours","Do not reimburse",Complete,"Feb 25, 2019","Oct 31, 2019",PC0159-000,"Bayer Inc."
Vizimpro,Dacomitinib,"Non-Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Sep 19, 2018","May 31, 2019",PC0129-000,"Pfizer Canada Inc."
Votrient,"Pazopanib hydrochloride","Metastatic Renal Cell Carcinoma",Reimburse,Complete,"Feb 20, 2013","Aug 29, 2013",PC0022-000,"GlaxoSmithKline Inc."
Votrient,"Pazopanib Hydrochloride","Soft Tissue Sarcoma","Do not reimburse",Complete,"Jun 4, 2012","Nov 29, 2012",PC0009-000,"GlaxoSmithKline Inc."
Votrient,"Pazopanib hydrochloride","Metastatic Renal Cell Carcinoma",Reimburse,Complete,"Jul 14, 2011","Jan 5, 2012",PC0000-000,"GlaxoSmithKline Inc."
Xalkori,Crizotinib,"Advanced or Metastatic Non-Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 23, 2012","May 2, 2013",PC0017-000,"Pfizer Canada Inc."
Xalkori,Crizotinib,"First Line ALK Positive Advanced NSCLC","Reimburse with clinical criteria and/or conditions",Complete,"Feb 17, 2015","Jul 21, 2015",PC0054-000,"Pfizer Canada Inc."
Xalkori,Crizotinib,"ROS1-positive advanced non-small cell lung cancer (NSCLC)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 30, 2018","May 23, 2019",PC0151-000,"Pfizer Canada Inc."
Xalkori,Crizotinib,"Advanced Non-Small Cell Lung Cancer","Do not reimburse",Complete,"Mar 26, 2012","Oct 4, 2012",PC0008-000,"Pfizer Canada Inc."
Xospata,Gilteritinib,,"Reimburse with clinical criteria and/or conditions",Complete,"Oct 28, 2019","May 20, 2020","PC0202 -000","Astellas Pharma Canada Inc."
Xtandi,Enzalutamide,"Metastatic Castration Resistant Prostate Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 4, 2013","Jul 23, 2013",PC0023-000,"Astellas Pharma Canada Inc."
Xtandi,Enzalutamide,"Non-metastatic castration-resistant prostate cancer (nm-CRPC)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 24, 2018","Mar 26, 2019",PC0149-000,"Astellas Pharma Canada, Inc."
Xtandi,Enzalutamide,"First Line Metastatic Castration-Resistant Prostate Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 2, 2014","Jun 22, 2015",PC0044-000,"Astellas Pharma Canada, Inc."
Xtandi,Enzalutamide,mHSPC,"Reimburse with clinical criteria and/or conditions",Complete,"Feb 24, 2020","Sep 23, 2020",PC0209-000,"Astellas Pharma Canada, Inc."
Yervoy,Ipilimumab,"First Line Advanced Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 15, 2014","Dec 22, 2014",PC0042-000,"Bristol-Myers Squibb Canada"
Yervoy,Ipilimumab,"Advanced Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 1, 2011","Apr 18, 2012",PC0003-000,"Bristol-Myers Squibb Canada"
Yondelis,Trabectedin,"Metastatic Liposarcoma or Leiomyosarcoma","Do not reimburse",Complete,"Dec 22, 2015","Aug 5, 2016",PC0071-000,"Janssen Inc."
Zaltrap,Aflibercept,"Metastatic Colorectal Cancer","Do not reimburse",Complete,"Nov 26, 2013","Sep 5, 2014",PC0035-000,"Sanofi-aventis Canada Inc."
Zejula,Niraparib,"First Line OC","Reimburse with clinical criteria and/or conditions",Complete,"Sep 21, 2020","Apr 29, 2021",PC0224-000,"GlaxoSmithKline Inc."
Zejula,Niraparib,"Ovarian Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 7, 2020","Sep 3, 2020",PC0203-000,"GlaxoSmithKline Inc."
Zelboraf,Vemurafenib,"Metastatic Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 6, 2011","Jun 1, 2012",PC0006-000,"Hoffmann-La Roche Limited"
Zydelig,Idelalisib,"Chronic lymphocytic leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Apr 7, 2015","Aug 18, 2015",PC0057-000,"Gilead Sciences, Inc."
Zydelig,Idelalisib,"Follicular Lymphoma","Do not reimburse",Complete,"Apr 12, 2016","Sep 29, 2016",PC0075-000,"Gilead Sciences, Inc."
Zykadia,Ceritinib,"Metastatic Non-Small Cell Lung Cancer","Do not reimburse",Complete,"Jun 5, 2015","Dec 3, 2015",PC0062-000,"Novartis Pharmaceuticals Inc."
"Zykadia (Resubmission)",Ceritinib,"metastatic non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 19, 2016","Mar 21, 2017",PC0094-000,"Novartis Pharmaceuticals Canada Inc."
Zytiga,"Abiraterone acetate","Metastatic Castration Resistant Prostate Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 28, 2013","Oct 22, 2013",PC0028-000,"Janssen Inc."
Zytiga,Abiraterone,,,Withdrawn,"Feb 25, 2019",,PC0166-000,"Janssen Inc."
"Zytiga (Resubmission)",Abiraterone,"Prostate Cancer Resubmission",,Withdrawn,"Jul 29, 2019",,PC0201-000,"Janssen Inc."
(TBC),tislelizumab,"recurrent or metastatic nasopharyngeal carcinoma",,Pending,,,PC0399-000,"BeiGene (Canada) ULC"
Abecma,"idecabtagene vicleucel","Multiple myeloma","Do not reimburse",Complete,"Dec 16, 2020","Nov 12, 2021",PG0240-000,"Celgene Inc., a Bristol Myers Squibb company"
Abilify,Aripiprazole,"Schizophrenia and related psychotic disorders","List with clinical criteria and/or conditions",Complete,"Mar 29, 2011","Jul 18, 2011",SF0226-000,"Bristol-Myers Squibb"
Abilify,Aripiprazole,"Depression, Major Depressive Disorder","Do not list",Complete,"Oct 1, 2013","Oct 22, 2014",SR0354-000,"Bristol-Myers Squibb Canada"
Abilify,Aripiprazole,Schizophrenia,"Do not list",Complete,"Nov 6, 2009","Apr 27, 2010",SR0183-000,"Bristol-Myers Squibb Canada"
"Abilify Maintena",Aripiprazole,Schizophrenia,"List with criteria/condition",Complete,"Jan 6, 2014","Dec 19, 2014",SR0366-000,"Otsuka Canada Pharmaceutical Inc. & Lundbeck Canada Inc."
Abstral,"Fentanyl citrate","Pain, breakthrough cancer pain","Do not list",Complete,"Jun 30, 2011","Dec 16, 2011",SR0240-000,"Paladin Labs Inc."
Aclasta,"Zoledronic acid",Osteoporosis,"List with clinical criteria and/or conditions",Complete,"Jul 20, 2011","Nov 16, 2011",SF0242-000,"Novartis Pharmaceuticals Canada Inc."
Aclasta,"Zoledronic acid","Osteoporosis, postmenopausal women","Do not list",Complete,"Nov 29, 2007","Jun 25, 2008",SR0114-000,"Novartis Pharmaceuticals Canada Inc."
Actemra,Tocilizumab,"Arthritis, polyarticular juvenile idiopathic","List with criteria/condition",Complete,"Jul 29, 2013","Mar 19, 2014",SR0343-000,"Hoffmann-La Roche Limited"
Actemra,Tocilizumab,"Arthritis, Rheumatoid","List with clinical criteria and/or conditions",Complete,"May 27, 2010","Nov 17, 2010",SR0201-000,"Hoffmann-La Roche Limited"
Actemra,Tocilizumab,"Arthritis, rheumatoid","List with criteria/condition",Complete,"Mar 3, 2014","Feb 19, 2015",SR0374-000,"Hoffmann-La Roche Limited"
Actemra,Tocilizumab,"Arthritis, juvenile idiopathic","List with clinical criteria and/or conditions",Complete,"Jan 30, 2012","Jul 19, 2012",SR0267-000,"Hoffman-La Roche Ltd."
Actemra,tocilizumab,"Giant cell arteritis (GCA)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 25, 2017","Mar 27, 2018",SR0534-000,"Hoffmann-La Roche Limited"
Actikerall,"Fluorouracil and Salicylic Acid","Hyperkeratotic actinic keratosis","Reimburse with clinical criteria and/or conditions",Complete,"Aug 31, 2016","Mar 22, 2017",SR0498-000,"Cipher Pharmaceuticals Inc."
Adcetris,"brentuximab vedotin","Hodgkin lymphoma",,Withdrawn,,,PC0311-000,"Seagen Canada Inc."
Adcetris,"Brentuximab vedotin","Hodgkin lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Apr 18, 2024","Aug 29, 2024",PC0371-000,"Seagen Canada Inc."
Adcirca,Tadalafil,"Pulmonary arterial hypertension","List with clinical criteria and/or conditions",Complete,"Feb 5, 2010","Jul 15, 2010",SR0197-000,"Eli Lilly Canada Inc."
"Adderall XR","Mixed amphetamine salts","Attention deficit hyperactivity disorder, Adult","Do not list",Complete,"Nov 29, 2007","Jun 25, 2008",SR0116-000,"Shire Canada Inc."
"Adderall XR","Mixed amphetamine salts","Attention deficit hyperactivity disorder","Do not list",Complete,"Apr 13, 2004","Nov 24, 2004",SR0010-000,"Shire BioChem Inc."
"Adderall XR","Mixed amphetamine salts","Attention deficit hyperactivity disorder",,Withdrawn,"Dec 15, 2004",,SR0027-000,"Shire BioChem Inc."
Adempas,Riociguat,"Chronic thromboembolic pulmonary hypertension","List with criteria/condition",Complete,"Sep 30, 2013","Jul 17, 2014",SR0353-000,"Bayer Inc."
Adempas,Riociguat,"Pulmonary arterial hypertension (WHO group 1)","List with clinical criteria and/or conditions",Complete,"Jun 25, 2015","Dec 17, 2015",SR0438-000,"Bayer Inc."
Adlyxine,lixisenatide,"Diabetes mellitus, Type 2","Reimburse with clinical criteria and/or conditions",Complete,"May 29, 2017","Nov 23, 2017",SR0520-000,"Sanofi-aventis Canada Inc."
Admelog,"Insulin lispro",,,Cancelled,,,SE0543-000,"sanofi-aventis Canada Inc."
Adtralza,tralokinumab,"atopic dermatitis (AD)","Do not reimburse",Complete,"Jun 5, 2023","May 8, 2024",SR0787-000,"LEO Pharma Inc."
Adtralza,tralokinumab,"atopic dermatitis","Do not reimburse",Complete,"Apr 27, 2021","Mar 7, 2022",SR0689-000,"LEO Pharma Inc."
Aduhelm,aducanumab,"Alzheimer’s disease",,Withdrawn,"Nov 26, 2021",,SR0705-000,"Biogen Canada Inc."
Advicor,Niacin/lovastatin,"Hypercholesterolemia and mixed dyslipidemia",List,Complete,"Oct 18, 2005","Apr 26, 2006",SR0042-000,"Oryx Pharmaceuticals Inc."
"Aermony RespiClick","fluticasone propionate",Asthma,"Reimburse with clinical criteria and/or conditions",Complete,"Oct 4, 2017","Dec 19, 2018",SR0539-000,"TEVA Canada Innovation"
Afinitor,Everolimus,"Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)","Do not list",Complete,"Mar 8, 2013","Sep 25, 2013",SR0315-000,"Novartis Pharmaceuticals Canada Inc."
Afinitor,Everolimus,"Subependymal giant cell astrocytoma associated with tuberous sclerosis complex","Do not list",Complete,"Mar 19, 2014","Apr 15, 2015",SR0376-000,"Novartis Pharmaceuticals Canada Inc."
Aimovig,erenumab,Migraine,"Reimburse with clinical criteria and/or conditions",Complete,"May 2, 2019","Jul 22, 2020",SR0578-000,"Novartis Pharmaceuticals Canada Inc."
Ajovy,fremanezumab,migraine,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 3, 2020","Mar 24, 2021",SR0641-000,"Teva Canada Innovation"
Akeega,"niraparib abiraterone acetate","Metastatic castration-resistant prostate cancer (mCRPC)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 14, 2023","Feb 1, 2024",PC0326-000,"Janssen Inc."
Akynzeo,"netupitant / palonosetron","Nausea and vomiting (chemotherapy induced) prevention","Reimburse with clinical criteria and/or conditions",Complete,"Dec 8, 2017","Jun 20, 2018",SR0548-000,"Purdue Pharma"
Albrioza,"sodium phenylbutyrate and ursodoxicoltaurine","Amyotrophic lateral sclerosis (ALS)","Reimburse with clinical criteria and/or conditions",Complete,"Nov 24, 2021","Jul 21, 2022",SR0711-000,"Amylyx Canada"
Aldurazyme,Laronidase,"Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie","Do not list",Complete,"Feb 3, 2005","Jul 14, 2005",SR0032-000,"Genzyme Canada"
Alecensaro,alectinib,"ALK-positive NSCLC","Reimburse with clinical criteria and/or conditions",Complete,"Apr 18, 2024","Oct 30, 2024",PC0350-000,"Hoffmann-La Roche Limited"
"Aloxi (capsule)","Palonosetron hydrochloride","Chemotherapy-induced nausea and vomiting","Do not list",Complete,"Oct 5, 2012","Apr 24, 2013",SR0294-000,"Eisai Ltd."
"Aloxi (capsule)",Palonosetron,"Chemotherapy-induced nausea and vomiting",,Withdrawn,"Feb 6, 2015",,SR0415-000,"Eisai Limited"
"Aloxi (injection)","Palonosetron hydrochloride","Chemotherapy-induced nausea and vomiting","Do not list at the submitted price",Complete,"Oct 5, 2012","May 15, 2013",SR0293-000,"Eisai Ltd."
Alsitek,"masitinib mesylate","Amyotrophic lateral sclerosis (ALS)",,Suspended,"Oct 28, 2022",,SR0766-000,"AB Science SA"
"Altace HCT",Ramipril/hydrochlorothiazide,Hypertension,,Cancelled,"Oct 26, 2006",,SR0083-000,"Sanofi –Aventis Canada inc."
"Altace HCT",Ramipril/hydrochlorothiazide,Hypertension,List,Complete,"Mar 26, 2007","Jun 14, 2007",SR0095-000,"Sanofi-Aventis Canada Inc."
"Altace Plus Felodipine","Ramipril/felodipine extended release",Hypertension,"Do not list",Complete,"Jun 22, 2006","Nov 15, 2006",SR0067-000,"Sanofi-Aventis Canada Inc."
Altuviiio,"efanesoctocog alfa","congenital factor VIII deficiency",,Active,"Sep 18, 2024",,ST0840-000,"Sanofi-aventis Canada Inc."
Alvesco,Ciclesonide,asthma,List,Complete,"Jul 24, 2006","Dec 20, 2006",SR0074-000,"Altana Pharma Inc."
Alyftrek,"vanzacaftor, tezacaftor, deutivacaftor","Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older",,Received,"May 9, 2025",,SR0896-000,"Vertex Inc."
Amevive,Alefacept,"Psoriasis, moderate to severe chronic plaque","Do not list",Complete,"Nov 16, 2004","May 26, 2005",SR0024-000,"Biogen Idec Canada Inc."
Amevive,Alefacept,"Psoriasis, moderate to severe chronic plaque","Do not list",Complete,"Feb 28, 2006","Sep 27, 2006",SR0053-000,"Biogen Idec Canada Inc."
Amvuttra,vutrisiran,"Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis)","Reimburse with clinical criteria and/or conditions",Complete,"Jul 4, 2023","Jan 29, 2024",SR0801-000,"Alnylam Netherlands B.V."
"Anoro Ellipta",Umeclidinium/vilanterol,"Chronic obstructive pulmonary disease","List with criteria/condition",Complete,"Feb 26, 2014","Jan 15, 2015",SR0371-000,"GlaxoSmithKline Inc."
Apidra,"Insulin glulisine","Diabetes, Mellitus (Type 1 & 2)","List in a similar manner to other drugs in class",Complete,"Aug 29, 2008","Feb 19, 2009",SR0144-000,"Sanofi-Aventis Canada Inc."
Apprilon,"Doxycycline monohydrate",Rosacea,"Do not list",Complete,"Apr 27, 2012","Mar 27, 2013",SR0279-000,"Galderma Canada Inc."
Apretude,cabotegravir,"HIV-1 infection, pre-exposure prophylaxis","Reimburse with clinical criteria and/or conditions",Complete,"Feb 1, 2024","Aug 14, 2024",SR0825-000,"ViiV Healthcare ULC"
Aptiom,"Eslicarbazepine acetate","Epilepsy, partial-onset seizures","List with criteria/condition",Complete,"Aug 15, 2014","Apr 16, 2015",SR0391-000,"Sunovion Pharmaceuticals Canada Inc."
Aptivus,Tipranavir,"HIV infection","List with clinical criteria and/or conditions",Complete,"Dec 15, 2005","May 17, 2006",SR0047-000,"Boehringer Ingelheim (Canada) Inc."
"Arbesda RespiClick","fluticasone propionate / salmeterol xinafoate",Asthma,"Reimburse with clinical criteria and/or conditions",Complete,"Oct 4, 2017","Dec 19, 2018",SR0540-000,"TEVA Canada Innovation"
"Arnuity Ellipta","Fluticasone furoate",Asthma,"List with criteria/condition",Complete,"Jun 26, 2015","Dec 17, 2015",SR0439-000,"GlaxoSmithKline Inc."
ASMANEX,"Mometasone furoate",Asthma,List,Complete,"Nov 10, 2011","May 16, 2012",SR0258-000,"Merck Canada Inc."
Asparlas,"calaspargase pegol","Acute lymphoblastic leukemia (ALL)","Reimburse with clinical criteria and/or conditions",Complete,"May 12, 2023","Jan 4, 2024",PC0321-000,"Servier Canada Inc."
"Atectura Breezhaler","indacaterol /mometasone furoate","Asthma maintenance (adults, children 12 or older)","Reimburse with clinical criteria and/or conditions",Complete,"May 19, 2020","Nov 24, 2020",SR0646-000,"Novartis Pharmaceuticals Canada Inc."
Atriance,nelarabine,"T-cell acute lymphoblastic leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Mar 6, 2023","Sep 29, 2023",PC0307-000,N/A
Atripla,"Efavirenz, emtricitabine, tenofovir disoproxil fumarate",HIV,"List with clinical criteria and/or conditions",Complete,"Oct 30, 2007","Apr 17, 2008",SR0111-000,"Bristol-Myers Squibb and Gilead Sciences"
Aubagio,Teriflunomide,"Multiple sclerosis, relapsing-remitting","Do not list at the submitted price",Complete,"Aug 28, 2013","Jun 18, 2014",SR0350-000,"Genzyme Canada, a Division of Sanofi Aventis Canada Inc."
Avodart,Dutasteride,"Prostatic hyperplasia, benign","List in a similar manner to other drugs in class",Complete,"Aug 24, 2004","Jan 20, 2005",SR0019-000,"GlaxoSmithKline Inc."
Awiqli,"insulin icodec","Diabetes mellitus, type 2","Reimburse with clinical criteria and/or conditions",Complete,"Oct 18, 2023","May 17, 2024",SR0790-000,"Novo Nordisk Canada Inc."
Axert,Almotriptan,Migraine,"List in a similar manner to other drugs in class",Complete,"Dec 24, 2003","May 27, 2004",SR0005-000,"Janssen-Ortho Inc."
Ayvakyt,avapritinib,"Advanced Systemic Mastocytosis","Reimburse with clinical criteria and/or conditions",Complete,"Apr 19, 2024","Oct 31, 2024",PC0335-000,"Medison Pharma Canada Inc."
Azarga,"Brinzolamide and timolol maleate suspension","Glaucoma and ocular hypertension","List in a similar manner to other drugs in class",Complete,"Aug 28, 2009","Feb 18, 2010",SR0173-000,"Alcon Canada Inc."
Azilect,"Rasagiline mesylate","Parkinson's disease",N/A,Complete,"Mar 10, 2009",,SF0161-000,"Teva Pharmaceuticals Industries Ltd."
Azilect,"Rasagiline mesylate","Parkinson's disease","Do not list",Complete,"Sep 1, 2006","Mar 28, 2007",SR0073-000,"Teva Neurosciences"
Balversa,erdafitinib,"locally advanced unresectable or metastatic urothelial carcinoma (UC)","Reimburse with clinical criteria and/or conditions",Active,"Jun 14, 2024","Jan 9, 2025",PC0375-000,"Janssen Inc."
Banzel,Rufinamide,"Lennox-Gastaut syndrome","List with clinical criteria and/or conditions",Complete,"Sep 20, 2011","Mar 15, 2012",SR0252-000,"Eisai Limited"
Baqsimi,glucagon,"Severe hypoglycemic reactions","Reimburse with clinical criteria and/or conditions",Complete,"Jul 24, 2019","Jan 22, 2020",SR0626-000,"Eli Lilly Canada Inc."
Baraclude,Entecavir,"Hepatitis B (chronic)","List with clinical criteria and/or conditions",Complete,"Dec 12, 2006","Nov 28, 2007",SR0089-000,"Bristol-Myers Squibb Canada"
Basaglar,"Insulin glargine","Diabetes mellitus, type 1; diabetes mellitus, type 2","List with clinical criteria and/or conditions",Complete,"Oct 5, 2015","Apr 14, 2016",SE0451-000,"Eli Lilly Canada Inc."
Benlysta,belimumab,"Lupus nephritis","Reimburse with clinical criteria and/or conditions",Complete,"Jul 7, 2022","Jan 19, 2023",SR0746-000,"GlaxoSmithKline Inc."
Benlysta,Belimumab,"Systemic lupus erythematosus","Do not list",Complete,"Sep 19, 2011","Apr 25, 2012",SR0251-000,"GlaxoSmithKline Inc."
Benlysta,Belimumab,"systemic lupus erythematosus","Do not reimburse",Complete,"May 29, 2019","Apr 22, 2020",SR0616-000,"GlaxoSmithKline Inc."
Beovu,brolucizumab,"Macular degeneration, age-related","Reimburse with clinical criteria and/or conditions",Complete,"Sep 26, 2019","May 21, 2020",SR0632-000,"Novartis Pharmaceuticals Canada Inc."
Beovu,brolucizumab,"Diabetic macular edema","Reimburse with clinical criteria and/or conditions",Complete,"Jun 30, 2022","Jan 18, 2023",SR0747-000,"Novartis Pharmaceuticals Canada Inc."
Beqvez,"fidanacogene elaparvovec","Hemophilia B","Reimburse with clinical criteria and/or conditions",Complete,"Aug 1, 2023","Feb 16, 2024",SG0802-000,"Pfizer Canada ULC"
Bijuva,"estradiol and progesterone","Vasomotor symptoms associated with menopause","Reimburse with clinical criteria and/or conditions",Complete,"Jun 30, 2021","Feb 10, 2022",SR0697-000,"Knight Therapeutics Inc."
Biktarvy,"bictegravir/emtricitabine/tenofovir alafenamide","HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Apr 30, 2018","Oct 25, 2018",SR0567-000,"Gilead Sciences Canada, Inc."
Bimzelx,bimekizumab,"Psoriatic arthritis","Reimburse with clinical criteria and/or conditions",Complete,"Oct 5, 2023","May 15, 2024",SR0803-000,"UCB Canada Inc."
Bimzelx,bimekizumab,"Hidradenitis suppurative",,Active,"Oct 18, 2024",,SR0856-000,"UCB Canada Inc."
Bimzelx,bimekizumab,"Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Aug 17, 2021","Mar 30, 2022",SR0698-000,"UCB Canada Inc."
Bimzelx,bimekizumab,"Ankylosing spondylitis","Reimburse with clinical criteria and/or conditions",Complete,"Oct 19, 2023","May 16, 2024",SR0809-000,"UCB Canada Inc."
Blincyto,blinatumomab,"B-cell precursor acute lymphoblastic leukemia","Reimburse with clinical criteria and/or conditions",Active,"Oct 18, 2024","May 1, 2025",PC0365-000,"Amgen Canada Inc."
Botox,OnabotulinumtoxinA,Migraine,"Do not list",Complete,"Aug 15, 2013","May 28, 2014",SR0345-000,"Allergan Inc."
Botox,OnabotulinumtoxinA,"Urinary incontinence","List with criteria/condition",Complete,"Nov 25, 2013","Nov 12, 2014",SR0362-000,"Allergan Inc."
Botox,OnabotulinumtoxinA,"Neurogenic detrusor overactivity","List with clinical criteria and/or conditions",Complete,"Jan 31, 2012","Jul 19, 2012",SR0268-000,"Allergan Inc."
Botox,onabotulinumtoxinA,"Migraine, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Nov 2, 2018","Oct 17, 2019",SR0584-000,"Allergan Canada Inc."
Braftovi,encorafenib,"Metastatic colorectal cancer","Reimburse with clinical criteria and/or conditions",Complete,"Dec 16, 2020","Jul 26, 2021",PC0233-000,"Pfizer Canada ULC"
"Braftovi and Mektovi","encorafenib and binimetinib","Advanced Melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 16, 2020","Jul 26, 2021",PC0232-000,"Pfizer Canada ULC"
Brenzys,Etanercept,"Rheumatoid arthritis, Ankylosing spondylitis","Reimburse with clinical criteria and/or conditions",Complete,"Apr 20, 2016","Oct 25, 2016",SE0485-000,"Merck Canada Inc."
"Breo Ellipta","Fluticasone furoate /vilanterol","Chronic Obstructive Pulmonary Disease (COPD)","List with criteria/condition",Complete,"Oct 29, 2013","Aug 18, 2014",SR0358-000,GlaxoSmithKline
"Breo Ellipta","Fluticasone Furoate and Vilanterol (as trifenatate)",Asthma,"List with clinical criteria and/or conditions",Complete,"Aug 10, 2015","Feb 18, 2016",SR0442-000,"GlaxoSmithKline Inc."
"Breo Ellipta","fluticasone furoate/vilanterol",COPD,,Withdrawn,"Jun 28, 2017",,SR0524-000,"GlaxoSmithKline Inc."
"Breo Ellipta","fluticasone furoate/vilanterol",Asthma,,Withdrawn,"May 2, 2018",,SR0568-000,"GlaxoSmithKline Inc."
Breyanzi,"lisocabtagene maraleucel","Relapsed or refractory large B-cell lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"May 8, 2024","Nov 27, 2024",PG0358-000,"Bristol Myers Squibb Canada"
Breyanzi,"lisocabtagene maraleucel","Relapsed or refractory large B-cell lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 9, 2021","Jun 29, 2022",PG0258-000,"Celgene Inc., a Bristol Myers Squibb company (Celgene)"
"Breztri Aerosphere","budesonide/ glycopyrronium /formoterol fumarate","chronic obstructive pulmonary disease (COPD)","Reimburse with clinical criteria and/or conditions",Complete,"Jan 28, 2021","Sep 14, 2021",SR0675-000,"AstraZeneca Canada Inc."
Brilinta,Ticagrelor,"Acute coronary syndromes","Do not list",Complete,"Jun 1, 2011","Dec 16, 2011",SR0234-000,"AstraZeneca Canada Inc"
Brilinta,Ticagrelor,"Acute Coronary Syndromes",,Cancelled,"Jun 8, 2010",,SR0203-000,"AstraZeneca Canada Inc"
Brilinta,ticagrelor,"Prevention of atherothrombotic events with history of myocardial infarction","Reimburse with clinical criteria and/or conditions",Complete,"Feb 18, 2016","Aug 25, 2016",SR0474-000,"AstraZeneca Canada Inc"
Brineura,"cerliponase alfa","Neuronal Ceroid Lipofuscinosis Type 2","Reimburse with clinical criteria and/or conditions",Complete,"Jul 31, 2018","May 23, 2019",SR0574-000,"Biomarin Pharmaceutical (Canada) Inc."
Brivlera,Brivaracetam,"Epilepsy, partial-onset seizures","Reimburse with clinical criteria and/or conditions",Complete,"Apr 19, 2016","Jan 25, 2017",SR0484-000,"UCB Canada Inc."
Brukinsa,zanubrutinib,"Waldenström’s macroglobulinemia","Reimburse with clinical criteria and/or conditions",Complete,"May 21, 2021","Dec 21, 2021",PC0248-000,"BeiGene, Ltd."
Brukinsa,zanubrutinib,"Mantle cell lymphoma (MCL)","Do not reimburse",Complete,"Sep 30, 2021","Jul 27, 2022",PC0267-000,"BeiGene Canada ULC"
Brukinsa,zanubrutinib,"Relapsed or refractory follicular lymphoma","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0037-000,"BeiGene Canada ULC"
Brukinsa,zanubrutinib,"Chronic lymphocytic leukemia /small lymphocytic lymphoma.","Reimburse with clinical criteria and/or conditions",Complete,"Jan 20, 2023","Sep 1, 2023",PC0310-000,"BeiGene Canada ULC"
BuTrans,"Buprenorphine transdermal patch","Pain, persistent (moderate intensity)",,Cancelled,"Oct 15, 2010",,SR0211-000,"Purdue Pharma"
BuTrans,"Buprenorphine transdermal patch","Pain, moderate intensity persistent pain","Do not list",Complete,"May 9, 2011","Sep 28, 2011",SR0233-000,"Purdue Pharma"
Byetta,Exenatide,"Diabetes mellitus, type 2","Do not list",Complete,"Aug 23, 2011","Jul 19, 2012",SR0246-000,"Eli Lilly Canada"
Bylvay,odevixibat,"Alagille syndrome",,Active,"Feb 28, 2025",,SR0884-000,"Medison Pharma Canada Inc."
Bylvay,odevixibat,"Progressive familial intrahepatic cholestasis (PFIC)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 23, 2023","Feb 13, 2024",SR0788-000,"Medison Pharma Canada Inc."
Bystolic,Nebivolol,Hypertension,"Do not list at the submitted price",Complete,"Feb 4, 2013","Jul 18, 2013",SR0307-000,"Forest Laboratories Canada Inc."
Cablivi,caplacizumab,"Acquired thrombotic thrombocytopenic purpura (aTTP)","Do not reimburse",Complete,"Sep 13, 2019","Aug 26, 2020",SR0633-000,"Sanofi-Genzyme, a division of sanofi-aventis Canada Inc."
Cablivi,caplacizumab,"Acquired thrombotic thrombocytopenic purpura (aTTP)","Do not reimburse",Complete,"Jun 7, 2022","Apr 5, 2023",SR0736-000,"sanofi-aventis Canada Inc."
Cabometyx,cabozantinib,"Advanced or metastatic renal cell carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Feb 17, 2023","Nov 3, 2023",PC0312-000,"Ipsen Biopharmaceuticals Canada Inc."
Cabometyx,cabozantinib,"Differentiated thyroid carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Apr 27, 2022","Nov 2, 2022",PC0287-000,"Ipsen Biopharmaceuticals Canada Inc."
Cabtreo,"clindamycin plus benzoyl peroxide and adapalene","acne vulgaris","Reimburse with clinical criteria and/or conditions",Complete,"Mar 8, 2024","Oct 18, 2024",SR0794-000,"Bausch Health, Canada Inc."
Caduet,"Amlodipine besylate/ atorvastatin calcium","Hypertension/ Dyslipidemia","List with clinical criteria and/or conditions",Complete,"Dec 15, 2005","May 17, 2006",SR0048-000,"Pfizer Canada Inc."
Calquence,Acalabrutinib,"Chronic Lymphocytic Leukemia (CLL)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 7, 2020",,PC0211-000,"AstraZeneca Canada Inc"
Calquence,acalabrutinib,"Chronic lymphocytic leukemia (CLL).",,Pending,,,PC0412-000,"AstraZeneca Canada Inc."
Calquence,Acalabrutinib,"Chronic Lymphocytic Leukemia (CLL)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 7, 2020","Nov 17, 2020",PC0211-000,"AstraZeneca Canada Inc"
Calquence,acalabrutinib,"Mantle cell lymphoma (MCL)",,Active,"Mar 26, 2025",,PC0413-000,"AstraZeneca Canada Inc."
Camcevi,"leuprolide mesylate","Prostate cancer",,Active,,,PC0370-000,"Accord Healthcare Inc."
Campral,"Acamprosate calcium","Alcohol Abstinence",N/A,Complete,"Jul 22, 2008",,SF0143-000,"Prempharm Inc."
Campral,"Acamprosate calcium","Alcohol Abstinence","List with clinical criteria and/or conditions",Complete,"Aug 29, 2007","Mar 27, 2008",SR0108-000,"Prempharm Inc."
Camzyos,mavacamten,"Obstructive hypertrophic cardiomyopathy","Reimburse with clinical criteria and/or conditions",Complete,"Sep 22, 2022","Apr 14, 2023",SR0755-000,"Bristol Myers Squibb"
Carvykti,"ciltacabtagene autoleucel","Relapsed or refractory multiple myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Sep 23, 2022","May 1, 2023",PG0302-000,"Janssen Inc."
Carvykti,"ciltacabtagene autoleucel","Relapsed or refractory multiple myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Apr 18, 2024","Nov 1, 2024",PG0361-000,"Janssen Inc."
Casgevy,"exagamglogene autotemcel","Transfusion-dependent β-thalassemia","Reimburse with clinical criteria and/or conditions",Active,"May 27, 2024","Dec 11, 2024",SG0831-000,"Vertex Pharmaceuticals (Canada) Incorporated"
Casgevy,"exagamglogene autotemcel","Sickle cell disease (SCD)","Reimburse with clinical criteria and/or conditions",Complete,"May 27, 2024","Dec 11, 2024",SG0830-000,"Vertex Pharmaceuticals (Canada) Incorporated"
Cayston,"Aztreonam for inhalation solution","Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections","List with clinical criteria and/or conditions",Complete,"Dec 2, 2010","Jul 18, 2011",SR0220-000,"Gilead Sciences Canada Inc."
Celsentri,Maraviroc,HIV,,Withdrawn,"Nov 2, 2007",,SR0113-000,"Pfizer Canada Inc."
Celsentri,Maraviroc,HIV,"List with clinical criteria and/or conditions",Complete,"May 7, 2008","Nov 12, 2008",SR0136-000,"Pfizer Canada Inc."
Celsentri,Maraviroc,"HIV infection","Do not list",Complete,"Dec 8, 2010","Jul 18, 2011",SR0221-000,GlaxoSmithKline
Cerdelga,Eliglustat,"Gaucher disease","Reimburse with clinical criteria and/or conditions",Complete,"Jan 20, 2017","Jul 26, 2017",SR0511-000,"Sanofi Genzyme"
Champix,"Varenicline tartrate",Smoking-cessation,"List with clinical criteria and/or conditions",Complete,"Mar 21, 2007","Aug 16, 2007",SR0094-000,"Pfizer Canada Inc."
Cibinqo,abrocitinib,"Atopic dermatitis, moderate to severe","Reimburse with clinical criteria and/or conditions",Complete,"Apr 26, 2021","Aug 19, 2022",SR0686-000,"Pfizer Canada ULC"
Cimzia,"Certolizumab pegol","Arthritis, psoriatic","List with criteria/condition",Complete,"Sep 2, 2014","Apr 17, 2015",SR0394-000,"UCB Canada Inc."
Cimzia,"Certolizumab pegol","Arthritis, rheumatoid","Do not list",Complete,"Sep 3, 2009","May 27, 2010",SR0175-000,"UCB Pharma Canada Inc."
Cimzia,"certolizumab pegol","Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"May 13, 2019","Nov 20, 2019",SR0587-000,"UCB Canada Inc."
Cimzia,"Certolizumab pegol","Ankylosing spondylitis","List with criteria/condition",Complete,"Jun 23, 2014","Apr 17, 2015",SR0385-000,"UCB Canada Inc."
Cinqair,Reslizumab,"Asthma, eosinophilic","Reimburse with clinical criteria and/or conditions",Complete,"Aug 4, 2016","Mar 22, 2017",SR0495-000,"TEVA Canada Innovation"
Cinqair,reslizumab,"Asthma, eosinophilic","Reimburse with clinical criteria and/or conditions",Complete,"Oct 24, 2018","Mar 27, 2019",SF0591-000,"TEVA Canada Innovation"
Cipralex,"Escitalopram oxalate","Depression, Major Depressive Disorder (MDD)","Do not list",Complete,"Jun 8, 2006","Jan 24, 2007",SR0064-000,"Lundbeck Canada Inc."
Cipralex,"Escitalopram oxalate","Depression, Major Depressive Disorder (MDD)",,Withdrawn,"Aug 3, 2005",,SR0039-000,"Lundbeck Canada Inc."
Ciprodex,"Ciprofloxacin hydrochloride and dexamethasone otic suspension","Otitis media with otorrhea & otitis externa, acute","Do not list",Complete,"Jun 11, 2004","Jan 26, 2005",SR0014-000,"Alcon Canada Inc."
Ciprodex,"Ciprofloxacin hydrochloride & dexamethasone otic suspension","Otitis media with otorrhea & otitis externa, acute","List with clinical criteria and/or conditions",Complete,"Jun 15, 2007","Oct 18, 2007",SF0101-000,"Alcon Canada Inc."
Clolar,clofarabine,"Acute lymphoblastic leukemia","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0020-000,"Sanofi-aventis Canada Inc."
Columvi,glofitamab,"Relapsed or refractory diffuse large B-cell lymphoma",,Active,"Mar 7, 2025",,PC0406-000,"Hoffmann-La Roche Limited"
Columvi,glofitamab,"Relapsed or refractory diffuse large B-cell lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Jul 18, 2023","Feb 2, 2024",PC0320-000,"Hoffmann-La Roche Limited"
"Combigan Ophthalmic Solution","Brimonidine tartrate/timolol maleate",Glaucoma,"List with clinical criteria and/or conditions",Complete,"Dec 15, 2003","May 27, 2004",SR0001-000,"Allergan Canada Inc."
COMPLERA,"Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate","HIV infection",List,Complete,"Oct 19, 2011","Apr 19, 2012",SR0256-000,"Gilead Science Canada Ltd."
Constella,Linaclotide,"Irritable bowel syndrome with constipation","Do not list",Complete,"Dec 17, 2014","Sep 23, 2015",SR0409-000,"Actavis Specialty Pharmaceuticals Co."
Contrave,"naltrexone hydrochloride and bupropion hydrochloride","Chronic weight management in adults","Do not reimburse",Complete,"May 1, 2019","May 27, 2020",SR0610-000,"Bausch Health, Canada Inc."
Copaxone,"Glatiramer acetate","Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis","Do not list",Complete,"Apr 29, 2009","Nov 25, 2009",SR0164-000,"Teva Pharmaceutical Industries Ltd."
Cortiment,Budesonide,"Ulcerative Colitis","Do not reimburse",Complete,"May 24, 2016","Mar 22, 2017",SR0491-000,"Ferring Inc."
Corzyna,ranolazine,"Stable angina pectoris, adults","Do not reimburse",Complete,"Aug 17, 2020","May 27, 2021",SR0655-000,"KYE Pharmaceuticals Inc."
Cosentyx,Secukinumab,"ankylosing spondylitis","Reimburse with clinical criteria and/or conditions",Complete,"Feb 19, 2016","Aug 23, 2016",SR0475-000,"Novartis Pharmaceuticals Canada Inc."
Cosentyx,secukinumab,"Hidradenitis suppurativa","Reimburse with clinical criteria and/or conditions",Complete,"May 10, 2023","Sep 12, 2024",SR0781-000,"Novartis Pharmaceuticals Canada Inc."
Cosentyx,Secukinumab,"Arthritis, psoriatic","Reimburse with clinical criteria and/or conditions",Complete,"Feb 19, 2016","Aug 23, 2016",SR0476-000,"Novartis Pharmaceuticals Canada Inc."
Cosentyx,Secukinumab,"Plaque psoriasis","List with criteria/condition",Complete,"Dec 8, 2014","Oct 28, 2015",SR0407-000,"Novartis Pharmaceuticals Canada Inc."
Cresemba,isavuconazole,"Treatment of invasive aspergillosis and mucormycosis","Reimburse with clinical criteria and/or conditions",Complete,"Nov 2, 2018","May 15, 2019",SR0586-000,"AVIR Pharma Inc."
Crysvita,burosumab,"Treatment of X-Linked Hypophosphatemia","Reimburse with clinical criteria and/or conditions",Complete,"Jan 2, 2024","Oct 10, 2024",SR0818-000,"Kyowa Kirin Canada, Inc."
Crysvita,burosumab,"Treatment of X-Linked Hypophosphatemia","Reimburse with clinical criteria and/or conditions",Complete,"Jul 23, 2019","May 27, 2020",SR0602-000,"Kyowa Kirin Limited"
Cubicin,Daptomycin,"Skin and skin structure infections & bacteremia","Do not list",Complete,"Mar 6, 2008","Sep 24, 2008",SR0127-000,"Cubist Pharmaceuticals Inc."
Cuvposa,glycopyrrolate,"chronic severe drooling, neurologic (pediatric)","Do not reimburse",Complete,"May 31, 2019","Jun 24, 2020",SR0613-000,"MEDEXUS Pharmaceuticals, Inc."
Cymbalta,"Duloxetine hydrochloride","Depressive, Major Disorder (MDD)","Do not list",Complete,"Feb 8, 2008","Aug 14, 2008",SR0125-000,"Eli Lilly Canada Inc."
Cymbalta,"Duloxetine hydrochloride","Pain, Neuropathic, Diabetic","List with clinical criteria and/or conditions",Complete,"Feb 8, 2008","Aug 14, 2008",SR0126-000,"Eli Lilly Canada Inc."
Cystadrops,cysteamine,"Corneal cystine crystal deposits","Reimburse with clinical criteria and/or conditions",Complete,"Dec 10, 2018","Jun 18, 2019",SR0595-000,"Recordati Rare Diseases Canada Inc."
Daklinza,Daclatasvir,"Hepatitis C, Chronic","List with clinical criteria and/or conditions",Complete,"Feb 13, 2015","Sep 21, 2015",SR0417-000,"Bristol-Myers Squibb Canada Inc."
Daklinza,daclatasvir,"Hepatitis C, Chronic","Reimburse with clinical criteria and/or conditions",Complete,"Jan 6, 2016","May 19, 2016",SF0467-000,"Bristol Myers Squibb Canada Inc."
Darzalex,daratumumab,"Light chain (AL) amyloidosis","Reimburse with clinical criteria and/or conditions",Complete,"Jul 15, 2021","Jan 28, 2022",PC0257-000,"Janssen Inc."
Darzalex,daratumumab,"Multiple myeloma, eligible for autologous stem cell transplant","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0031-000,"Janssen Canada Inc."
"Darzalex SC",daratumumab,"Multiple myeloma, eligible for autologous stem cell transplant","Reimburse with clinical criteria and/or conditions",Active,"Oct 1, 2024","May 2, 2025",PC0388-000,"Janssen Inc."
Daxas,Roflumilast,"Chronic obstructive pulmonary disease","Do not list",Complete,"Nov 30, 2010","Jul 27, 2011",SR0218-000,"Nycomed Canada Inc."
Daybue,trofinetide,"Rett syndrome (RTT)",,Active,"Oct 29, 2024",,SR0829-000,"Acadia Pharmaceuticals Canada Inc."
Dayvigo,lemborexant,Insomnia,"Do not reimburse",Complete,"Feb 28, 2022","Jan 10, 2023",SR0716-000,"Eisai Limited"
Dayvigo,lemborexant,Insomnia,,Active,"Apr 10, 2025",,SR0895-000,"Eisai Limited"
Delstrigo,"doravirine lamuvidine tenofovir disoproxil fumarate","HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Nov 16, 2018","May 14, 2019",SR0581-000,"Merck Canada Inc."
Demylocan,decitabine,"Myelodysplastic Syndromes","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0001-000,"Pharmascience Inc."
Denavir,Penciclovir,"Herpes labialis (cold sores)","Do not list",Complete,"Sep 20, 2006","Apr 26, 2007",SR0075-000,"Novartis Consumer Health Care Inc."
Descovy,"Emtricitabine /tenofovir alafenamide","HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Jan 29, 2016","Aug 24, 2016",SR0470-000,"Gilead Sciences Canada, Inc."
Diacomit,Stiripentol,"Dravet Syndrome","List with criteria/condition",Complete,"Oct 30, 2013","Oct 16, 2014",SR0360-000,Biocodex
Dificid,fidaxomicin,"Clostridium difficile infection",N/A,Withdrawn,"Jan 29, 2024",,SF0847-000,"Merck Canada Inc."
Dificid,Fidaxomicin,"Clostridium difficile infection","Do not list at the submitted price",Complete,"Jul 10, 2012","Dec 19, 2012",SR0285-000,"Optimer Pharmaceuticals Canada, Inc."
Dojolvi,triheptanoin,"Long-chain fatty acid oxidation disorders","Reimburse with clinical criteria and/or conditions",Complete,"Mar 31, 2021","Jan 21, 2022",SR0684-000,"Ultragenyx Canada Inc"
Doptelet,avatrombopag,"Chronic immune thrombocytopenia (ITP)","Do not reimburse",Complete,"Feb 3, 2022","May 8, 2024",SR0721-000,"Sobi Canada, Inc."
Dovato,"dolutegravir / lamivudine","HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Feb 21, 2019","Sep 30, 2019",SR0601-000,"ViiV Healthcare"
"Duaklir Genuair","Aclidinium bromide/formoterol fumarate dihydrate","Chronic obstructive pulmonary disease","List with clinical criteria and/or conditions",Complete,"Apr 1, 2015","Sep 18, 2015",SR0423-000,"AstraZeneca Canada Inc."
Duobrii,"Halobetasol propionate and tazarotene","Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Jan 24, 2020","Oct 28, 2020",SR0638-000,"Bausch Health, Canada Inc."
Duodopa,"Levodopa / carbidopa (Drug Plan Submission)","Parkinson's disease","Reimburse with clinical criteria and/or conditions",Complete,"Feb 8, 2018","Aug 22, 2018",SR0557-000,"AbbVie Corporation"
Duodopa,"Levodopa / carbidopa","Parkinson's disease","Do not list",Complete,"Dec 19, 2008","Jul 22, 2009",SR0154-000,"Solvay Pharma Inc."
DuoTrav,"Travoprost and timolol maleate",Glaucoma,"List with clinical criteria and/or conditions",Complete,"Mar 24, 2006","Aug 24, 2006",SR0057-000,"Alcon Canada Inc."
Dupixent,dupilumab,"atopic dermatitis","Do not reimburse",Complete,"Oct 27, 2017","Jun 27, 2018",SR0533-000,Sanofi-Genzyme
Dupixent,dupilumab,"atopic dermatitis","Reimburse with clinical criteria and/or conditions",Complete,"Jul 15, 2022","Jan 18, 2023",SF0754-000,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc."
Dupixent,Dupilumab,"Chronic  obstructive pulmonary disease (COPD)",,Active,"Dec 11, 2024",,SR0870-000,"sanofi-aventis Canada Inc."
Dupixent,dupilumab,Asthma,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 28, 2022","Jan 20, 2023",SR0745-000,"Sanofi-aventis Canada Inc."
Dupixent,dupilumab,"Prurigo nodularis (PN)",,Active,"Dec 20, 2024",,SR0876-000,"sanofi-aventis Canada Inc."
Dupixent,dupilumab,Asthma,"Reimburse with clinical criteria and/or conditions",Complete,"Nov 26, 2020","Jun 8, 2021",SR0667-000,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc."
Dupixent,dupilumab,"Atopic dermatitis, pediatrics","Reimburse with clinical criteria and/or conditions",Complete,"Mar 29, 2023","Oct 13, 2023",SR0774-000,"Sanofi-aventis Canada Inc."
Dupixent,dupilumab,"Chronic rhinosinusitis with nasal polyps",,Active,"Dec 18, 2024",,SR0878-000,"sanofi-aventis Canada Inc."
Dupixent,dupilumab,"atopic dermatitis","Reimburse with clinical criteria and/or conditions",Complete,"Oct 22, 2019","Apr 22, 2020",SR0636-000,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc."
Dymista,"Azelastine  HCl and fluticasone propionate","Seasonal allergic rhinitis","Do not list",Complete,"Dec 9, 2014","Jun 17, 2015",SR0408-000,"Meda Pharmaceuticals Ltd."
"Dysport Therapeutic",abobotulinumtoxinA,"Cervical dystonia","Reimburse with clinical criteria and/or conditions",Complete,"Jan 31, 2017","Jul 26, 2017",SR0512-000,"IPSEN Biopharmaceuticals Canada, Inc."
"Dysport Therapeutic",abobotulinumtoxinA,"lower limb spasticity","Reimburse with clinical criteria and/or conditions",Complete,"Feb 7, 2018","Aug 23, 2018",SR0556-000,"Ipsen Biopharmaceuticals Canada Inc."
"Dysport Therapeutic",abobotulinumtoxinA,"Upper limb spasticity","Reimburse with clinical criteria and/or conditions",Complete,"Apr 24, 2017","Oct 24, 2017",SR0517-000,"IPSEN Biopharmaceuticals Canada, Inc."
Ebglyss,lebrikizumab,"atopic dermatitis","Do not reimburse",Complete,"Nov 1, 2023","Oct 9, 2024",SR0819-000,"Eli Lilly Canada, Inc."
Ebixa,"Memantine hydrochloride","Dementia (Alzheimer type), moderate to severe","Do not list",Complete,"Dec 21, 2004","Nov 23, 2005",SR0025-000,"Lundbeck Canada Inc."
Edarbi,"Azilsartan medoxomil",Hypertension,"Do not list at the submitted price",Complete,"Mar 8, 2013","Oct 17, 2013",SR0317-000,"Takeda Canada Inc."
Edarbyclor,"Azilsartan medoxomil + chlorthalidone",Hypertension,"Do not list",Complete,"Mar 8, 2013","Oct 17, 2013",SR0318-000,"Takeda Canada Inc."
Edurant,Rilpivirine,"HIV infection",List,Complete,"Jul 29, 2011","Feb 15, 2012",SR0243-000,"Janssen Inc."
Effient,Prasugrel,"Acute coronary syndrome","Do not list",Complete,"Dec 12, 2011","Jun 14, 2012",SR0263-000,"Eli Lily Canada Inc."
Effient,"Prasugrel hydrochloride","Acute Coronary Syndrome","Do not list",Complete,"May 5, 2010","Feb 16, 2011",SR0200-000,"Eli Lilly Canada Inc."
Egrifta,Tesamorelin,"Lipodystrophy, HIV-infected patients","Do not reimburse",Complete,"Mar 2, 2016","Aug 24, 2016",SR0477-000,"Theratechnologies Inc."
Elaprase,Idursulfase,"Mucopolysarccharidosis II (MPS II), Hunter Syndrome","Do not list",Complete,"Jul 13, 2007","Dec 19, 2007",SR0104-000,"Shire Human Genetic Therapies, Inc."
Elelyso,"Taliglucerase alfa","Gaucher disease","Do not list",Complete,"Aug 15, 2014","Oct 28, 2015",SR0390-000,"Pfizer Canada Inc."
Eliquis,Apixaban,"Venous thromboembolic events, prevention","List with clinical criteria and/or conditions",Complete,"Dec 20, 2011","Jun 14, 2012",SR0264-000,"Bristol-Myers Squibb and Pfizer Canada Alliance"
Eliquis,Apixaban,"Venous thromboembolic events, treatment and prevention of recurrence","List with clinical criteria and/or conditions",Complete,"Sep 18, 2014","May 7, 2015",SR0397-000,"Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance"
Eliquis,Apixaban,"Thromboembolic events prevention, (atrial fibrillation)","List with clinical criteria and/or conditions",Complete,"Sep 25, 2012","Mar 20, 2013",SR0288-000,"Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance"
Elrexfio,elranatamab,"Relapsed or refractory multiple myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Nov 9, 2023","May 31, 2024",PC0315-000,"Pfizer Canada ULC"
Emend,Aprepitant,"Nausea and Vomiting, Chemotherapy induced","List with clinical criteria and/or conditions",Complete,"Aug 29, 2007","Feb 20, 2008",SR0109-000,"Merck Frosst Canada Ltd."
Emgality,galcanezumab,"Episodic cluster headache","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0019-000,"Eli Lilly Canada Inc."
Emgality,galcanezumab,"Prevention of migraine","Reimburse with clinical criteria and/or conditions",Complete,"Jun 3, 2021","Dec 15, 2021",SR0693-000,"Eli Lilly Canada Inc. (Lilly)"
Empaveli,pegcetacoplan,"Paroxysmal nocturnal hemoglobinuria","Reimburse with clinical criteria and/or conditions",Complete,"Aug 26, 2022","Mar 20, 2023",SR0748-000,"SOBI Canada Inc."
Enablex,"Darifenacin hydrobromide","Bladder, overactive","List with clinical criteria and/or conditions",Complete,"Oct 1, 2008","Apr 16, 2009",SR0147-000,"Novartis Pharmaceuticals Canada Inc."
Enablex,"Darifenacin hydrobromide","Bladder, overactive","Do not list",Complete,"Apr 26, 2006","Oct 19, 2006",SR0061-000,"Novartis Pharmaceuticals Canada Inc."
"Enerzair Breezhaler","indacaterol  glycopyrronium  mometasone furoate","Asthma maintenance, adults","Reimburse with clinical criteria and/or conditions",Complete,"May 19, 2020","Nov 24, 2020",SR0645-000,"Novartis Pharmaceuticals Canada Inc."
Enhertu,"trastuzumab deruxtecan","Gastric or gastroesophageal junction (GEJ) adenocarcinoma","Time-limited reimbursement recommendation",Active,"Sep 16, 2024","Apr 3, 2025",PC0367-000,"AstraZeneca Canada Inc."
Enhertu,"trastuzumab deruxtecan","Metastatic HER2 positive breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 23, 2022","Sep 28, 2022",PC0285-000,"AstraZeneca Canada Inc."
Enhertu,"trastuzumab deruxtecan","unresectable or metastatic HER2-low breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Dec 13, 2022","Jun 29, 2023",PC0305-000,"AstraZeneca Canada Inc."
Enhertu,"trastuzumab deruxtecan","HER2-low or HER2-ultralow breast cancer",,Received,"May 15, 2025",,PC0401-000,"AstraZeneca Canada Inc."
Enhertu,"trastuzumab deruxtecan","Metastatic HER2-positive breast cancer","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0035-000,"AstraZeneca Canada Inc."
Enspryng,satralizumab,"Neuromyelitis optica spectrum disorder","Reimburse with clinical criteria and/or conditions",Complete,"Oct 22, 2020","Apr 21, 2021",SR0663-000,"Hoffmann-La Roche Limited"
Entresto,Sacubitril/valsartan,"Heart failure, NYHA class II or III","List with clinical criteria and/or conditions",Complete,"Sep 18, 2015","Mar 18, 2016",SR0447-000,"Novartis Pharmaceuticals Canada Inc."
Entresto,sacubitril/valsartan,"Heart failure, NYHA Class II or III","Reimburse with clinical criteria and/or conditions",Complete,"May 22, 2020","Mar 24, 2021",SR0644-000,"Novartis Pharma Inc."
"Entuzity KwikPen","human insulin","Diabetes mellitus","Reimburse with clinical criteria and/or conditions",Complete,"Jan 27, 2021","Aug 23, 2021",SR0672-000,"Eli Lilly Canada Inc."
Entyvio,Vedolizumab,"Crohn's disease","Reimburse with clinical criteria and/or conditions",Complete,"Apr 27, 2016","Oct 31, 2016",SR0487-000,"Takeda Canada Inc."
Entyvio,vedolizumab,"Crohn’s disease","Reimburse with clinical criteria and/or conditions",Complete,"Jul 23, 2020","Jan 21, 2021",SR0647-000,"Takeda Canada Inc."
Entyvio,vedolizumab,"Ulcerative Colitis","Reimburse with clinical criteria and/or conditions",Complete,"Nov 21, 2019","May 19, 2020",SR0635-000,"Takeda Canada Inc."
Entyvio,Vedolizumab,"Ulcerative colitis","List with clinical criteria and/or conditions",Complete,"Feb 20, 2015","Oct 28, 2015",SR0421-000,"Takeda Canada Inc."
Epclusa,"sofosbuvir / velpatasvir","Hepatitis C, chronic","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0024-000,"Gilead Sciences Canada, Inc."
Epclusa,"Sofosbuvir/ velpatasvir","Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Apr 22, 2016","Oct 26, 2016",SR0486-000,"Gilead Sciences Canada, Inc."
Epidiolex,cannabidiol,"Lennox-Gastaut Syndrome (LGS)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 20, 2023","Apr 18, 2024",SR0800-000,"Jazz Pharmaceuticals Canada, Inc."
Epidiolex,cannabidiol,"Seizures associated with Tuberous Sclerosis Complex (TSC)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 29, 2023","Apr 18, 2024",SR0798-000,"Jazz Pharmaceuticals Canada, Inc."
Epidiolex,cannabidiol,"Dravet Syndrome (DS)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 25, 2023","Apr 18, 2024",SR0799-000,"Jazz Pharmaceuticals Canada, Inc."
Epkinly,epcoritamab,"Relapsed or refractory diffuse large B-cell lymphoma","Time-limited reimbursement recommendation",Complete,"Nov 14, 2023","May 31, 2024",PC0334-000,"AbbVie Corporation"
Erelzi,Etanercept,"Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis","Reimburse with clinical criteria and/or conditions",Complete,"Feb 2, 2017","Jul 25, 2017",SE0513-000,"Sandoz Canada Inc."
Esbriet,Pirfenidone,"Idiopathic pulmonary fibrosis","Do not list",Complete,"Oct 5, 2012","Apr 18, 2013",SR0292-000,"InterMune Canada Inc."
Esbriet,Pirfenidone,"Idiopathic pulmonary fibrosis","List with criteria/condition",Complete,"Aug 29, 2014","Apr 15, 2015",SR0393-000,"Hoffmann-La Roche Ltd."
Eucrisa,crisaborole,"atopic dermatitis","Do not reimburse",Complete,"May 25, 2018","Mar 27, 2019",SR0570-000,"Pfizer Canada Inc."
Evenity,romosozumab,"Osteoporosis, postmenopausal women","Reimburse with clinical criteria and/or conditions",Complete,"Feb 1, 2021","Nov 11, 2021",SR0676-000,"Amgen Canada Inc."
Evkeeza,evinacumab,"Homozygous familial hypercholesterolemia (HoFH)","Reimburse with clinical criteria and/or conditions",Complete,"May 10, 2023","Jan 12, 2024",SR0778-000,"Ultragenyx Pharmaceutical Inc."
Evra,"Norgelestromin/ethinyl estradiol","Contraceptive, patch","Do not list",Complete,"Dec 19, 2003","Jun 23, 2004",SR0004-000,"Janssen-Ortho Inc."
Evrysdi,risdiplam,"Spinal muscular atrophy","Reimburse with clinical criteria and/or conditions",Complete,"Nov 19, 2020","Aug 26, 2021",SR0661-000,"Hoffmann La-Roche Ltd."
"Exelon Patch",Rivastigmine,"Dementia (Alzheimer's type)","Do not list",Complete,"Dec 21, 2007","Jul 23, 2008",SR0123-000,"Novartis Pharmaceuticals Canada Inc."
Exjade,Deferasirox,"Iron overload","List with clinical criteria and/or conditions",Complete,"Oct 26, 2006","Apr 19, 2007",SR0081-000,"Novartis Pharmaceuticals Canada Inc."
Eylea,Aflibercept,"Macular edema, diabetic","List with clinical criteria and/or conditions",Complete,"Sep 16, 2014","May 7, 2015",SR0396-000,"Bayer Inc."
Eylea,Aflibercept,"Macular edema, central retinal vein occlusion","List with clinical criteria and/or conditions",Complete,"Oct 17, 2014","May 7, 2015",SR0401-000,"Bayer Inc."
Eylea,Aflibercept,"Macular edema, branch retinal vein occlusion","Reimburse with clinical criteria and/or conditions",Complete,"Dec 14, 2015","Jul 27, 2016",SR0460-000,"Bayer Inc."
Eylea,Aflibercept,"Macular degeneration, age-related","List with criteria/condition",Complete,"Nov 18, 2013","Oct 20, 2014",SR0361-000,"Bayer Canada Inc."
"Eylea HD","aflibercept 8mg/0.07mL","diabetic macular edema","Reimburse with clinical criteria and/or conditions",Complete,"Aug 18, 2023","Jun 5, 2024",SR0813-000,"Bayer Inc."
"Eylea HD","aflibercept 8mg/0.07mL","macular degeneration, age related","Reimburse with clinical criteria and/or conditions",Complete,"Aug 18, 2023","Jun 5, 2024",SR0812-000,"Bayer Inc."
Fabhalta,iptacopan,"paroxysmal nocturnal hemoglobinuria (PNH)","Reimburse with clinical criteria and/or conditions",Active,"Aug 15, 2024","Mar 12, 2025",SR0851-000,"Novartis Pharmaceuticals Canada Inc."
Fabrazyme,"Agalsidase beta","Fabry Disease","Do not list",Complete,"Dec 10, 2004","May 18, 2005",SR0028-000,"Genzyme Canada"
Fabrazyme,"Agalsidase beta","Fabry Disease","Do not list",Complete,"Feb 24, 2004","Nov 24, 2004",SR0007-000,"Genzyme Canada"
Fampyra,Fampridine,"Multiple sclerosis, improve walking disability",,Withdrawn,"Nov 6, 2014",,SR0404-000,"Biogen Idec Canada Inc."
Fampyra,Fampridine,"Multiple sclerosis, improve walking disability","Do not list",Complete,"Apr 16, 2012","Nov 28, 2012",SR0275-000,"Biogen Idec Canada Inc."
Fasenra,benralizumab,"Asthma, severe eosinophilic","Reimburse with clinical criteria and/or conditions",Complete,"Oct 24, 2018","Mar 27, 2019",SF0592-000,"AstraZeneca Canada Inc."
Fasenra,benralizumab,"Asthma, severe eosinophilic","Reimburse with clinical criteria and/or conditions",Complete,"Feb 23, 2018","Aug 21, 2018",SR0561-000,"AstraZeneca Canada Inc."
Fentora,"Fentanyl buccal","Pain (breakthrough), cancer (adults)","Do not reimburse",Complete,"Jul 12, 2016","Feb 21, 2017",SR0494-000,"Teva Canada Innovation"
Ferinject,"ferric carboxymaltose","Iron deficiency in adult patients with heart failure","Reimburse with clinical criteria and/or conditions",Active,"Mar 1, 2024","Apr 16, 2025",SR0852-000,"CSL Vifor"
Ferinject,"ferric carboxymaltose","Iron deficiency anemia","Reimburse with clinical criteria and/or conditions",Complete,"May 10, 2024","Dec 11, 2024",SR0842-000,"CSL Vifor"
Ferriprox,Deferiprone,"Transfusional iron overload","List with clinical criteria and/or conditions",Complete,"Sep 24, 2015","Mar 18, 2016",SR0448-000,"ApoPharma Inc."
Ferriprox,deferiprone,"Transfusional iron overload","Reimburse with clinical criteria and/or conditions",Complete,"Jun 8, 2022","Jan 19, 2023",SR0741-000,"Chiesi Canada Corp."
Fibristal,"ulipristal acetate","Uterine fibroids (signs and symptoms)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 28, 2019","Jul 24, 2019",SF0609-000,"Allergan Inc."
Fibristal,"ulipristal acetate","Uterine fibroids (signs and symptoms)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 21, 2017","Nov 22, 2017",SF0528-000,"Allergan Canada Inc."
Fibristal,"Ulipristal acetate","Uterine fibroids","List with criteria/condition",Complete,"Apr 17, 2013","Nov 15, 2013",SR0326-000,"Actavis Specialty Pharmaceuticals Co."
Finacea,"Azelaic acid",Rosacea,List,Complete,"Aug 31, 2010","Feb 16, 2011",SR0209-000,"Bayer Inc."
Firazyr,Icatibant,"Hereditary angioedema","List with clinical criteria and/or conditions",Complete,"Mar 4, 2014","Dec 19, 2014",SR0375-000,"Shire Human Genetic Therapies (Canada) Inc."
Firazyr,icatibant,"Acute attacks of hereditary angioedema","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0014-000,"Takeda Canada Inc."
Firdapse,"amifampridine phosphate","Lambert-Eaton Myasthenic Syndrome, adults","Reimburse with clinical criteria and/or conditions",Complete,"Nov 15, 2021","Jun 16, 2022",SR0664-000,"KYE Pharmaceuticals Inc."
Forteo,"Teriparatide (rDNA origin) injection","Osteoporosis, glucocorticoid induced","Do not list",Complete,"Dec 18, 2008","Jul 22, 2009",SR0152-000,"Eli Lilly Canada Inc."
Forteo,"Teriparatide (rDNA origin) injection",Osteoporosis,,Withdrawn,"May 29, 2006",,SR0065-000,"Eli Lilly Canada Inc."
Forteo,"Teriparatide (rDNA origin) injection",Osteoporosis,,Withdrawn,"Dec 18, 2008",,SR0157-000,"Eli Lilly Canada Inc."
Forteo,"Teriparatide (rDNA origin) injection",Osteoporosis,"Do not list",Complete,"Jun 8, 2004","Dec 22, 2004",SR0015-000,"Eli Lilly Canada Inc."
Forteo,"Teriparatide (rDNA origin) injection",Osteoporosis,,Withdrawn,"Jun 12, 2009",,SR0169-000,"Eli Lilly Canada Inc."
Forteo,"Teriparatide (rDNA origin) injection","Osteoporosis (in women), Severe","Do not list",Complete,"Oct 23, 2009","Mar 17, 2010",SR0180-000,"Eli Lilly Canada Inc."
Forxiga,dapagliflozin,"Heart failure with reduced ejection fraction","Reimburse with clinical criteria and/or conditions",Complete,"Mar 31, 2020","Dec 23, 2020",SR0642-000,"AstraZeneca Canada Inc."
Forxiga,dapagliflozin,"Chronic kidney disease","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0021-000,"AstraZeneca Canada Inc."
Forxiga,Dapagliflozin,"Diabetes mellitus, type 2","Do not list",Complete,"Sep 4, 2015","Apr 27, 2016",SR0445-000,"AstraZeneca Canada Inc."
Forxiga,Dapagliflozin,"Diabetes mellitus, type 2","List with clinical criteria and/or conditions",Complete,"Apr 30, 2015","Nov 20, 2015",SR0428-000,"AstraZeneca Canada Inc."
Fosavance,"Alendronate sodium/cholecalciferol",Osteoporosis,"Do not list",Complete,"Mar 27, 2006","Sep 27, 2006",SR0059-000,"Merck Frosst Canda Ltd."
"Fosavance 70/5600","Alendronate sodium / cholecalciferol",Osteoporosis,"List in a similar manner to other drugs in class",Complete,"Dec 18, 2008","Jun 17, 2009",SR0153-000,"Merck Frosst Canda Ltd."
Fosrenol,"Lanthanum carbonate hydrate","Hyperphosphatemia, end-stage renal disease","Do not list",Complete,"Jun 28, 2007","Jan 30, 2008",SR0100-000,"Shire BioChem Inc."
Fruzaqla,fruquintinib,"Metastatic colorectal cancer (mCRC)","Reimburse with clinical criteria and/or conditions",Complete,"May 22, 2024","Nov 27, 2024",PC0352-000,"Takeda Canada Inc."
Fulphila,pegfilgrastim,"Febrile neutropenia in non-myeloid malignancies",N/A,Complete,"Nov 14, 2018",,SE0588-000,"BGP PHARMA ULC"
Fycompa,Perampanel,"Epilepsy, partial onset seizures","List with criteria/condition",Complete,"Mar 8, 2013","Oct 17, 2013",SR0316-000,"Eisai Ltd."
Fycompa,Perampanel,"Epilepsy, primary generalized tonic-clonic seizures","Reimburse with clinical criteria and/or conditions",Complete,"Nov 24, 2015","May 18, 2016",SR0458-000,"Eisai Limited"
Galafold,migalastat,"Fabry Disease","Reimburse with clinical criteria and/or conditions",Complete,"Jun 9, 2017","Jan 24, 2018",SR0522-000,"Amicus Therapeutics"
Galexos,Simeprevir,"Hepatitis C, chronic","List with criteria/condition",Complete,"Aug 22, 2013","Jun 18, 2014",SR0347-000,"Janssen Inc."
Gavreto,pralsetinib,"RET fusion-positive non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 9, 2022","Sep 29, 2022",PC0283-000,"Hoffmann-La Roche Ltd."
Gelnique,"Oxybutynin Chloride Gel","Overactive bladder","Do not list",Complete,"Oct 25, 2011","May 24, 2012",SR0260-000,"Watson Pharma Company"
Genotropin,Somatropin,"Growth hormone deficiency, adult","List with criteria/condition",Complete,"May 27, 2013","Dec 20, 2013",SR0332-000,"Pfizer Canada Inc."
Genotropin,Somatropin,"Growth hormone deficiency, children","List with criteria/condition",Complete,"May 27, 2013","Dec 20, 2013",SR0333-000,"Pfizer Canada Inc."
Genotropin,Somatropin,"Turner Syndrome","List with criteria/condition",Complete,"May 27, 2013","Dec 20, 2013",SR0334-000,"Pfizer Canada Inc."
Genvoya,"Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide","HIV infection",List,Complete,"Sep 24, 2015","Mar 18, 2016",SR0449-000,"Gilead Sciences Canada, Inc."
Gilenya,Fingolimod,"Multiple Sclerosis, relapsing-remitting","List with clinical criteria and/or conditions",Complete,"May 10, 2011","Nov 16, 2011",SR0228-000,"Novartis Pharmaceuticals Canada Inc."
Givlaari,givosiran,"Acute hepatic porphyria (AHP) in adults","Reimburse with clinical criteria and/or conditions",Complete,"Feb 23, 2021","Sep 8, 2021",SR0679-000,"Alnylam Netherlands B.V."
Glatect,"Glatiramer acetate","Relapsing Remitting Multiple Sclerosis (RRMS)","Reimburse with clinical criteria and/or conditions",Complete,"Jan 20, 2017","Jul 25, 2017",SE0510-000,Pendopharm
Grastek,"Phleum pratense","Allergic rhinitis","Do not list",Complete,"Sep 30, 2013","Sep 24, 2014",SR0352-000,"Merck Canada Inc."
Grastofil,Filgrastim,Neutropenia,"List with clinical criteria and/or conditions",Complete,"Sep 11, 2015","Mar 18, 2016",SE0446-000,"Apotex Inc."
Gynazole.1,"Butoconazole nitrate","Vaginal infection","Do not list",Complete,"Jun 30, 2004","Jan 26, 2005",SR0017-000,"Ferring Pharmaceuticals"
Harvoni,"Ledipasvir / Sofosbuvir","Hepatitis C, chronic","List with criteria/condition",Complete,"Sep 15, 2014","Mar 18, 2015",SR0395-000,"Gilead Sciences Canada Inc."
Harvoni,"ledipasvir, sofosbuvir","Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Jan 6, 2016","May 18, 2016",SF0465-000,"Gilead Sciences Canada Inc."
Hemangiol,"Propranolol oral solution","Infantile hemangioma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 25, 2016","Feb 21, 2017",SR0496-000,"Pierre Fabre Dermo-Cosmétique"
Hemangiol,Propranolol,"Infantile hemangioma",,Withdrawn,"Dec 23, 2014",,SR0411-000,"Pierre Fabre Dermo-Cosmétique Canada Inc."
Hemgenix,"etranacogene dezaparvovec","Hemophilia B","Reimburse with clinical criteria and/or conditions",Complete,"Oct 4, 2023","Apr 19, 2024",SG0805-000,"CSL Behring Canada Inc."
Hemlibra,emicizumab,"Bleeding prevention, hemophilia A","Reimburse with clinical criteria and/or conditions",Complete,"Jun 30, 2020","Dec 21, 2020",ST0651-000,"Hoffmann-La Roche Ltd."
Hepcludex,bulevirtide,"chronic hepatitis delta virus (HDV) infection",,Active,"Apr 9, 2025",,SR0881-000,"Gilead Sciences Canada, Inc."
Hepsera,"Adefovir dipivoxil","Hepatitis B","List with clinical criteria and/or conditions",Complete,"Jun 29, 2007","Oct 18, 2007",SF0103-000,"gilead Sciences Canada Inc."
Hepsera,"Adefovir dipivoxil","Hepatitis B","Do not list",Complete,"Apr 24, 2006","Nov 29, 2006",SR0060-000,"Gilead Sciences Canada Inc."
"Holkira Pak","ombitasvir/paritaprevir/ritonavir and dasabuvir","Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Jan 6, 2016","May 19, 2016",SF0466-000,"AbbVie Corporation"
"Holkira Pak","Ombitasvir/paritaprevir/ritonavir and dasabuvir","Hepatitis C, chronic","List with clinical criteria and/or conditions",Complete,"Dec 3, 2014","Jun 18, 2015",SR0406-000,"AbbVie Corporation"
Humira,Adalimumab,"Ulcerative colitis","Do not list at the submitted price",Complete,"Sep 25, 2015","Apr 15, 2016",SR0450-000,"AbbVie Corporation"
Humira,Adalimumab,"Arthritis, Psoriatic","List with clinical criteria and/or conditions",Complete,"Jun 21, 2006","Nov 29, 2006",SR0066-000,"Abbott Laboratories Limited"
Humira,Adalimumab,"ulcerative colitis",,Withdrawn,"Dec 23, 2013",,SR0365-000,AbbVie
Humira,Adalimumab,"Arthritis, juvenile idiopathic","List with clinical criteria and/or conditions",Complete,"Feb 4, 2013","Jul 18, 2013",SR0308-000,"AbbVie Corporation"
Humira,Adalimumab,"Crohn's disease","List with clinical criteria and/or conditions",Complete,"Jul 12, 2007","Dec 19, 2007",SR0105-000,"Abbott Laboratories, Limited"
Humira,Adalimumab,Psoriasis,"List with clinical criteria and/or conditions",Complete,"Apr 15, 2008","Oct 16, 2008",SR0130-000,"Abbott Laboratories, Limited"
Humira,Adalimumab,"Ankylosing spondylitis (AS)","List with clinical criteria and/or conditions",Complete,"Nov 17, 2006","Jun 27, 2007",SR0087-000,"Abbott Laboratories, Limited"
Humira,Adalimumab,"Arthritis, Rheumatoid","List with clinical criteria and/or conditions",Complete,"Sep 24, 2004","Feb 11, 2005",SR0022-000,"Abbott Laboratories Limited"
Humira,Adalimumab,"Hidradenitis suppurativa","Reimburse with clinical criteria and/or conditions",Complete,"Nov 3, 2015","May 19, 2016",SR0455-000,"AbbVie Corporation"
HyQvia,"immune globulin human and recombinant human hyaluronidase","Humoral immunodeficiency","Reimburse with clinical criteria and/or conditions",Complete,"Jun 24, 2021","Jun 15, 2022",ST0695-000,"Takeda Canada Inc."
Ikervis,cyclosporine,"keratitis, severe",,Withdrawn,"May 15, 2017",,SR0518-000,"Santen Canada Incorporated"
Ilaris,Canakinumab,"Cryopyrin-Associated Periodic Syndrome","Do not list",Complete,"Jul 7, 2010","Jan 26, 2011",SR0204-000,"Novartis Pharmaceuticals Canada Inc."
Ilaris,Canakinumab,"Systemic Juvenile Idiopathic Arthritis","Reimburse with clinical criteria and/or conditions",Complete,"Dec 23, 2015","Jun 17, 2016",SR0463-000,"Novartis Pharmaceuticals Inc."
Ilumya,tildrakizumab,"Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Jul 15, 2019","Jun 21, 2021",SR0624-000,"Sun Pharma Canada"
Iluvien,"fluocinolone acetonide","Diabetic macular edema (DME)",,Withdrawn,"Dec 21, 2017",,SR0549-000,"Knight Therapeutics Inc."
Iluvien,"fluocinolone acetonide intravitreal implant","diabetic macular edema","Do not reimburse",Complete,"Apr 3, 2019","Sep 26, 2019",SR0608-000,"Knight Therapeutics Inc."
Imbruvica,ibrutinib,Leukemia,"Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0005-000,"Janssen Canada Inc."
Imbruvica,ibrutinib,"Chronic lymphocytic leukemia (CLL)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 21, 2023","Nov 2, 2023",PC0317-000,"Janssen Inc."
Imbruvica,ibrutinib,"Chronic graft versus host disease","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0009-000,"Janssen Canada Inc."
Imbruvica,ibrutinib,"Waldenström’s Macroglobulinemia","Reimburse with clinical criteria and/or conditions",Complete,"Jun 20, 2023","Jan 5, 2024",PC0328-000,"Janssen Inc."
Imbruvica,ibrutinib,Leukemia,"Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0004-000,"Janssen Canada Inc."
Imcivree,setmelanotide,"Bardet-Biedl syndrome","Reimburse with clinical criteria and/or conditions",Complete,"Mar 7, 2023","Oct 16, 2023",SR0769-000,"Rhythm Pharmaceuticals, Inc."
Imcivree,setmelanotide,"Weight management for pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0041-000,"Rhythm Pharmaceuticals, Inc."
Imdelltra,tarlatamab,"Extensive stage small cell lung cancer","Reimburse with clinical criteria and/or conditions",Active,"Aug 14, 2024","Feb 28, 2025",PC0351-000,"Amgen Canada Inc."
Imfinzi,durvalumab,"limited-stage small cell lung cancer (LS-SCLC)",,Active,"Nov 15, 2024",,PC0389-000,"AstraZeneca Canada Inc."
Imfinzi,durvalumab,"resectable non-small cell lung cancer (NSCLC)",,Active,"Aug 13, 2024",,PC0372-000,"AstraZeneca Canada Inc."
Imfinzi,durvalumab,"Muscle invasive bladder cancer",,Pending,,,PC0414-000,"AstraZeneca Canada"
Imfinzi,"durvalumab, carboplatin, paclitaxel","Endometrial cancer that is mismatch repair deficient (dMMR)","Reimburse with clinical criteria and/or conditions",Active,"Oct 16, 2024","May 5, 2025",PC0366-000,"AstraZeneca Canada Inc."
Imfinzi,durvalumab,"Extensive-stage small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Dec 1, 2020","Jul 27, 2021",PC0234-000,"AstraZeneca Canada Inc."
Imfinzi,durvalumab,"Biliary tract cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jul 14, 2022","Feb 3, 2023",PC0296-000,"AstraZeneca Canada Inc."
"Imfinzi and Imjudo","durvalumab and tremelimumab","unresectable hepatocellular carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 15, 2022","Nov 3, 2023",PC0308-000,"AstraZeneca Canada Inc."
"Imfinzi, Imjudo","durvalumab, tremelimumab","Metastatic non-small cell lung cancer (NSCLC)",,Active,"Oct 17, 2024",,PC0390-000,"AstraZeneca Canada Inc."
"Imfinzi, Lynparza","durvalumab, olaparib, carboplatin, paclitaxel","Endometrial cancer that is mismatch repair proficient (pMMR)",,Withdrawn,"Oct 16, 2024",,PC0366-001,"AstraZeneca Canada Inc."
Imvexxy,estradiol,Dyspareunia,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 23, 2021","Jan 20, 2022",SR0694-000,"Knight Therapeutics Inc."
Incivek,Telaprevir,"Hepatitis C, chronic","List with clinical criteria and/or conditions",Complete,"Aug 23, 2011","Feb 15, 2012",SR0249-000,"Vertex Pharmaceuticals Inc."
Incivek,Telaprevir,"Hepatitis C, chronic","List with criteria/condition",Complete,"Feb 19, 2013","Jun 13, 2013",SF0311-000,"Vertex Pharmaceuticals Canada Inc."
Incivek,Telaprevir,"Hepatitis C, chronic","List with criteria/condition",Complete,"Dec 21, 2012","Jun 13, 2013",SF0305-000,"Vertex Pharmaceuticals Canada Inc."
Increlex,mecasermin,"Severe primary insulin-like growth factor-1 deficiency","Reimburse with clinical criteria and/or conditions",Complete,"Jun 14, 2021","Jan 21, 2022",SR0692-000,"Ipsen Biopharmaceuticals Canada, Inc."
"Incruse Ellipta",Umeclidinium,"Chronic obstructive pulmonary disease","List with criteria/condition",Complete,"Mar 4, 2015","Sep 18, 2015",SR0422-000,"GlaxoSmithKline Inc."
Inflectra,Infliximab,"Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis","List with criteria/condition",Complete,"Jun 17, 2014","Dec 19, 2014",SE0384-000,"Hospira Healthcare Corporation"
"Inflectra (Subsequent Entry Biologic)",Infliximab,"Crohn’s disease and Ulcerative Colitis","Reimburse with clinical criteria and/or conditions",Complete,"Apr 12, 2016","Oct 25, 2016",SE0483-000,"Hospira HealthCare Corporation, a Pfizer Company"
Inrebic,fedratinib,Myelofibrosis,"Reimburse with clinical criteria and/or conditions",Complete,"Nov 5, 2020","Jun 21, 2021",PC0205-000,"Celgene Inc., a Bristol Myers Squibb Company"
"Inspiolto Respimat","Tiotropium / olodaterol","Chronic obstructive pulmonary disease","List with criteria/condition",Complete,"Jun 4, 2015","Dec 17, 2015",SR0436-000,"Boehringer Ingelheim (Canada) Ltd."
Inspra,Eplerenone,"Post myocardial infarction","Do not list",Complete,"May 6, 2009","Nov 25, 2009",SR0165-000,"Pfizer Canada Inc."
Inspra,Eplerenone,"Heart failure, NYHA class II","Do not list at the submitted price",Complete,"Jul 12, 2013","Apr 24, 2014",SR0342-000,"Pfizer Canada Inc."
Intelence,Etravirine,HIV,"List with clinical criteria and/or conditions",Complete,"Apr 2, 2008","Aug 14, 2008",SR0129-000,"Janssen-Ortho Inc."
Intrarosa,prasterone,"Postmenopausal vulvovaginal atrophy","Reimburse with clinical criteria and/or conditions",Complete,"Oct 1, 2021","Apr 14, 2022",SR0707-000,"Lupin Pharma Canada Ltd."
"Intuniv XR","Guanfacine hydrochloride","Attention-deficit/hyperactivity disorder (ADHD)","Do not list",Complete,"Aug 27, 2013","Sep 24, 2014",SR0349-000,"Shire Canada Inc."
Invega,Paliperidone,Schizophrenia,"Do not list",Complete,"Nov 1, 2007","May 28, 2008",SR0112-000,"Janssen-Ortho Inc."
"Invega Sustenna","Paliperidone palmitate",Schizophrenia,"Do not list",Complete,"Jul 9, 2010","Apr 25, 2011",SR0206-000,"Janssen-Ortho Inc."
Invokamet,"Canagliflozin and metformin hydrochloride","diabetes mellitus, type 2","Reimburse with clinical criteria and/or conditions",Complete,"Mar 3, 2016","Aug 25, 2016",SR0480-000,"Janssen Inc."
Invokana,Canagliflozin,"Diabetes mellitus, type 2","List with criteria/condition",Complete,"Feb 24, 2014","Jan 15, 2015",SR0370-000,"Janssen Inc."
Invokana,Canagliflozin,"Diabetes Mellitus, Type 2",,Withdrawn,"Jun 5, 2013",,SR0335-000,"Janssen Inc."
Iqirvo,elafibranor,"Primary biliary cholangitis (PBC)",,Active,"Nov 27, 2024",,SR0865-000,"Ipsen Biopharmaceuticals Canada Inc."
Iressa,Gefitinib,"Cancer, Lung , non-small cell","Do not list",Complete,"Dec 22, 2003","Jun 23, 2004",SR0003-000,AstraZeneca
Isentress,Raltegravir,"HIV (treatment naïve)","Do not list",Complete,"Dec 4, 2009","Jun 23, 2010",SR0191-000,"Merck Frosst Canada Ltd."
Isentress,Raltegravir,HIV,"List with clinical criteria and/or conditions",Complete,"Nov 29, 2007","May 14, 2008",SR0115-000,"Merck Frosst Canada Ltd."
Isturisa,osilodrostat,"Endogenous Cushing’s syndrome",,Suspended,"Oct 16, 2023",,SR0804-000,"Recordati Rare Diseases Canada Inc."
Itovebi,inavolisib,"Advanced or metastatic breast cancer",,Active,"Feb 19, 2025",,PC0382-000,"Hoffmann-La Roche Limited"
Izba,"travoprost ophthalmic solution","Glaucoma and ocular hypertension","Reimburse with clinical criteria and/or conditions",Complete,"Mar 1, 2017","Oct 25, 2017",SR0516-000,"Novartis Pharmaceuticals Canada Inc."
Jakavi,ruxolitinib,"Graft versus host disease","Reimburse with clinical criteria and/or conditions",Complete,"Aug 10, 2021","Jul 15, 2022",SR0706-000,"Novartis Pharmaceuticals Canada Inc."
Jakavi,ruxolitinib,"Graft versus host disease","Reimburse with clinical criteria and/or conditions",Complete,"Aug 10, 2021","Sep 15, 2022",SR0688-000,"Novartis Pharmaceuticals Canada Inc."
Janumet,"Sitagliptin phosphate monohydrate / metformin hydrochloride","Diabetes mellitus (Type 2)","List with clinical criteria and/or conditions",Complete,"Nov 4, 2009","Jun 23, 2010",SR0182-000,"Merck Frosst Canada Ltd."
Januvia,"Sitagliptin phosphate","Diabetes mellitus (Type 2)","List with clinical criteria and/or conditions",Complete,"Oct 29, 2009","Jun 23, 2010",SR0181-000,"Merck Frosst Canada Ltd."
Januvia,"Sitagliptin phosphate","Diabetes mellitus (Type 2)","Do not list",Complete,"Dec 20, 2007","Jun 18, 2008",SR0122-000,"Merck Frosst Canada Ltd."
Jardiance,empagliflozin,"Heart failure","Reimburse with clinical criteria and/or conditions",Complete,"Apr 6, 2022","Oct 14, 2022",SR0726-000,"Boehringer Ingelheim Canada Ltd."
Jardiance,Empagliflozin,"Diabetes mellitus, type 2 with high cardiovascular risk","Reimburse with clinical criteria and/or conditions",Complete,"Apr 27, 2016","Oct 26, 2016",SR0488-000,"Boehringer Ingelheim (Canada) Ltd."
Jardiance,empagliflozin,"Chronic kidney disease","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0040-000,"Boehringer Ingelheim (Canada) Ltd."
Jardiance,Empagliflozin,"Diabetes mellitus, type 2","List with clinical criteria and/or conditions",Complete,"Apr 23, 2015","Oct 15, 2015",SR0427-000,"Boehringer Ingelheim (Canada) Ltd."
Jemperli,dostarlimab,"Endometrial cancer","Do not reimburse",Complete,"Oct 7, 2021","Aug 24, 2022",PC0263-000,"GlaxoSmithKline Inc."
Jemperli,dostarlimab,"Endometrial cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 18, 2023","May 3, 2024",PC0325-000,"GlaxoSmithKline Inc."
Jemperli,dostarlimab,"Endometrial cancer",,Active,"Aug 15, 2024",,PC0381-000,"GlaxoSmithKline Inc."
Jentadueto,Linagliptin-metformin,"Diabetes mellitus, type 2","List with criteria/condition",Complete,"Mar 8, 2013","Oct 17, 2013",SR0306-000,"Boehringer Ingelheim (Canada) Ltd."
Jetrea,Ocriplasmin,"Vitreomacular adhesion","List with criteria/condition",Complete,"Jun 6, 2013","Dec 20, 2013",SR0337-000,"Alcon Canada Inc."
Jinarc,Tolvaptan,"Autosomal dominant polycystic kidney disease","Do not list",Complete,"May 29, 2015","Feb 24, 2016",SR0435-000,"Otsuka Canada Pharmaceutical Inc."
Jorveza,budesonide,"Maintenance of Eosinophilic esophagitis in adults","Reimburse with clinical criteria and/or conditions",Complete,"Nov 5, 2020","Aug 23, 2021",SR0666-000,"AVIR Pharma Inc"
Jorveza,budesonide,"Eosinophilic esophagitis, adults","Reimburse with clinical criteria and/or conditions",Complete,"Nov 8, 2019","Oct 28, 2020",SR0634-000,"AVIR Pharma Inc."
Jublia,efinaconazole,Onychomycosis,"Do not reimburse",Complete,"Aug 2, 2018","May 23, 2019",SR0577-000,"Bausch Health, Canada Inc."
Juluca,"Dolutegravir rilpivirine","HIV infection","Reimburse with clinical criteria and/or conditions",Complete,"Dec 21, 2017","Jun 20, 2018",SR0551-000,"ViiV Healthcare ULC"
Jurnista,"Hydromorphone hydrochloride","Pain, Chronic (moderate to severe)","Do not list",Complete,"Dec 4, 2009","May 19, 2010",SR0190-000,"Janssen-Ortho Inc."
Juxtapid,Lomitapide,"Hypercholesterolemia, homozygous familial","Do not list",Complete,"Jul 8, 2014","Apr 17, 2015",SR0386-000,"Aegerion Pharmaceuticals (Canada) Ltd."
Kalydeco,Ivacaftor,"Cystic fibrosis, G551D mutation","List with criteria/condition",Complete,"Sep 27, 2012","Mar 22, 2013",SR0291-000,"Vertex Pharmaceuticals  Inc."
Kalydeco,Ivacaftor,"Cystic fibrosis, R117H CFTR gating mutation","List with criteria/condition",Complete,"May 8, 2015","Nov 19, 2015",SR0430-000,"Vertex Pharmaceuticals (Canada) Incorporated"
Kalydeco,Ivacaftor,"Cystic Fibrosis, CFTR gating mutations","List with criteria/condition",Complete,"May 1, 2014","Dec 19, 2014",SR0379-000,"Vertex Pharmaceuticals Canada"
Kanuma,"sebelipase alfa","Lysosomal acid lipase deficiency","Reimburse with clinical criteria and/or conditions",Complete,"Nov 2, 2017","Sep 26, 2018",SR0544-000,"Alexion Pharmaceuticals"
Kazano,"Alogliptin plus metformin","Diabetes mellitus, type 2","Do not list",Complete,"Jan 30, 2014","Jan 15, 2015",SR0367-000,"Takeda Canada Inc."
Kerendia,finerenone,"Chronic kidney disease","Reimburse with clinical criteria and/or conditions",Complete,"May 20, 2022","Mar 8, 2023",SR0737-000,"Bayer Inc."
Kesimpta,ofatumumab,"Multiple Sclerosis, relapsing","Reimburse with clinical criteria and/or conditions",Complete,"Aug 25, 2020","Feb 25, 2021",SR0657-000,"Novartis Pharmaceuticals Canada Inc."
Kevzara,sarilumab,"Arthritis, Rheumatoid","Reimburse with clinical criteria and/or conditions",Complete,"Oct 12, 2016","Apr 18, 2017",SR0503-000,"Sanofi Genzyme"
Keytruda,pembrolizumab,"Triple-negative breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jun 20, 2022","Jan 6, 2023",PC0295-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Classical Hodgkin lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Jan 29, 2021","Nov 1, 2021",PC0236-000,"Merck Canada"
Keytruda,pembrolizumab,"Gastric or gastroesophageal junction (GEJ) adenocarcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Mar 13, 2024","Oct 4, 2024",PC0356-000,"Merck Canada"
Keytruda,pembrolizumab,"Melanoma Adjuvant Treatment","Reimburse with clinical criteria and/or conditions",Complete,"Apr 26, 2022","Nov 4, 2022",PC0286-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Cervical cancer",,Active,"Mar 25, 2025",,PC0411-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Colorectal cancer","Reimburse with clinical criteria and/or conditions",Complete,"Nov 30, 2020","Jul 27, 2021",PC0235-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Esophageal carcinoma, gastroesophageal junction adenocarcinoma","Reimburse with clinical criteria and/or conditions",Complete,"May 26, 2021","Dec 20, 2021",PC0250-000,"Merck Canada"
Keytruda,pembrolizumab,"Primary mediastinal B-cell lymphoma","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0034-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Advanced endometrial cancer","Reimburse with clinical criteria and/or conditions",Complete,"Dec 15, 2021","Feb 3, 2023",PC0280-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Triple-negative breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 17, 2022","Aug 31, 2022",PC0279-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Non-small cell lung cancer (NSCLC)","Reimburse with clinical criteria and/or conditions",Complete,"Jul 15, 2024","Jan 30, 2025",PC0369-000,"Merck Canada"
Keytruda,pembrolizumab,"Advanced or recurrent endometrial carcinoma",,Active,"Nov 14, 2024",,PC0383-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Renal cell carcinoma, adjuvant","Reimburse with clinical criteria and/or conditions",Complete,"Mar 3, 2022","Sep 29, 2022",PC0273-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Gastric or gastroesophageal junction adenocarcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Nov 22, 2023","Jun 26, 2024",PC0343-000,"Merck Canada"
Keytruda,pembrolizumab,"Biliary tract carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 7, 2023","Jul 11, 2024",PC0344-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Head and neck squamous cell carcinoma",,Active,"Mar 18, 2025",,PC0410-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Unresectable or metastatic MSI-H or dMMR solid tumors","Reimburse with clinical criteria and/or conditions",Complete,"Jul 16, 2024","Jan 31, 2025",PC0377-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"recurrent, or metastatic cervical cancer","Reimburse with clinical criteria and/or conditions",Complete,"May 20, 2022","Dec 1, 2022",PC0292-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Advanced or metastatic malignant pleural mesothelioma",,Active,"Nov 27, 2024",,PC0387-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Non-Small Cell Lung Cancer, neoadjuvant","Reimburse with clinical criteria and/or conditions",Active,"Sep 17, 2024","Apr 4, 2025",PC0385-000,"Merck Canada Inc."
Keytruda,pembrolizumab,"Gastrointestinal Cancer","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0012-000,"Merck Canada Inc."
"Keytruda and Lenvima","pembrolizumab and lenvatinib","Advanced endometrial cancer",,Withdrawn,"Dec 15, 2021",,PC0271-000,"Merck Canada"
"Keytruda and Lenvima","pembrolizumab and lenvatinib","Advanced endometrial cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 7, 2022","Sep 9, 2022",PC0288-000,"Merck Canada Inc."
Kimmtrak,tebentafusp,"unresectable or metastatic uveal melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Apr 21, 2022","Jan 4, 2023",PC0290-000,"Medison Canada"
Kineret,anakinra,"Still's disease",,Withdrawn,"Dec 21, 2020",,SR0662-000,"Swedish Orphan Biovitrum AB"
Kisqali,ribociclib,"Adjuvant treatment of HR-positive, HER2-negative early breast cancer",,Active,"Dec 19, 2024",,PC0395-000,"Novartis Pharmaceuticals Canada Inc."
Kivexa,Abacavir/lamivudine,"HIV infection","List in a similar manner to other drugs in class",Complete,"Jul 26, 2005","Dec 7, 2005",SR0038-000,GlaxoSmithKline
Komboglyze,"Saxagliptin + metformin","Diabetes Mellitus, type 2","List with criteria/condition",Complete,"Aug 23, 2013","Jun 20, 2014",SR0348-000,"AstraZeneca Canada Inc."
Komboglyze,"Saxagliptin + metformin","Diabetes Mellitus, Type 2",,Withdrawn,"Jun 6, 2013",,SR0336-000,"Bristol-Myers Squibb / AstraZeneca Canada Inc."
Korsuva,difelikefalin,"Chronic kidney disease","Do not reimburse",Complete,"Sep 22, 2022","Jul 13, 2023",SR0752-000,"Otsuka Canada Pharmaceutical Inc."
Koselugo,selumetinib,"Neurofibromatosis type 1","Reimburse with clinical criteria and/or conditions",Complete,"Oct 28, 2022","May 10, 2023",SR0764-000,"Alexion Pharma GmbH"
Kuvan,"Sapropterin dihydrochloride","Phenylketonuria (PKU)","Do not list",Complete,"Jul 8, 2010","Jan 26, 2011",SR0205-000,"BioMarin Pharmaceutical Canada Inc."
Kuvan,"Sapropterin dihydrochloride",Phenylketonuria,N/A,Complete,"Jun 1, 2011",,SF0236-000,"BioMarin Pharmaceutical Canada Inc."
Kuvan,"Sapropterin dihydrochloride","Phenylketonuria (PKU)","Reimburse with clinical criteria and/or conditions",Complete,"Feb 1, 2016","Oct 26, 2016",SR0472-000,"BioMarin Pharmaceutical (Canada) Inc."
Kymriah,tisagenlecleucel,"Relapsed or refractory follicular lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Feb 1, 2023","Sep 1, 2023",PG0306-000,"Novartis Pharmaceuticals Canada Inc."
Kynmobi,"apomorphine hydrochloride","Parkinson’s Disease",,Withdrawn,"Feb 25, 2019",,SR0604-000,"Sunovion Pharmaceuticals Canada Inc."
Kynmobi,"apomorphine hydrochloride","Parkinson’s disease","Reimburse with clinical criteria and/or conditions",Complete,"Jun 25, 2020","Feb 24, 2021",SR0650-000,"Sunovion Pharmaceuticals Canada Inc."
Lancora,Ivabradine,"Heart failure, NYHA class II or III","Reimburse with clinical criteria and/or conditions",Complete,"Nov 8, 2016","May 24, 2017",SR0506-000,"Servier Canada Inc."
Lantus,"Insulin glargine (rDNA origin)","Diabetes mellitus, Type 1 & 2","Do not list",Complete,"Mar 27, 2006","Oct 25, 2006",SR0058-000,"Sanofi-Aventis Canada Inc."
Lantus,"Insulin glargine (rDNA origin)","Diabetes mellitus, Type 1 & 2","Do not list",Complete,"Feb 11, 2005","Sep 28, 2005",SR0033-000,"Aventis Pharma Inc."
Lantus,"Insulin glargine (rDNA origin)","Diabetes mellitus, Type 1 & 2",N/A,Complete,"Jun 9, 2009",,SF0166-000,"Sanofi-Aventis Canada Inc."
Lapelga,Pegfilgrastim,"Febrile neutropenia",N/A,Complete,"Feb 23, 2018",,SE0555-000,Apobiologix
Latuda,lurasidone,"Bipolar I disorder","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0010-000,"Sunovion Pharmaceuticals Inc."
Latuda,Lurasidone,Schizophrenia,"Do not list",Complete,"Jul 3, 2012","Jan 23, 2013",SR0284-000,"Sunovion Pharmaceuticals Inc."
Latuda,Lurasidone,Schizophrenia,"List with criteria/condition",Complete,"May 9, 2013","Dec 20, 2013",SR0331-000,"Sunovion Pharmaceuticals Inc."
"Lazcluze and Rybrevant","lazertinib and amivantamab","Locally advanced or metastatic non-small cell lung cancer (NSCLC)",,Active,"Dec 18, 2024",,PC0392-000,"Janssen Inc."
Ledaga,"chlormethine hydrochloride","T-cell lymphoma","Do not reimburse",Complete,"Dec 21, 2020","Nov 24, 2021",PC0242-000,"Recordati Rare Diseases Canada Inc."
Lemtrada,Alemtuzumab,"Multiple sclerosis, relapsing-remitting",,Withdrawn,"Oct 1, 2013",,SR0355-000,"Genzyme Canada, a Division of sanofi-aventis Canada Inc."
Lemtrada,Alemtuzumab,"Multiple sclerosis, relapsing-remitting","List with criteria/condition",Complete,"Nov 27, 2014","Jun 18, 2015",SR0405-000,"Genzyme Canada, a Division of Sanofi-Aventis Canada Inc."
"Lenvima and Keytruda","lenvatinib and pembrolizumab","advanced or metastatic renal cell carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Nov 15, 2021","Jun 23, 2022",PC0268-000,"Eisai Limited"
Leqembi,lecanemab,"Alzheimer’s disease",,Suspended,"Jun 14, 2024",,SR0822-000,"Eisai Canada"
Leqvio,inclisiran,"Primary hypercholesterolemia","Reimburse with clinical criteria and/or conditions",Complete,"Sep 19, 2023","Aug 15, 2024",SR0791-000,"Novartis Pharmaceuticals Canada Inc."
Leqvio,inclisiran,"Primary hypercholesterolemia","Do not reimburse",Complete,"Mar 17, 2021","Feb 7, 2022",SR0681-000,"Novartis Pharmaceuticals Canada Inc."
Leqvio,inclisiran,"Primary hypercholesterolemia","Do not reimburse",Complete,"Sep 19, 2023","Apr 22, 2024",SR0791-001,"Novartis Pharmaceuticals Canada Inc."
Levemir,"Insulin detemir","Diabetes mellitus Type1, Pediatrics","Do not list",Complete,"Mar 10, 2009","Aug 20, 2009",SR0172-000,"Novo Nordisk Canada Inc."
Levemir,"Insulin detemir","Diabetes mellitus",,Withdrawn,"Feb 2, 2009",,SR0158-000,"Novo Nordisk Canada Inc."
Levemir,"Insulin detemir","Diabetes mellitus","Do not list",Complete,"Dec 19, 2005","Aug 2, 2006",SR0049-000,"Novo Nordisk Canada Inc."
Levemir,"Insulin detemir","Diabetes mellitus","Do not list",Complete,"Mar 10, 2009","Aug 20, 2009",SR0160-000,"Novo Nordisk Canada Inc."
Libtayo,cemiplimab,"Basal cell carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 19, 2021","Mar 4, 2022",PC0260-000,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc."
Libtayo,cemiplimab,"Locally advanced or metastatic NSCLC (first line)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 27, 2023","May 2, 2024",PC0331-000,"sanofi-aventis Canada Inc."
Libtayo,cemiplimab,"Non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 13, 2021","Jun 2, 2022",PC0262-000,"Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc."
Livmarli,maralixibat,"Alagille syndrome","Reimburse with clinical criteria and/or conditions",Complete,"May 5, 2023","Apr 22, 2024",SR0780-000,"Mirum Pharmaceuticals Inc."
Livtencity,maribavir,"Post-transplant cytomegalovirus infection","Reimburse with clinical criteria and/or conditions",Complete,"Mar 31, 2022","Nov 4, 2022",SR0720-000,"Takeda Canada Inc."
"Lixiana NVAF",Edoxaban,"Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism.","Reimburse with clinical criteria and/or conditions",Complete,"Sep 9, 2016","Mar 21, 2017",SR0500-000,"Daiichi Sankyo, Inc."
"Lixiana VTE",Edoxaban,"Venous thromboembolism, treatment and recurrence prevention.","Reimburse with clinical criteria and/or conditions",Complete,"Sep 9, 2016","May 25, 2017",SR0499-000,"Daiichi Sankyo, Inc."
Lodalis,"Colesevelam hydrochloride",Hypercholesterolemia,"Do not list at the submitted price",Complete,"Apr 27, 2012","Dec 19, 2012",SR0274-000,"Valeant Canada LP"
Lokelma,"sodium zirconium cyclosilicate","Hyperkalemia, adults","Do not reimburse",Complete,"May 17, 2019","Mar 25, 2020",SR0612-000,"AstraZeneca Canada Inc."
Lonsurf,"trifluridine and tipiracil","Metastatic colorectal cancer","Reimburse with clinical criteria and/or conditions",Complete,"Aug 15, 2023","Feb 29, 2024",PC0330-000,"Taiho Pharma Canada, Inc."
Lorbrena,lorlatinib,"ALK-positive locally advanced or metastatic non-small cell lung","Reimburse with clinical criteria and/or conditions",Complete,"Jun 18, 2021","Mar 17, 2022",PC0249-000,"Pfizer Canada"
Lotemax,"Loteprednol etabonate","Post-operative inflammation following cataract surgery","Do not list",Complete,"Dec 2, 2009","May 19, 2010",SR0186-000,"Bausch & Lomb"
Lucentis,Ranibizumab,"Macular edema, diabetic","List with clinical criteria and/or conditions",Complete,"Sep 14, 2011","Mar 19, 2012",SR0253-000,"Novartis Pharmaceuticals Canada Inc."
Lucentis,Ranibizumab,"Myopic choroidal neovascularisation","List with criteria/condition",Complete,"Feb 28, 2014","Feb 19, 2015",SR0373-000,"Novartis Pharmaceuticals Canada Inc."
Lucentis,"Ranibizumab injection","Macular edema, secondary to retinal vein occlusion","List with clinical criteria and/or conditions",Complete,"Apr 25, 2012","Oct 18, 2012",SR0276-000,"Novartis Pharmaceuticals Canada Inc."
Lucentis,Ranibizumab,"Macular degeneration, age-related","List with clinical criteria and/or conditions",Complete,"Jul 12, 2007","Mar 27, 2008",SR0098-000,"Novartis Pharmaceuticals Inc."
Lumakras,sotorasib,"KRAS G12C-mutated advanced NSCLC","Do not reimburse",Complete,"Aug 19, 2022","Feb 29, 2024",PC0300-000,"Amgen Canada Inc."
Lutathera,"lutetium oxodotreotide","Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 23, 2022","Sep 28, 2022",PC0284-000,"Advanced Accelerator Applications (AAA)"
Luxturna,"voretigene neparvovec","Vision loss, inherited retinal dystrophy","Reimburse with clinical criteria and/or conditions",Complete,"Apr 23, 2020","Nov 12, 2020",SG0643-000,"Novartis Pharmaceuticals Canada Inc."
Lynparza,olaparib,"Metastatic castration-resistant prostate cancer (mCRPC)","Reimburse with clinical criteria and/or conditions",Complete,"May 19, 2023","Jan 31, 2024",PC0319-000,"AstraZeneca Canada Inc."
Lynparza,olaparib,"Breast Cancer","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0013-000,"AstraZeneca Canada"
Lynparza,olaparib,"gBRCAm, HER2-negative high-risk early breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Aug 3, 2022","Mar 1, 2023",PC0299-000,"AstraZeneca Canada Inc."
Lyrica,Pregabalin,"diabetic peripheral neuropathy","Do not list",Complete,"Mar 20, 2009","Sep 23, 2009",SR0162-000,"Pfizer Canada Inc."
Lyrica,Pregabalin,"Pain, Neuropathic","Do not list",Complete,"Jun 27, 2005","Jan 25, 2006",SR0036-000,"Pfizer Canada Inc."
Macugen,"Pegaptanib sodium","Macular degeneration, age-related","Do not list",Complete,"Oct 20, 2005","May 25, 2006",SR0044-000,"Pfizer Canada Inc."
MAR-Trientine,"Trientine Hydrochloride","Wilson's Disease","Reimburse with clinical criteria and/or conditions",Complete,"Apr 19, 2021","Nov 11, 2021",SR0680-000,"Marcan Pharmaceuticals Inc."
Mavenclad,cladribine,"Multiple Sclerosis, relapsing-remitting","Reimburse with clinical criteria and/or conditions",Complete,"Dec 1, 2017","Oct 24, 2018",SR0546-000,"EMD Serono, a Division of EMD Inc., Canada"
Maviret,"glecaprevir pibrentasvir","Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Jun 9, 2017","Jan 23, 2018",SR0523-000,"AbbVie Corporation"
Maviret,"glecaprevir / pibrentasvir","Hepatitis C, chronic","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0023-000,"Pfizer Canada Inc."
Mayzent,siponimod,"Secondary progressive multiple sclerosis","Reimburse with clinical criteria and/or conditions",Complete,"Sep 26, 2019","Jul 21, 2020",SR0631-000,"Novartis Pharmaceuticals Canada Inc."
MDK-Nitisinone,nitisinone,"Hereditary tyrosinemia type 1","Reimburse with clinical criteria and/or conditions",Complete,"Sep 29, 2017","Apr 25, 2018",SR0538-000,"MendeliKABS Inc"
Mictoryl,"Propiverine hydrochloride","Overactive bladder (OAB)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 14, 2016","Apr 19, 2017",SR0504-000,"Duchesnay Inc."
Mifegymiso,"Mifepristone and misoprostol","Medical termination of pregnancy (gestational age up to 49 days)",Reimburse,Complete,"Oct 7, 2016","Apr 18, 2017",SR0502-000,"Celopharma Inc."
Mifegymiso,"Mifepristone and misoprostol","Medical termination of pregnancy (gestational age up to 49 days)",,Withdrawn,"Feb 12, 2016",,"SR0473 -000","Celopharma Inc."
Minjuvi,tafasitamab,"Diffuse large B-cell lymphoma (DLBCL)","Do not reimburse",Complete,"Nov 19, 2021","Sep 29, 2022",PC0266-000,"Incyte Biosciences Canada Corporation"
Monoferric,"Iron (III) Isomaltoside 1000","iron deficiency anemia","Reimburse with clinical criteria and/or conditions",Complete,"Jun 26, 2019","Mar 25, 2020",SR0622-000,"Pharmacosmos A/S"
Monoprost,latanoprost,"glaucoma and ocular hypertension","Reimburse with clinical criteria and/or conditions",Complete,"Oct 25, 2017","Apr 24, 2018",SR0541-000,"Laboratoires Théa"
Movapo,"apomorphine hydrochloride","Parkinson's disease","Reimburse with clinical criteria and/or conditions",Complete,"Jul 6, 2017","Jan 23, 2018",SR0527-000,"Paladin Labs Inc."
Mozobil,Plerixafor,"Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma","Do not list",Complete,"Jan 24, 2012","Sep 26, 2012",SR0265-000,"Genzyme Canada Inc."
Multaq,"Dronedarone hydrochloride","Atrial fibrillation","Do not list",Complete,"Sep 18, 2009","May 27, 2010",SR0177-000,"Sanofi-Aventis Canada Inc."
Myalepta,metreleptin,"Leptin deficiency in lipodystrophy","Reimburse with clinical criteria and/or conditions",Complete,"Jul 25, 2023","May 9, 2024",SR0784-000,"Medison Pharma Canada Inc."
Myfembree,"relugolix, estradiol, and norethindrone acetate","Management of heavy menstrual bleeding associated with uterine fibroids",,Active,"Feb 4, 2025",,SR0885-000,"Pfizer Canada ULC and Sumitomo Pharma Switzerland GmbH"
Myfortic,"Mycophenolate sodium","Organ rejection in allogeneic renal transplants, Prophylaxis","List in a similar manner to other drugs in class",Complete,"Mar 3, 2005","Jul 8, 2005",SR0034-000,"Novartis Pharmaceuticals Canada Inc."
Myinfla,colchicine,"Atherothrombotic events in coronary artery disease","Do not reimburse",Complete,"May 28, 2021","Mar 8, 2022",SR0691-000,"Pendopharm, a division of Pharmascience Inc."
Myozyme,Alglucosidase,"Pompe's disease","List with clinical criteria and/or conditions",Complete,"Oct 10, 2006","Jun 14, 2007",SR0080-000,"Genzyme Canada Inc."
Myrbetriq,Mirabegron,"Overactive bladder","List with criteria/condition",Complete,"Nov 27, 2013","Nov 12, 2014",SR0363-000,"Astellas Pharma Canada Inc."
Myrbetriq,Mirabegron,"Overactive bladder",,Withdrawn,"Mar 8, 2013",,SR0319-000,"Astellas Pharma Canada, Inc."
n/a,"abiraterone acetate and prednisolone","High-risk non-metastatic prostate cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 23, 2022","Sep 8, 2023","PX0291-000 - PC0291-000",n/a
N/A,"brentuximab vedotin","Hodgkin lymphoma",,Received,"May 6, 2025",,PX0381-000,N/A
N/A,panitumumab,"Left-sided metastatic colorectal cancer (mCRC)","Reimburse with clinical criteria and/or conditions",Complete,"May 19, 2023","Apr 18, 2024",PX0333-000,
N/A,naloxagol,"Management of opioid-induced constipation (OIC).",,Active,"Nov 19, 2024",,SX0753-000,N/A
N/A,ibrutinib,Hematology,,Received,,,PX0380-000,
N/A,rivaroxaban,"Venous thromboembolic events (VTE)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 29, 2022","Nov 2, 2023","SX0750-000 - SR0750-000",N/A
N/A,cabozantinib,"Neuroendocrine tumours",,Active,,,PX0378-000,N/A
N/A,Pembrolizumab,"Melanoma (Skin)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 16, 2023","Aug 1, 2024",PX0346-000,N/A
N/A,nab-paclitaxel,"Gastrointestinal cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 12, 2024",,PX0360-000,N/A
N/A,"nivolumab ipilimumab",Melanoma,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 25, 2024","Feb 4, 2025",PX0371-000,N/A
N/A,Mepolizumab,"Eosinophilic Granulomatosis with Polyangiitis","Reimburse with clinical criteria and/or conditions",Complete,"Dec 19, 2023","Nov 25, 2024",SX0839-000,
N/A,dapagliflozin,"Chronic kidney disease","Reimburse with clinical criteria and/or conditions",Complete,"Jun 17, 2022","Aug 23, 2023","SX0749-000 - SR0749-000",N/A
N/A,fidaxomicin,"Clostridioides difficile infection",,Active,"Nov 13, 2024",,SX0754-000,N/A
N/A,"guanfacine hydrochloride extended-release","Attention Deficit Hyperactivity Disorder (ADHD)",,Pending,"Mar 6, 2025",,SX0755-000,N/A
N/A,"abiraterone, prednisone, docetaxel","Metastatic castration sensitive prostate cancer (mCSPC)",Reimburse,Complete,"Jun 13, 2022","Sep 8, 2023","PX0298-000 - PC0298-000",N/A
N/A,"Nivolumab and Ipilimumab","Melanoma (Skin)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 16, 2023","Aug 1, 2024",PX0347-000,N/A
N/A,Nab-paclitaxel,"Solid tumours","Reimburse with clinical criteria and/or conditions",Complete,"Oct 16, 2023","Jul 24, 2024",PX0348-000,N/A
N/A,"dimethyl fumarate","Multiple Sclerosis (MS)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 21, 2024","Feb 4, 2025",SX0751-000,N/A
N/A,trametinib,"Gynecological cancers","Reimburse with clinical criteria and/or conditions",Complete,"Aug 28, 2024","Apr 2, 2025",PX0372-000,N/A
N/A,"Dabrafenib trametinib","Head and neck cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 7, 2024","May 16, 2025",PX0373-000,N/A
N/A,everolimus,"Tuberous Sclerosis Complex (TSC)","Reimburse with clinical criteria and/or conditions",Complete,"Dec 13, 2023","Dec 3, 2024",SX0836-000,N/A
N/A,Nab-paclitaxel,"Gastrointestinal cancer","Do not reimburse",Complete,"Dec 21, 2023",,PX0354-000,N/A
N/A,imiquimod,"Gynecological cancers",,Withdrawn,"Mar 6, 2024",,PX0364-000,N/A
N/A,tofacitinib,"Juvenile idiopathic arthritis, idiopathic arthritis",,Pending,"May 1, 2025",,SX0757-000,N/A
N/A,everolimus,"Renal angiomyolipoma associated with tuberous sclerosis","Reimburse with clinical criteria and/or conditions",Complete,"Jul 6, 2023","Apr 18, 2024",SX0814-000,N/A
N/A,nivolumab,"Hodgkin lymphoma",,Active,"Nov 12, 2024",,PX0376-000,N/A
N/A,trabectedin,"Soft tissue and uterine leiomyosarcoma",,Active,,,PX0377-000,N/A
N/A,Aripiprazole,Depression,,Active,"Mar 11, 2025",,SX0756-000,
N/A,Enzalutamide,"Genito-urinary cancer (prostate cancer)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 30, 2024","Nov 26, 2024",PX0366-000,N/A
N/A,eltrombopag,"Severe Aplastic Anemia (SAA)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 3, 2023","Jan 10, 2024",SX0777-000,N/A
N/A,pertuzumab,"HER2+ breast cancer",,Active,,,PX0379-000,N/A
N/A,blinatumomab,"Acute lymphoblastic leukemia, pediatrics","Reimburse with clinical criteria and/or conditions",Complete,"Jun 11, 2024","Feb 4, 2025",PX0367-000,N/A
N/A,"bevacizumab and lomustine","Recurrent glioblastoma multiform","Reimburse with clinical criteria and/or conditions",Complete,"Feb 17, 2023","Dec 20, 2023",PX0318-000,N/A
N/A,teriflunomide,"Multiple Sclerosis (MS)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 21, 2024","Feb 4, 2025",SX0752-000,N/A
N/A,regorafenib,"Metastatic osteosarcoma",,Active,"Oct 7, 2024",,PX0374-000,N/A
Naglazyme,"Galsulfase (Drug Plan Submission)","Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","List with clinical criteria and/or conditions",Complete,"Aug 20, 2015","Feb 19, 2016",SR0434-000,"BioMarin Pharmaceutical (Canada) Inc."
Nesina,Alogliptin,"Diabetes mellitus, type 2","Do not list",Complete,"Jan 30, 2014","Jan 15, 2015",SR0368-000,"Takeda Canada Inc."
Neulasta,Pegfilgrastim,Neutropenia,"List with clinical criteria and/or conditions",Complete,"Mar 29, 2004","Oct 27, 2004",SR0009-000,"Amgen Canada Inc."
Neupro,Rotigotine,"Parkinson's disease","Do not list",Complete,"Jul 31, 2013","May 28, 2014",SR0344-000,"UCB Canada Inc."
Neupro,Rotigotine,"Parkinson’s disease","List with clinical criteria and/or conditions",Complete,"May 21, 2015","Nov 19, 2015",SR0432-000,"UCB Canada Inc."
Nexavar,"Sorafenib tablets","Cancer, Renal cell carcinoma","Do not list",Complete,"Jul 31, 2006","Feb 28, 2007",SR0071-000,"Bayer Inc."
Nexplanon,etonogestrel,"Prevention of pregnancy","Reimburse with clinical criteria and/or conditions",Complete,"Jun 3, 2020","Oct 20, 2020",SR0648-000,"Merck Canada Inc."
Nexviazyme,"avalglucosidase alfa","Pompe disease","Reimburse with clinical criteria and/or conditions",Complete,"Sep 30, 2021","Jul 5, 2022",SR0703-000,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc."
Ngenla,somatrogon,"Growth hormone deficiency","Reimburse with clinical criteria and/or conditions",Complete,"Jun 3, 2021","Mar 8, 2022",SR0683-000,"Pfizer Canada ULC"
Nitisinone,nitisinone,"Hereditary tyrosinemia type 1","Reimburse with clinical criteria and/or conditions",Complete,"Jan 25, 2018","Aug 23, 2018",SR0554-000,"Cycle Pharmaceuticals Ltd."
Norprolac,"Quinagolide hydrochloride",Hyperprolactinemia,"Do not list",Complete,"Dec 16, 2004","Sep 28, 2005",SR0026-000,"Ferring Pharmaceuticals"
Norprolac,"Quinagolide hydrochloride",Hyperprolactinemia,"List with clinical criteria and/or conditions",Complete,"Nov 23, 2005","May 17, 2006",SR0046-000,"Ferring Pharmaceuticals"
"NovoMix 30","Insulin aspart/insulin aspart protamine","Diabetes mellitus","Do not list",Complete,"Oct 13, 2005","Apr 26, 2006",SR0041-000,"Novo Nordisk Canada Inc."
Nplate,Romiplostim,"Chronic immune (idiopathic) thrombocytopenic purpura (ITP)","Do not list",Complete,"Sep 29, 2009","May 27, 2010",SR0179-000,"Amgen Canada Inc."
Nubeqa,darolutamide,"Metastatic castration-sensitive prostate cancer",,Active,"Apr 28, 2025",,PC0404-000,"Bayer Inc."
Nubeqa,darolutamide,"Metastatic castration-sensitive prostate cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jun 16, 2022","Jan 5, 2023",PC0294-000,"Bayer Inc."
Nucala,Mepolizumab,"Asthma, severe eosinophilic","Reimburse with clinical criteria and/or conditions",Complete,"Dec 18, 2015","Jun 16, 2016",SR0461-000,"GlaxoSmithKline Inc."
Nucala,mepolizumab,"Asthma, severe eosinophilic","Reimburse with clinical criteria and/or conditions",Complete,"Oct 24, 2018","Mar 27, 2019",SF0593-000,"GlaxoSmithKline Inc."
Nucala,mepolizumab,"Severe chronic rhinosinusitis with nasal polyps","Reimburse with clinical criteria and/or conditions",Complete,"May 11, 2022","Nov 16, 2022",SR0735-000,"GlaxoSmithKline Inc."
Nucala,mepolizumab,"Eosinophilic granulomatosis with polyangiitis","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0018-000,"GlaxoSmithKline Inc."
Nucala,mepolizumab,"chronic obstructive pulmonary disease",,Pending,,,SR0888-000,"GlaxoSmithKline Inc."
Nucala,mepolizumab,"Asthma, severe eosinophilic (pediatric)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0027-000,"GlaxoSmithKline Inc."
Nucynta,"tapentadol hydrochloride","pain, severe","Do not reimburse",Complete,"Apr 17, 2018","Oct 23, 2018",SR0563-000,"Paladin Labs Inc."
"Nucynta CR",Tapentadol,"Pain, moderate to moderately severe","Do not list",Complete,"Feb 1, 2011","Sep 28, 2011",SR0224-000,"Janssen Inc."
"Nurtec ODT",rimegepant,"Migraine, prevention",,Withdrawn,"Aug 15, 2023",,SR0797-000,"Pfizer Canada ULC"
NuvaRing,"Etonogestrel/ethinyl estradiol","Contraceptive, ring","List with clinical criteria and/or conditions",Complete,"May 5, 2006","Nov 29, 2006",SR0062-000,"Organon Canada Ltd."
Ocaliva,"Obeticholic Acid","Primary Biliary Cholangitis","Reimburse with clinical criteria and/or conditions",Complete,"Dec 22, 2016","Jul 25, 2017",SR0509-000,"Intercept Pharma Canada, Inc."
Ocrevus,ocrelizumab,"Primary progressive multiple sclerosis","Reimburse with clinical criteria and/or conditions",Complete,"Oct 26, 2017","Apr 26, 2018",SR0542-000,"Hoffman-La Roche Limited"
Ocrevus,ocrelizumab,"multiple sclerosis, relapsing","Reimburse with clinical criteria and/or conditions",Complete,"May 16, 2017","Nov 21, 2017",SR0519-000,"Hoffman-La Roche Limited"
Odefsey,"emtricitabine/rilpivirine/ tenofovir alafenamide","HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Nov 24, 2016","May 25, 2017",SR0507-000,"Gilead Sciences Canada, Inc."
Ofev,Nintedanib,"Idiopathic pulmonary fibrosis","List with clinical criteria and/or conditions",Complete,"Apr 23, 2015","Oct 15, 2015",SR0426-000,"Boehringer Ingelheim (Canada) Ltd."
Ofev,nintedanib,"chronic fibrosing interstitial lung diseases","Reimburse with clinical criteria and/or conditions",Complete,"Jul 24, 2020","Feb 24, 2021",SR0654-000,"Boehringer Ingelheim (Canada) Ltd."
Ojjaara,momelotinib,Myelofibrosis,"Reimburse with clinical criteria and/or conditions",Active,"Jun 19, 2024","Jan 8, 2025",PC0355-000,"GlaxoSmithKline Inc."
Okedi,risperidone,"Schizophrenia, adults",,Active,"Mar 21, 2025",,SR0879-000,"Bausch Health, Canada Inc."
Olmetec,"Olmesartan medoxomil",Hypertension,"List in a similar manner to other drugs in class",Complete,"Nov 28, 2008","May 27, 2009",SR0150-000,"Schering-Plough Canada Inc."
"Olmetec Plus","Olmesartan medoxomil + hydrochlorothiazide",Hypertension,"List in a similar manner to other drugs in class",Complete,"Nov 28, 2008","May 27, 2009",SR0151-000,"Schering-Plough Canada Inc."
Olumiant,baricitinib,"Arthritis, Rheumatoid","Reimburse with clinical criteria and/or conditions",Complete,"Dec 20, 2018","Aug 2, 2019",SR0597-000,"Eli Lilly Canada Inc."
Olumiant,baricitinib,"Alopecia areata, severe","Reimburse with clinical criteria and/or conditions",Complete,"Mar 4, 2024","Sep 13, 2024",SR0843-000,"Eli Lilly Canada Inc."
Omnaris,"Ciclesonide nasal spray","Allergic Rhinitis (seasonal and perennial)","Do not list",Complete,"May 7, 2008","Nov 12, 2008",SR0137-000,"Nycomed Canada Inc."
Omnitrope,"Somatropin (rDNA origin)","Growth hormone deficiency in children and adults",N/A,Complete,"Jun 12, 2009",,SR0167-000,"Sandoz Canada Inc."
Omvoh,mirikizumab,"Crohn’s disease",,Active,"Mar 4, 2025",,SR0880-000,"Eli Lilly Canada Inc."
Omvoh,mirikizumab,"Ulcerative colitis","Reimburse with clinical criteria and/or conditions",Complete,"Mar 7, 2023","Nov 16, 2023",SR0773-000,"Eli Lilly Canada"
Onbrez,Indacaterol,"Chronic obstructive pulmonary disease","List in a similar manner",Complete,"Feb 29, 2012","Aug 16, 2012",SR0273-000,"Novartis Pharmaceuticals Canada Inc."
Oncaspar,pegaspargase,"Adult Acute Lymphocytic Leukemia (ALL)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0002-000,"Servier Canada Inc."
Ondexxya,"andexanet alfa","Reversal of FXa inhibitor anticoagulant effects","Do not reimburse",Complete,"Mar 2, 2023","Dec 5, 2023",ST0772-000,"AstraZeneca Canada Inc."
Onglyza,Saxagliptin,"Diabetes mellitus, type 2",,Withdrawn,"May 28, 2012",,SR0280-000,"Bristol-Myers Squibb / AstraZeneca Canada Inc."
Onglyza,Saxagliptin,"Diabetes mellitus (Type 2)","Do not list",Complete,"Nov 9, 2009","Jun 17, 2010",SR0185-000,"Bristol-Myers Squibb Canada"
Onglyza,Saxagliptin,"Diabetes mellitus, type 2","List with criteria/condition",Complete,"May 9, 2013","Nov 15, 2013",SR0329-000,"Bristol-Myers Squibb / AstraZeneca Canada Inc."
Onpattro,patisiran,"Polyneuropathy in hereditary transthyretin-mediated amyloidosis","Reimburse with clinical criteria and/or conditions",Complete,"Jan 25, 2019","Jul 25, 2019",SR0598-000,"Alnylam Netherlands BV"
Onsolis,"Fentanyl Citrate","Pain, breakthrough cancer pain","Do not list",Complete,"Aug 22, 2011","Feb 15, 2012",SR0248-000,"Meda Valeant Pharma Canada Inc."
Onsolis,"Fentanyl Citrate","Pain, breakthrough cancer pain",,Withdrawn,"May 10, 2011",,SR0229-000,"Meda Valeant Pharma Canada Inc."
Onstryv,safinamide,"Parkinson's disease","Do not reimburse",Complete,"May 29, 2019","Mar 25, 2020",SR0617-000,"Valeo Pharma Inc."
Onureg,azacitidine,"Acute myeloid leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Mar 1, 2021","Oct 20, 2021",PC0245-000,"Celgene Inc., a Bristol-Myers Squibb Company"
Opdivo,nivolumab,"Stage IIB or IIC melanoma, adjuvant","Reimburse with clinical criteria and/or conditions",Complete,"Nov 6, 2023","May 29, 2024",PC0339-000,"Bristol Myers Squibb Canada"
Opdivo,nivolumab,"Urothelial carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Feb 22, 2022","Sep 28, 2022",PC0272-000,"Bristol Myers Squibb Canada"
Opdivo,nivolumab,"Esophageal or gastroesophageal junction cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jul 7, 2021","Jan 26, 2022",PC0253-000,"Bristol-Myers Squibb"
Opdivo,nivolumab,"Gastric, gastroesophageal junction, or esophageal adenocarcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 18, 2021","Mar 4, 2022",PC0259-000,"Bristol-Myers Squibb"
Opdivo,nivolumab,"Resectable Non-Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Sep 13, 2022","Mar 30, 2023",PC0303-000,"Bristol-Myers Squibb"
"Opdivo and Yervoy","Nivolumab and ipilimumab","Unresectable or advanced hepatocellular carcinoma (HCC)",,Received,"May 22, 2025",,PC0420-000,"Bristol Myers Squibb Canada Co. (BMS)"
"Opdivo and Yervoy","nivolumab and ipilimumab","Unresectable or metastatic MSI-H or dMMR colorectal cancer",,Active,"Mar 26, 2025",,PC0396-000,"Bristol Myers Squibb Canada Co."
Opdivo-Yervoy,Nivolumab-Ipilimumab,NSCLC,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 23, 2020",,PC0218-000,"Bristol-Meyers Squibb Canada"
Opdivo-Yervoy,nivolumab-ipilimumab,"Malignant Pleural Mesothelioma (MPM)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 9, 2020","Aug 4, 2021",PC0229-000,"Bristol-Myers Squibb"
Opdualag,"nivolumab and relatlimab","unresectable or metastatic melanoma","Reimburse with clinical criteria and/or conditions",Complete,"Jul 10, 2023","Feb 2, 2024",PC0329-000,"Bristol Myers Squibb"
Opsumit,Macitentan,"Pulmonary arterial hypertension","List with clinical criteria and/or conditions",Complete,"Dec 18, 2013","Jan 28, 2015",SR0364-000,"Actelion Pharmaceuticals Canada Inc."
Opsynvi,"macitentan and tadalafil","Pulmonary arterial hypertension","Reimburse with clinical criteria and/or conditions",Complete,"May 20, 2021","Dec 14, 2021",SR0690-000,"Janssen Inc."
Opzelura,ruxolitinib,"Nonsegmental vitiligo",,Active,"Oct 17, 2024",,SR0835-000,"Incyte Biosciences Canada Corporation"
Opzelura,ruxolitinib,"atopic dermatitis","Do not reimburse",Active,"Oct 27, 2023","May 6, 2025",SR0807-000,"Incyte Biosciences Canada Corporation"
Oralair,"Grass Pollen Allergen Extract","Allergic rhinitis","List with criteria/condition",Complete,"Sep 21, 2012","Mar 20, 2013",SR0290-000,"Paladin Labs Inc."
Orencia,Abatacept,"Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid","List with clinical criteria and/or conditions",Complete,"Aug 29, 2008","Apr 22, 2009",SR0145-000,"Bristol-Myers Squibb Canada"
Orencia,Abatacept,"Arthritis, rheumatoid","List with clinical criteria and/or conditions",Complete,"Nov 29, 2012","Jul 18, 2013",SR0299-000,"Bristol-Myers Squibb Canada"
Orencia,Abatacept,"Arthritis, Rheumatoid","List in a similar manner",Complete,"Dec 2, 2009","Jun 17, 2010",SR0187-000,"Bristol-Myers Squibb Canada"
Orencia,Abatacept,"Arthritis, Rheumatoid","List with clinical criteria and/or conditions",Complete,"Oct 26, 2006","Jun 27, 2007",SR0084-000,"Bristol-Myers Squibb Canada"
Orfadin,nitisinone,"Hereditary tyrosinemia type 1","Reimburse with clinical criteria and/or conditions",Complete,"Aug 29, 2017","Feb 21, 2018",SR0531-000,"Sobi Canada Inc."
Orgovyx,relugolix,"Advanced prostate cancer","Reimburse with clinical criteria and/or conditions",Complete,"Nov 14, 2023","Jul 22, 2024",PC0342-000,"Sumitomo Pharma Canada, Inc."
Orilissa,elagolix,"Moderate to severe pain associated with endometriosis","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0011-000,"AbbVie Corporation"
Orkambi,lumacaftor/ivacaftor,"Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older","Do not reimburse",Complete,"Feb 22, 2018","Sep 26, 2018",SR0559-000,"Vertex Pharmaceuticals (Canada) Incorporated"
Orkambi,lumacaftor/ivacaftor,"Cystic Fibrosis, F508del CFTR mutation","Do not reimburse",Complete,"Jan 28, 2016","Oct 26, 2016",SR0471-000,"Vertex Pharmaceuticals (Canada) Incorporated."
Orladeyo,berotralstat,"hereditary angioedema (HAE)","Reimburse with clinical criteria and/or conditions",Complete,"Feb 22, 2022","Feb 17, 2023",SR0723-000,"BioCryst Pharmaceuticals Inc."
Osphena,ospemifene,"Dyspareunia, vaginal dryness","Reimburse with clinical criteria and/or conditions",Complete,"Oct 26, 2021","May 13, 2022",SR0709-000,"Duchesnay Inc."
Otezla,Apremilast,"Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Mar 3, 2016","Oct 26, 2016",SR0478-000,Celgene
Otezla,Apremilast,"Arthritis, psoriatic","List with criteria/condition",Complete,"Jun 8, 2015","Dec 17, 2015",SR0437-000,Celgene
Otezla,Apremilast,"Plaque psoriasis","Do not list",Complete,"Oct 8, 2014","Jul 22, 2015",SR0400-000,Celgene
Oxervate,cenegermin,"Neurotrophic keratitis","Reimburse with clinical criteria and/or conditions",Complete,"Oct 29, 2021","Jun 23, 2022",SR0704-000,"Dompé Farmaceutici S.p.A"
Oxlumo,lumasiran,"Primary hyperoxaluria type 1","Reimburse with clinical criteria and/or conditions",Complete,"May 10, 2022","Feb 8, 2023",SR0734-000,"Alnylam Netherlands B.V."
Ozanex,ozenoxacin,Impetigo,"Do not reimburse",Complete,"Jan 25, 2018","Oct 24, 2018",SR0553-000,"Ferrer Internacional, S.A."
Ozempic,semaglutide,"Diabetes mellitus, type 2","Reimburse with clinical criteria and/or conditions",Complete,"Nov 23, 2018","May 15, 2019",SR0594-000,"Novo Nordisk Canada Inc."
Ozurdex,dexamethasone,"Diabetic macular edema","Do not reimburse",Complete,"Sep 26, 2017","Oct 24, 2018",SR0535-000,"Allergan Inc."
Ozurdex,"dexamethasone intravitreal implant","Non-infectious uveitis","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0033-000,"AbbVie Corporation"
Ozurdex,"Dexamethasone intravitreal implant","Macular edema, central retinal vein occlusion","Do not list",Complete,"Sep 1, 2011","Apr 25, 2012",SR0247-000,Allergan
Ozurdex,"dexamethasone intravitreal implant","Diabetic macular edema","Do not reimburse",Complete,"Jun 8, 2022","Dec 13, 2022",SR0739-000,"Allergan, an AbbVie Company"
Padcev,"enfortumab vedotin","Metastatic urothelial cancer","Reimburse with clinical criteria and/or conditions",Complete,"May 22, 2024","Nov 29, 2024",PC0353-000,"Seagen Canada Inc."
Padcev,"enfortumab vedotin","Locally advanced or metastatic urothelial carcinoma","Reimburse with clinical criteria and/or conditions",Complete,"Jun 23, 2021","Jan 6, 2022",PC0251-000,"Seagen Canada Inc."
Palynziq,pegvaliase,Phenylketonuria,"Reimburse with clinical criteria and/or conditions",Complete,"Dec 22, 2021","Nov 9, 2022",SR0712-000,"BioMarin Pharmaceutical Inc."
"Pantoloc M","Pantoprazole magnesium","Gastric acid secretion, reduction of","List in a similar manner to other drugs in class",Complete,"Mar 17, 2006","Jul 20, 2006",SR0054-000,"Altana Pharma Inc."
Paxlovid,nirmatrelvir/ritonavir,"Mild-to-moderate COVID-19, treatment","Reimburse with clinical criteria and/or conditions",Complete,"Sep 15, 2023","Apr 11, 2024",SR0808-000,"Pfizer Canada ULC"
pdp-levETIRAcetam,Levetiracetam,Epilepsy,"Reimburse with clinical criteria and/or conditions",Complete,"Jul 17, 2020","Feb 3, 2021",SR0653-000,"Pendopharm, a division of Pharmascience Inc."
"Pegasys RBV","Peginterferon alfa-2a and Ribavirin","Hepatitis C, chronic","List in a similar manner to other drugs in class",Complete,"May 14, 2004","Oct 14, 2004",SR0013-000,"Hoffman-La Roche Ltd."
Pemazyre,pemigatinib,Cholangiocarcinoma,"Reimburse with clinical criteria and/or conditions",Active,"Oct 18, 2024","May 5, 2025",PC0391-000,"Incyte Biosciences Canada Corporation"
Pemazyre,pemigatinib,Cholangiocarcinoma,"Do not reimburse",Complete,"Jun 23, 2021","Mar 23, 2022",PC0252-000,"Incyte Biosciences Canada Corporation"
Perjeta,pertuzumab,"Early stage breast cancer","Do not reimburse",Complete,"Apr 14, 2021","Jan 25, 2022",PC0241-000,"Hoffmann-La Roche Limited"
Perseris,risperidone,"Schizophrenia, adults","Reimburse with clinical criteria and/or conditions",Complete,"Jan 29, 2021","Sep 8, 2021",SR0671-000,"HLS Therapeutics Inc."
Pheburane,"Sodium phenylbutyrate","Urea cycle disorders",List,Complete,"Oct 20, 2015","Apr 15, 2016",SR0452-000,"Médunik Canada"
Picato,"Ingenol mebutate","Actinic keratosis","Do not list",Complete,"May 9, 2013","Jan 22, 2014",SR0330-000,"LEO Pharma Inc."
Picato,"Ingenol mebutate","Actinic keratosis",N/A,Complete,"May 26, 2014",,SF0382-000,"Leo Pharma Inc."
Pifeltro,doravirine,"HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Nov 16, 2018","May 14, 2019",SR0582-000,"Merck Canada Inc."
Piqray,alpelisib,"Advanced or Metastatic Breast Cancer","Do not reimburse",Complete,"Apr 21, 2021","Jan 26, 2022",PC0247-000,"Novartis Pharmaceuticals Canada Inc."
Plegridy,"Peginterferon beta-1a","Multiple sclerosis, relapsing-remitting","List with criteria/condition",Complete,"Jun 26, 2015","Dec 17, 2015",SR0440-000,"Biogen Canada Inc."
Pluvicto,"lutetium vipivotide tetraxetan","Metastatic castration-resistant prostate cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jul 21, 2022","Mar 3, 2023",PC0297-000,"Advanced Accelerator Applications USA, Inc."
Polivy,"polatuzumab vedotin","Large B-cell lymphoma","Do not reimburse",Complete,"Mar 1, 2023","Dec 20, 2023",PC0313-000,"Hoffmann La-Roche"
Polivy,"polatuzumab vedotin","Large B-cell lymphoma",,Active,"Nov 27, 2024",,PC0397-000,N/A
"Pombiliti with Opfolda","cipaglucosidase alfa with miglustat","Pompe disease",,Active,"Nov 29, 2024",,SR0871-000,"Amicus Therapeutics Canada Inc."
Poteligeo,mogamulizumab,"mycosis fungoides (MF), Sézary syndrome (SS)","Reimburse with clinical criteria and/or conditions",Complete,"Sep 13, 2021","Aug 12, 2022",PC0244-000,"Kyowa Kirin Canada"
Pradaxa,"Dabigatran etexilate","Atrial fibrillation prevention of stroke and systemic embolism",,Cancelled,"May 31, 2010",,SR0202-000,"Boehringer-Ingelheim (Canada) Ltd."
Pradaxa,"Dabigatran etexilate","Thromboembolism (venous), prevention","Do not list",Complete,"Jul 8, 2008","Jan 28, 2009",SR0140-000,"Boehringer Ingelheim (Canada) Ltd."
Pradaxa,"Dabigatran etexilate","Atrial fibrillation prevention of stroke and systemic embolism","List with clinical criteria and/or conditions",Complete,"Mar 18, 2013","Jul 18, 2013",SF0320-000,"Boehringer Ingelheim (Canada) Ltd"
Pradaxa,"Dabigatran etexilate","Atrial fibrillation prevention of stroke and systemic embolism","List with clinical criteria and/or conditions",Complete,"Oct 28, 2010","Jun 22, 2011",SR0214-000,"Boehringer Ingelheim"
Praluent,Alirocumab,"Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia","Reimburse with clinical criteria and/or conditions",Complete,"Jan 12, 2016","Jul 20, 2016",SR0469-000,"Sanofi-aventis Canada Inc."
Praxbind,"Idarucizumab (Drug Plan Submission)","Reversal of dabigatran anticoagulant effects",,Withdrawn,"May 30, 2016",,SR0492-000,"Boehringer Ingelheim (Canada) Ltd."
Prevymis,letermovir,"Cytomegalovirus infection (CMV), prophylaxis",,Withdrawn,"Oct 30, 2023",,SR0824-000,"Merck Canada Inc."
Prevymis,letermovir,"Cytomegalovirus infection, prophylaxis","Reimburse with clinical criteria and/or conditions",Complete,"Dec 7, 2017","Jun 20, 2018",SR0545-000,"Merck Canada Inc."
Prexige,Lumiracoxib,"Osteoarthritis (Knee)","Do not list",Complete,"Dec 15, 2006","Jul 25, 2007",SR0090-000,"Novartis Pharmaceuticals Canada Inc."
Prezcobix,Darunavir/cobicistat,"HIV Infection","List with criteria/condition",Complete,"May 22, 2014","Mar 18, 2015",SR0381-000,"Janssen Inc."
Prezista,Darunavir,"HIV infection","List with clinical criteria and/or conditions",Complete,"Aug 29, 2006","Feb 14, 2007",SR0072-000,"Janssen-Ortho Inc."
Prezista,Darunavir,"HIV infection (Pediatric)","List with clinical criteria and/or conditions",Complete,"Dec 22, 2009","Jun 17, 2010",SR0194-000,"Janssen-Ortho Inc."
Prezista,Darunavir,"HIV (treatment naive)","List with clinical criteria and/or conditions",Complete,"Mar 27, 2009","Oct 14, 2009",SR0163-000,"Janssen-Ortho Inc."
Pristiq,"Desvenlafaxine succinate","Depressive, Major Disorder (MDD)","Do not list",Complete,"Mar 5, 2009","Sep 23, 2009",SR0159-000,"Wyeth Canada"
Probuphine,"buprenorphine hydrochloride","Opioid drug dependence, treatment","Reimburse with clinical criteria and/or conditions",Complete,"Dec 21, 2017","Aug 22, 2018",SR0550-000,"Knight Therapeutics Inc."
Procysbi,"cysteamine bitartrate","Nephropathic cystinosis","Reimburse with clinical criteria and/or conditions",Complete,"Aug 8, 2017","Jan 24, 2018",SR0526-000,"Horizon Pharma"
Prolia,"Denosumab (Drug Plan Submission)","Osteoporosis, men","List with clinical criteria and/or conditions",Complete,"Mar 10, 2015","Sep 21, 2015",SR0414-000,"Amgen Canada"
Prolia,Denosumab,"Osteoporosis, postmenopausal women","List with clinical criteria and/or conditions",Complete,"Aug 26, 2010","Mar 30, 2011",SR0208-000,"Amgen Canada Inc."
Prolia,Denosumab,Osteoporosis,"Reimburse with clinical criteria and/or conditions",Complete,"Oct 26, 2015","May 20, 2016",SF0453-000,"Amgen Canada Inc."
Qalsody,tofersen,"Amyotrophic  lateral sclerosis (ALS)",,Active,"Feb 27, 2025",,SR0883-000,"Biogen Canada Inc."
Qinlock,ripretinib,"Gastrointestinal stromal tumours","Reimburse with clinical criteria and/or conditions",Complete,"Oct 15, 2021","Apr 28, 2022",PC0265-000,"Medison Pharma Canada Inc."
Quinsair,Levofloxacin,"Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections","Reimburse with clinical criteria and/or conditions",Complete,"May 31, 2016","Nov 21, 2016",SR0493-000,"Raptor Pharmaceuticals Inc."
Qulipta,atogepant,"Migraine, prevention","Reimburse with clinical criteria and/or conditions",Complete,"Dec 21, 2023","Jul 15, 2024",SR0817-000,"AbbVie Corporation"
Qulipta,atogepant,"Migraine, prevention","Reimburse with clinical criteria and/or conditions",Complete,"Feb 23, 2022","Jun 14, 2023",SR0724-000,"Allergan Inc. (an AbbVie company)"
Quviviq,daridorexant,Insomnia,,Active,"Dec 5, 2024",,SR0862-000,"Idorsia Pharmaceuticals Canada Ltd."
Radicava,edaravone,"Amyotrophic lateral sclerosis","Reimburse with clinical criteria and/or conditions",Complete,"Mar 10, 2022","Dec 22, 2022",SR0727-000,"Mitsubishi Tanabe Pharma Canada, Inc."
Radicava,edaravone,"amyotrophic lateral sclerosis","Reimburse with clinical criteria and/or conditions",Complete,"Jul 5, 2018","Mar 27, 2019",SR0573-000,"Mitsubishi Tanabe Pharma Corporation"
Ralivia,"Tramadol hydrochloride",Pain,"Do not list",Complete,"Oct 29, 2007","Jun 25, 2008",SR0110-000,"Biovail Pharmaceuticals Canada"
RAPAFLO,Silodosin,"Benign prostatic hyperplasia","Do not list",Complete,"Oct 25, 2011","Apr 19, 2012",SR0261-000,"Watson Pharma Company"
Raptiva,Efalizumab,"Psoriasis, moderate to severe chronic plaque",N/A,Complete,"Jun 19, 2007",,SF0102-000,"Serono Canada Inc."
Raptiva,Efalizumab,"Psoriasis, moderate to severe chronic plaque","List with clinical criteria and/or conditions",Complete,"Oct 25, 2005","Aug 24, 2006",SR0043-000,"Serono Canada Inc."
Rasilez,Aliskiren,Hypertension,"Do not list",Complete,"Nov 30, 2007","Jun 25, 2008",SR0118-000,"Novartis Pharmaceuticals Canada Inc."
Ravicti,"glycerol phenylbutyrate","Urea cycle disorders","Reimburse with clinical criteria and/or conditions",Complete,"Aug 30, 2016","Mar 21, 2017",SR0497-000,"Horizon Therapeutics Canada/Horizon Pharma Ireland Ltd."
Rebif,"Interferon beta-1a","Clinically isolated syndrome","Do not list",Complete,"Mar 8, 2013","Aug 15, 2013",SR0298-000,"EMD Serono"
Reblozyl,luspatercept,"beta-thalassemia associated anemia","Reimburse with clinical criteria and/or conditions",Complete,"Nov 26, 2020","Jun 8, 2021",SR0669-000,"Celgene Inc. / Bristol-Myers Squibb Canada Co."
Reblozyl,luspatercept,"Myelodysplastic syndromes-associated anemia","Reimburse with clinical criteria and/or conditions",Complete,"Jan 28, 2021","Dec 7, 2021",SR0670-000,"Celgene Inc., a Bristol Myers Squibb company"
Rebyota,"fecal microbiota","Clostridioides difficile infection, prevention",,Active,"Jan 3, 2025",,SR0850-000,"Ferring Canada Inc."
Relistor,"Methylnaltrexone bromide","Constipation, Opioid-induced","Do not list",Complete,"May 7, 2008","Jan 28, 2009",SR0135-000,"Wyeth Canada"
Relpax,"Eletriptan hydrobromide",Migraine,"Do not list",Complete,"Sep 21, 2004","Mar 23, 2005",SR0021-000,"Pfizer Canada Inc."
Remicade,Infliximab,"Ulcerative Colitis","Do not list",Complete,"Sep 29, 2008","Apr 22, 2009",SR0146-000,"Centocor Inc."
Remodulin,"Treprostinil sodium","Pulmonary arterial hypertension (NYHA Class III and IV patients)","Do not list",Complete,"Jul 14, 2004","Nov 17, 2004",SR0011-000,"Northern Therapeutics Inc."
Remodulin,"Treprostinil sodium","Pulmonary arterial hypertension (NYHA Class III and IV patients)","List with clinical criteria and/or conditions",Complete,"Feb 24, 2006","Jul 20, 2006",SR0052-000,"Northern Therapeutics Inc."
Remsima,infliximab,"Ulcerative Colitis","Reimburse with clinical criteria and/or conditions",Complete,"Oct 4, 2023","Apr 22, 2024",SR0816-001,"Celltrion Healthcare Co., Ltd."
Remsima,infliximab,"Crohn’s disease","Reimburse with clinical criteria and/or conditions",Complete,"Oct 4, 2023","Apr 22, 2024",SR0816-000,"Celltrion Healthcare Co., Ltd."
Remsima,infliximab,"Rheumatoid arthritis","Reimburse with clinical criteria and/or conditions",Complete,"Sep 24, 2020","Apr 22, 2021",SR0659-000,"Celltrion Healthcare Co., Ltd"
Remsima,Infliximab,"Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis",,Withdrawn,"May 30, 2014",,SE0383-000,"Fresenius Kabi Canada"
Renflexis,infliximab,"rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis","Reimburse with clinical criteria and/or conditions",Complete,"Sep 5, 2017","Feb 20, 2018",SE0532-000,"Merck Canada Inc."
Repatha,Evolocumab,"Primary hyperlipidemia and mixed dyslipidemia","Reimburse with clinical criteria and/or conditions",Complete,"Feb 17, 2017","Nov 22, 2017",SR0515-000,"Amgen Canada Inc."
Repatha,evolocumab,"Primary hyperlipidemia","Reimburse with clinical criteria and/or conditions",Complete,"Nov 29, 2023","Aug 8, 2024",SR0821-000,"Amgen Canada Inc."
Repatha,Evolocumab,"Primary hyperlipidemia; mixed dyslipidemia","List with clinical criteria and/or conditions",Complete,"Jun 30, 2015","Feb 19, 2016",SR0441-000,"Amgen Canada Inc."
Replagal,"Agalsidase alfa","Fabry Disease","Do not list",Complete,"Feb 19, 2004","Nov 24, 2004",SR0006-000,"Transkaryotic Therapies Inc."
Resotran,Prucalopride,"Constipation, chronic","Do not list",Complete,"Jan 30, 2012","Jul 19, 2012",SR0266-000,"Janssen Inc."
"Restasis ophthalmic emulsion",Cyclosporine,"Dry eye disease","Do not list",Complete,"Dec 17, 2010","Jul 18, 2011",SR0222-000,"Allergan Inc."
Retevmo,selpercatinib,"RET fusion-positive non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Aug 17, 2021","Apr 28, 2022",PC0261-000,"Eli Lilly Canada Inc."
Retevmo,selpercatinib,"Thyroid cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 29, 2021","Jun 29, 2022",PC0274-000,"Eli Lilly Canada Inc"
Retevmo,selpercatinib,"Thyroid cancer","Reimburse with clinical criteria and/or conditions",Complete,"Oct 29, 2021","Sep 26, 2022",PC0264-000,"Eli Lilly Canada Inc."
Revatio,"Sildenafil citrate","Pulmonary arterial hypertension (WHO class II and III)","List in a similar manner",Complete,"Sep 20, 2006","Feb 14, 2007",SR0076-000,"Pfizer Canada Inc."
Revestive,Teduglutide,"Short bowel syndrome","Reimburse with clinical criteria and/or conditions",Complete,"Nov 26, 2015","Jul 27, 2016",SR0459-000,"Shire Pharma Canada ULC/NPS Pharma Holdings Limited"
Revestive,teduglutide,"Short Bowel Syndrome (SBS), pediatrics","Reimburse with clinical criteria and/or conditions",Complete,"May 29, 2019","Nov 19, 2019",SR0606-000,"Shire Pharmaceuticals Ireland Limited"
Revolade,eltrombopag,"Severe aplastic anemia","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0007-000,"Novartis Pharmaceuticals Canada Inc."
Revolade,"Eltrombopag olamine","Chronic immune thrombocytopenic purpura","Do not list",Complete,"Apr 26, 2011","Oct 24, 2011",SR0230-000,GlaxoSmithKline
Revolade,Eltrombopag,"Thrombocytopenia associated with chronic hepatitis c infection","List with criteria/condition",Complete,"Mar 31, 2014","Mar 18, 2015",SR0377-000,GlaxoSmithKline
Rexulti,Brexpiprazole,schizophrenia,"Reimburse with clinical criteria and/or conditions",Complete,"Feb 3, 2017","Nov 22, 2017",SR0514-000,Otsuka-Lundbeck
Reyataz,Atazanavir,"HIV infection","List in a similar manner to other drugs in class",Complete,"Dec 16, 2003","May 27, 2004",SR0002-000,"Bristol Myers Squibb"
Rezurock,belumosudil,"Graft-versus-host disease","Reimburse with clinical criteria and/or conditions",Complete,"Jul 26, 2023","Feb 15, 2024",SR0789-000,"Sanofi-aventis Canada Inc."
Rinvoq,upadacitinib,"Crohns disease","Reimburse with clinical criteria and/or conditions",Complete,"Jun 5, 2023","Dec 14, 2023",SR0775-000,"AbbVie Corporation"
Rinvoq,upadacitinib,"Psoriatic Arthritis, adults","Reimburse with clinical criteria and/or conditions",Complete,"Jan 4, 2021","Aug 20, 2021",SR0658-000,AbbVie
Rinvoq,upadacitinib,"Giant cell arteritis",,Received,"May 16, 2025",,SR0877-000,"AbbVie Corporation"
Rinvoq,upadacitinib,"ankylosing spondylitis","Reimburse with clinical criteria and/or conditions",Complete,"Oct 17, 2022","May 11, 2023",SR0759-000,"AbbVie Corporation"
Rinvoq,upadacitinib,"Arthritis, Rheumatoid","Reimburse with clinical criteria and/or conditions",Complete,"Jul 4, 2019","Feb 4, 2020",SR0614-000,AbbVie
Rinvoq,upadacitinib,"atopic dermatitis","Reimburse with clinical criteria and/or conditions",Complete,"Apr 13, 2021","Jun 8, 2022",SR0685-000,AbbVie
Rinvoq,upadacitinib,"Ulcerative colitis","Reimburse with clinical criteria and/or conditions",Complete,"Apr 18, 2022","Sep 1, 2023",SR0730-000,AbbVie
Rituxan,Rituximab,"Granulomatosis with polyangiitis and microscopic polyangiitis","List with clinical criteria and/or conditions",Complete,"Feb 24, 2012","Aug 16, 2012",SR0270-000,"Hoffman-La Roche Ltd."
Rituxan,Rituximab,"Arthritis, Rheumatoid","List with clinical criteria and/or conditions",Complete,"Jun 26, 2006","Feb 14, 2007",SR0068-000,"Hoffmann-La Roche Limited"
Rosiver,Ivermectin,Rosacea,"List with criteria/condition",Complete,"Apr 30, 2015","Nov 19, 2015",SR0429-000,"Galderma Canada Inc."
Rozlytrek,entrectinib,"Extracranial solid tumours with NTRK gene fusion","Reimburse with clinical criteria and/or conditions",Complete,"Jan 25, 2022","Nov 3, 2022",PC0278-000,"Hoffmann-La Roche Ltd."
Rukobia,fostemsavir,"Human immunodeficiency virus type 1 (HIV-1)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 28, 2022","May 10, 2023",SR0760-000,"ViiV Healthcare ULC"
Ruzurgi,amifampridine,"Lambert-Eaton myasthenic syndrome","Reimburse with clinical criteria and/or conditions",Complete,"Oct 5, 2020","Apr 20, 2021",SR0660-000,"Médunik Canada Inc."
Ryaltris,"olopatadine hydrochloride and mometasone","Seasonal allergic rhinitis","Do not reimburse",Active,"Jun 21, 2024","Apr 8, 2025",SR0848-000,"Bausch Health"
Rybelsus,semaglutide,"diabetes mellitus, type 2","Reimburse with clinical criteria and/or conditions",Complete,"Nov 26, 2020","Jun 8, 2021",SR0637-000,"Novo Nordisk Canada Inc."
Rybrevant,amivantamab,"Locally advanced or metastatic non-small cell lung cancer (NSCLC)",,Active,"Feb 20, 2025",,PC0393-000,"Janssen Inc."
Rybrevant,amivantamab,"Non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Apr 21, 2022","Mar 1, 2023",PC0289-000,"Janssen Inc."
Rybrevant,amivantamab,"Locally advanced or metastatic non-small cell lung cancer (NSCLC)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 21, 2024","Jan 10, 2025",PC0376-000,"Janssen Inc"
Rylaze,"crisantaspase recombinant","Acute lymphoblastic leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Aug 18, 2022","Apr 26, 2023",PC0301-000,"Jazz Pharmaceuticals Canada Inc."
Rystiggo,rozanolixizumab,"Generalized myasthenia gravis (gMG)",,Active,"Aug 2, 2024",,SR0846-000,"UCB Canada Inc."
Samsca,Tolvaptan,"Hyponatremia, non-hypovolemic","Do not list",Complete,"Jul 3, 2012","Feb 13, 2013",SR0283-000,"Otsuka Canada Pharmaceutical Inc."
Saphnelo,anifrolumab,"Systemic lupus erythematosus","Reimburse with clinical criteria and/or conditions",Complete,"Jan 28, 2022","Jan 20, 2023",SR0717-000,"AstraZeneca Canada Inc."
Saphris,Asenapine,Schizophrenia,"Do not list",Complete,"Dec 12, 2011","Jun 14, 2012",SR0262-000,"Lundbeck Canada Inc."
Saphris,Asenapine,"Bipolar I disorder","List with clinical criteria and/or conditions",Complete,"Dec 12, 2011","Jun 14, 2012",SR0262-001,"Lundbeck Canada Inc."
Sarclisa,isatuximab,"multiple myeloma not eligible for ASCT",,Active,"Oct 30, 2024",,PC0378-000,"Sanofi-Aventis Canada Inc. (Sanofi)"
Sarclisa,isatuximab,"Multiple myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Jul 15, 2021","Jan 28, 2022",PC0256-000,"Sanofi Genzyme, a division of sanofi-aventis Canada Inc."
Sativex,Delta-9-tetrahydrocannabinol/cannabidiol,"Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids)","Do not list",Complete,"Aug 7, 2007","Feb 20, 2008",SR0106-000,"GW  Pharma Ltd."
Sativex,Delta-9-tetrahydrocannabinol/cannabidiol,"Pain, Neuropathic (adjunctive) in MS.","Do not list",Complete,"Feb 27, 2007","Sep 26, 2007",SR0092-000,"GW  Pharma Ltd."
Saxenda,liraglutide,"Chronic weight management in adults","Do not reimburse",Complete,"Dec 23, 2020","Sep 1, 2021",SR0668-000,"Novo Nordisk Canada Inc."
Scemblix,asciminib,"Philadelphia chromosome-positive chronic myeloid leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Jan 20, 2022","Aug 5, 2022",PC0275-000,"Novartis Pharmaceuticals Canada Inc."
Scemblix,asciminib,"Philadelphia chromosome-positive chronic myeloid leukemia",,Active,"Mar 10, 2025",,PC0418-000,"Novartis Pharmaceuticals Canada Inc."
Scemblix,asciminib,"Philadelphia chromosome-positive chronic myeloid leukemia",,Active,"Mar 10, 2025",,PC0405-000,"Novartis Pharmaceuticals Canada"
Sebivo,Telbivudine,"Hepatitis B (chronic)","Do not list",Complete,"Dec 4, 2006","Sep 26, 2007",SR0088-000,"Novartis Pharmaceuticals Canada Inc."
Seebri,"Glycopyrronium bromide","Chronic obstructive pulmonary disease","List with criteria/condition",Complete,"Nov 30, 2012","May 15, 2013",SR0300-000,"Novartis Pharmaceuticals Canada Inc."
Segluromet,"ertugliflozin and metformin hydrochloride","Diabetes mellitus, Type 2","Do not reimburse",Complete,"Apr 30, 2018","Jan 23, 2019",SR0566-000,"Merck Canada Inc."
Semglee,"insulin glargine","Diabetes mellitus, Type 1 & 2",,Withdrawn,"Nov 14, 2018",,SE0589-000,"BGP PHARMA ULC"
Sensipar,"Cinacalcet hydrochloride","Secondary hyper-parathyroidism in chronic kidney disease","Do not list",Complete,"Aug 20, 2004","Mar 23, 2005",SR0018-000,"Amgen Canada Inc."
Signifor,"Pasireotide diaspartate","Cushing’s disease","Do not list",Complete,"Feb 27, 2014","Feb 24, 2015",SR0372-000,"Novartis Pharmaceuticals Inc."
"Signifor LAR",pasireotide,"​Acromegaly, adults",,Active,"Oct 2, 2024",,SR0859-000,"Recordati Rare Diseases Canada Inc."
Siliq,brodalumab,"Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Dec 14, 2017","Jun 20, 2018",SR0547-000,"Valeant Canada LP"
Silkis,Calcitriol,"Psoriasis, mild to moderate plaque","Do not list",Complete,"Mar 15, 2010","Sep 22, 2010",SR0199-000,"Galderma Canada Inc."
Simbrinza,"Brinzolamide / brimonidine","Glaucoma and ocular hypertension",List,Complete,"Nov 3, 2014","Jun 17, 2015",SR0403-000,"Alcon Canada Inc."
Simponi,Golimumab,"Arthritis, Rheumatoid","List in a similar manner",Complete,"Sep 3, 2009","Mar 17, 2010",SR0174-000,"Centocor Inc."
Simponi,Golimumab,"Ankylosing spondylitis","List in a similar manner",Complete,"Sep 3, 2009","Mar 17, 2010",SR0196-000,"Centocor Inc."
Simponi,Golimumab,"Ulcerative colitis","Do not list at the submitted price",Complete,"Jul 12, 2013","Mar 19, 2014",SR0341-000,"Janssen Inc."
Simponi,Golimumab,"Arthritis, psoriatic","List in a similar manner",Complete,"Sep 3, 2009","Mar 17, 2010",SR0195-000,"Centocor Inc."
"Simponi I.V.",Golimumab,"Arthritis, rheumatoid","List with criteria/condition",Complete,"Sep 12, 2013","Jul 17, 2014",SR0351-000,"Janssen Inc."
Sivextro,"Tedizolid phosphate","Acute bacterial skin and skin structure infections",,Withdrawn,"Jan 16, 2015",,SR0413-000,"Cubist Pharmaceuticals Canada, Inc."
Skyclarys,omaveloxolone,"Friedreich’s ataxia",,Active,"Oct 2, 2024",,SR0864-000,"Biogen Canada Inc."
Skyrizi,risankizumab,"Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Oct 22, 2018","May 28, 2019",SR0583-000,"AbbVie Corporation"
Skyrizi,risankizumab,"Crohn's disease","Reimburse with clinical criteria and/or conditions",Complete,"Oct 28, 2022","May 12, 2023",SR0767-000,AbbVie
Skyrizi,risankizumab,"Ulcerative colitis",,Active,"Mar 31, 2025",,SR0890-000,"AbbVie Corporation"
Slynd,drospirenone,"Contraceptive, oral","Reimburse with clinical criteria and/or conditions",Complete,"Aug 14, 2023","Mar 18, 2024",SR0806-000,"Duchesnay Inc."
Sogroya,somapacitan,"Growth Hormone Deficiency (GHD)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 27, 2023","Nov 17, 2023",SR0779-000,"Novo Nordisk Canada Inc."
Sohonos,palovarotene,"Fibrodysplasia Ossificans Progressiva","Reimburse with clinical criteria and/or conditions",Complete,"Oct 21, 2022","May 11, 2023",SR0761-000,"Ipsen Biopharmaceuticals Canada, Inc."
Soliqua,"lixisenatide + insulin glargine","Diabetes mellitus, Type 2","Reimburse with clinical criteria and/or conditions",Complete,"May 18, 2018","Dec 24, 2018",SR0564-000,"sanofi-aventis Canada Inc."
Soliris,Eculizumab,"Hemolytic Uremic Syndrome, Atypical","Do not list",Complete,"Jan 7, 2013","Jul 18, 2013",SR0304-000,"Alexion Pharma Canada"
Soliris,eculizumab,"Neuromyelitis optica spectrum disorder","Reimburse with clinical criteria and/or conditions",Complete,"Feb 25, 2020","Aug 19, 2020",SR0640-000,"Alexion Pharma Canada Corp."
Soliris,Eculizumab,"Atypical hemolytic uremic syndrome",N/A,Complete,"Feb 9, 2015",,SF0416-000,"Alexion Pharma Canada"
Soliris,eculizumab,"Myasthenia Gravis (gMG), adults","Reimburse with clinical criteria and/or conditions",Complete,"Apr 1, 2020","Oct 19, 2020",SR0605-000,"Alexion Pharma Canada Corp."
Soliris,Eculizumab,"Paroxysmal nocturnal hemoglobinuria (PNH)","Do not list",Complete,"Sep 18, 2009","Feb 18, 2010",SR0176-000,"Alexion Pharmaceuticals Inc."
"Somatuline Autogel","Lanreotide acetate",Acromegaly,"List in a similar manner to other drugs in class",Complete,"Feb 20, 2007","Jul 19, 2007",SR0091-000,"Ipsen Limited"
Somavert,Pegvisomant,acromegaly,"Do not list",Complete,"Jan 25, 2006","Aug 2, 2006",SR0050-000,"Pfizer Canada Inc."
Sotyktu,deucravacitinib,"Psoriasis, moderate to severe plaque","Do not reimburse",Complete,"Sep 27, 2022","Aug 8, 2023",SR0756-000,"Bristol-Myers Squibb Company"
Sovaldi,sofosbuvir,"Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Jan 6, 2016","May 18, 2016",SF0464-000,"Gilead Sciences Canada Inc."
Sovaldi,Sofosbuvir,"Hepatitis C, chronic","List with criteria/condition",Complete,"Oct 1, 2013","Aug 18, 2014",SR0356-000,"Gilead Sciences Canada Inc."
Spevigo,spesolimab,"generalized pustular psoriasis (GPP)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 4, 2024","Dec 12, 2024",SR0844-000,"Boehringer Ingelheim (Canada) Ltd."
Spinraza,nusinersen,"Spinal Muscular Atrophy","Reimburse with clinical criteria and/or conditions",Complete,"Jun 28, 2017","Dec 22, 2017",SR0525-000,"Biogen Canada Inc."
Spinraza,Nusinersen,"Spinal Muscular Atrophy","Reimburse with clinical criteria and/or conditions",Complete,"Jul 24, 2018","Feb 27, 2019",SR0576-000,"Biogen Canada Inc."
Spinraza,nusinersen,"Spinal Muscular Atrophy","Do not reimburse",Complete,"Dec 2, 2021","Aug 11, 2022",SR0713-000,"Biogen Canada Inc."
"Spiriva Respimat","Tiotropium bromide","Chronic obstructive pulmonary disease","List with clinical criteria and/or conditions",Complete,"Dec 23, 2014","Jul 16, 2015",SR0412-000,"Boehringer Ingelheim (Canada) Ltd."
Spravato,"esketamine hydrochloride","Major depressive disorder (MDD), adults","Do not reimburse",Complete,"Jun 24, 2019","Dec 16, 2020",SR0621-000,"Janssen Inc."
Spriafil,Posaconazole,"Aspergillus and Candida infections","Do not list",Complete,"May 24, 2007","Jan 30, 2008",SR0097-000,"Schering-Plough Canada Inc."
Stalevo,"Carbidopa, levodopa and entacapone","Parkinsons Disease","List in a similar manner",Complete,"Apr 15, 2008","Oct 16, 2008",SR0131-000,"Novartis Pharmaceuticals Canada Inc."
Steglatro,ertugliflozin,"Diabetes mellitus, Type 2","Do not reimburse",Complete,"Apr 30, 2018","Jan 23, 2019",SR0565-000,"Merck Canada Inc."
Stelara,Ustekinumab,Psoriasis,"List with clinical criteria and/or conditions",Complete,"Jan 7, 2009","Jun 17, 2009",SR0156-000,"Janssen-Ortho Inc."
Stelara,Ustekinumab,"Arthritis, psoriatic","Do not list at the submitted price",Complete,"Oct 30, 2013","Oct 20, 2014",SR0359-000,"Janssen Inc."
"Stelara/Stelara I.V",ustekinumab,"Ulcerative colitis","Reimburse with clinical criteria and/or conditions",Complete,"Aug 12, 2019","Jul 16, 2020",SR0627-000,"Janssen Inc."
"Stelara/Stelara I.V.",ustekinumab,"Crohn’s disease","Reimburse with clinical criteria and/or conditions",Complete,"Sep 12, 2016","Mar 21, 2017",SR0501-000,"Janssen Inc."
Strattera,"Atomoxetine hydrochloride","Attention deficit hyperactivity disorder",N/A,Complete,"Sep 25, 2006",,SF0085-000,"Eli Lilly Canada Inc."
Strattera,"Atomoxetine hydrochloride","Attention deficit hyperactivity disorder","Do not list",Complete,"Jan 25, 2005","Sep 28, 2005",SR0031-000,"Eli Lilly Canada Inc."
Strensiq,"Asfotase alfa","Hypophosphatasia, pediatric-onset","List with criteria/condition",Complete,"Aug 21, 2015","Mar 23, 2016",SR0443-000,"Alexion Pharmaceuticals Canada"
Stribild,"Elvitegravir/  Cobicistat/  Emtricitabine/  Tenofovir Disoproxil Fumarate","HIV infection","List with criteria/condition",Complete,"Nov 30, 2012","May 15, 2013",SR0301-000,"Gilead Sciences Canada Inc."
Sublinox,"Zolpidem tartrate",Insomnia,"Do not list",Complete,"Mar 7, 2013","Sep 25, 2013",SR0314-000,"Meda Valeant Pharma Canada Inc."
Sublocade,buprenorphine,"Opioid use disorder, treatment","Reimburse with clinical criteria and/or conditions",Complete,"Dec 20, 2018","Jun 19, 2019",SR0579-000,"Indivior Canada Ltd."
Suboxone,Buprenorphine/naloxone,"Opioid drug dependence (Substitution treatment)","List with clinical criteria and/or conditions",Complete,"Mar 6, 2008","Sep 24, 2008",SR0128-000,"Schering-Plough Canada Inc"
Sunosi,solriamfetol,"Excessive daytime sleepiness (narcolepsy)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0038-000,"Axsome Malta Ltd"
Sunosi,solriamfetol,"Excessive daytime sleepiness","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0039-000,"Axsome Malta Ltd"
Sunvepra,Asunaprevir,"Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Feb 13, 2015","Jul 20, 2016",SR0418-000,"Bristol-Myers Squibb Canada Inc."
Sutent,Sunitinib,"Gastrointestinal stromal tumour (GIST)","List with clinical criteria and/or conditions",Complete,"Jul 20, 2006","Mar 28, 2007",SR0069-000,"Pfizer Canada Inc."
Sutent,"Sunitinib malate","Cancer, Metastatic renal cell carcinoma","Do not list",Complete,"Sep 20, 2006","Apr 26, 2007",SR0077-000,"Pfizer Canada Inc."
Symdeko,tezacaftor/ivacaftor,"Cystic fibrosis, F508del mutation(s)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0008-000,"Vertex Pharmaceuticals Canada Inc."
Symtuza,"Darunavir/cobicistat/emtricitabine/tenofovir alafenamide","HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Dec 22, 2017","Jul 25, 2018",SR0552-000,"Janssen Inc."
Synjardy,"Empagliflozin and metformin","Diabetes mellitus (Type 2)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 29, 2016","Oct 25, 2016",SR0489-000,"Boehringer Ingelheim (Canada) Ltd."
Tabrecta,capmatinib,"Metastatic non-small cell lung cancer (NSCLC)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0036-000,"Novartis Pharmaceuticals Canada Inc."
"Tafinlar and Mekinist","dabrafenib and trametinib","Pediatric high-grade glioma with BRAF V600E","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0028-000,"Novartis Pharmaceuticals Canada Inc."
"Tafinlar and Mekinist","dabrafenib and trametinib","Pediatric low-grade glioma with BRAF V600E","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0029-000,"Novartis Pharmaceuticals Canada Inc."
Tafinlar-Mekinist,"dabrafenib trametinib","Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation",,Cancelled,,,PC0337-000,
Tagrisso,osimertinib,"Non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Dec 11, 2023","Oct 3, 2024",PC0336-000,"AstraZeneca Canada Inc."
Tagrisso,osimertinib,"Non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 24, 2021","Jan 10, 2022",PC0246-000,"AstraZeneca Canada Inc."
Tagrisso,osimertinib,"Unresectable (stage III) non-small cell lung cancer",,Active,"Feb 13, 2025",,PC0398-000,"AstraZeneca Canada Inc."
Takhzyro,lanadelumab,"Hereditary angioedema, prevention","Reimburse with clinical criteria and/or conditions",Complete,"May 29, 2019","Nov 19, 2019",SR0618-000,"Shire Pharma Canada ULC"
Taltz,ixekizumab,"Ankylosing spondylitis","Reimburse with clinical criteria and/or conditions",Complete,"Sep 20, 2019","Mar 24, 2020",SR0630-000,"Eli Lilly Canada Inc."
Taltz,ixekizumab,"Arthritis, psoriatic","Reimburse with clinical criteria and/or conditions",Complete,"Feb 20, 2018","Aug 21, 2018",SR0558-000,"Eli Lilly Canada Inc."
Taltz,Ixekizumab,"Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Mar 23, 2016","Oct 25, 2016",SR0481-000,"Eli Lilly Canada Inc."
Talvey,talquetamab,"Relapsed or refractory multiple myeloma","Do not reimburse",Active,"May 1, 2024","Feb 27, 2025",PC0363-000,"Janssen Inc."
Talzenna,talazoparib,"Metastatic castration-resistant prostate cancer",,Active,"Mar 27, 2025",,PC0417-000,"Pfizer Canada ULC"
Talzenna,talazoparib,"Breast Cancer","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0017-000,"Pfizer Canada Inc."
Talzenna,talazoparib,"Metastatic castration-resistant prostate cancer (mCRPC)",,Withdrawn,"Aug 15, 2023",,PC0316-000,"Pfizer Canada ULC"
Tarceva,Erlotinib,"Cancer, Lung , non-small cell","List with clinical criteria and/or conditions",Complete,"Jul 19, 2005","Dec 7, 2005",SR0037-000,"Hoffmann-La Roche Limited"
Targin,"Oxycodone / naloxone","Pain, Moderate to severe and relief of opioid-induced constipation",,Cancelled,"Nov 30, 2010",,SR0219-000,"Purdue Pharma"
Targin,"Oxycodone HCI / naloxone HCI","Pain, moderate to severe and relief of opioid-induced constipation","Do not list",Complete,"Jul 5, 2011","Jan 25, 2012",SR0241-000,"Purdue Pharma"
Tavalisse,fostamatinib,"Chronic immune thrombocytopenia","Do not reimburse",Complete,"Jul 22, 2021","Apr 5, 2022",SR0701-000,"Medison Pharma Canada"
Tavneos,avacopan,"Antineutrophil cytoplasmic antibody-associated vasculitis","Do not reimburse",Complete,"Oct 14, 2022","Aug 10, 2023",SR0732-000,"Otsuka Canada Pharmaceutical Inc."
TBC,filgotinib,"Arthritis, Rheumatoid",,Withdrawn,"Aug 4, 2020",,SR0656-000,"Gilead Sciences Canada, Inc."
TBC,nemolizumab,"Prurigo nodularis (PN)",,Active,"Jan 7, 2025",,SR0861-000,"Galderma Canada Inc."
TBC,abaloparatide,"Osteoporosis, postmenopausal women",,Withdrawn,"Aug 2, 2022",,SR0744-000,"Paladin Labs Inc."
TBC,ferumoxytol,"Iron deficiency anemia",,Withdrawn,"Aug 31, 2022",,SR0753-000,"Covis Pharma Canada Ltd."
TBC,"datopotamab deruxtecan","advanced or metastatic non-squamousnon-small cell lung cancer (NSCLC)",,Cancelled,,,PC0384-000,"AstraZeneca Canada Inc."
TBC,"Darunavir / cobicistat","HIV infection",,Withdrawn,"Apr 4, 2014",,SR0378-000,"Janssen Inc."
TBC,garadacimab,"Hereditary angioedema  (HAE)",,Active,"Jul 31, 2024",,SR0860-000,"CSL Behring Canada Inc."
TBC,leniolisib,"Activated phosphoinositide 3 kinase delta syndrome",,Suspended,"Apr 19, 2024",,SR0792-000,"Pharming Technologies BV"
TBC,daprodustat,"Anemia due to chronic kidney disease",,Withdrawn,"Oct 25, 2022",,SR0762-000,"GlaxoSmithKline Inc."
TBC,pegcetacoplan,"Geographic atrophy secondary to age-related macular degeneration",,Withdrawn,"Jul 23, 2024",,SR0810-000,"Apellis Canada, Inc."
TBC,ravulizumab,"Paroxysmal nocturnal hemoglobinuria.",,Withdrawn,"Jul 4, 2019",,SR0623-000,"Alexion Pharma Canada Corp"
TBC,"belantamab mafodotin, pomalidomide, dexamethasone","Previously treated multiple myeloma",,Active,"Dec 19, 2024",,PC0380-000,"GlaxoSmithKline Inc."
TBC,nemolizumab,"atopic dermatitis",,Active,"Feb 27, 2025",,SR0869-000,"Galderma Canada Inc."
TBC,crovalimab,"paroxysmal nocturnal  hemoglobinuria (PNH)",,Active,"Oct 1, 2024",,SR0858-000,"Hoffmann-La Roche Limited"
TBC,donanemab,"Alzheimer's disease",,Suspended,"Aug 28, 2024",,SR0857-000,"Eli Lilly Canada Inc."
TBC,risperidone,"Schizophrenia, adults",,Active,"Oct 13, 2023",,SR0811-000,"Teva Canada Innovation"
TBC,delgocitinib,"Chronic hand eczema",,Active,"Nov 25, 2024",,SR0875-000,"LEO Pharma Inc."
TBC,seladelpar,"primary biliary cholangitis",,Pending,,,SR0899-000,"Gilead Sciences Canada, Inc."
TBC,etonogestrel,"Prevention of pregnancy",,Withdrawn,"Sep 26, 2019",,SR0629-000,"Merck Canada Inc."
TBC,tirzepatide,"Diabetes mellitus, type 2",,Cancelled,"Aug 12, 2022",,SR0751-000,"Eli Lilly Canada Inc."
TBC,filgrastim,"Prevention or treatment of neutropenia in various indications",,Cancelled,"Nov 1, 2018",,SE0585-000,"Pfizer Canada Inc."
TBC,"mirvetuximab soravtansine","Epithelial ovarian, fallopian tube, or primary peritoneal cancer",,Active,"Mar 3, 2025",,PC0394-000,"AbbVie Corporation"
TBC,"halobetasol propionate and tazarotene","Psoriasis, moderate to severe plaque",,Withdrawn,"Feb 4, 2019",,SR0600-000,"Bausch Health, Canada Inc."
TBC,"pegunigalsidase alfa","Fabry disease",,Active,"Apr 4, 2025",,SR0872-000,"Chiesi Canada Corp."
TBC,filgrastim,,,Cancelled,,,SE0596-000,"Sandoz Canada Inc."
TBC,"dabrafenib trametinib","Pediatric low grade glioma (ped LGG)",,Active,"Oct 7, 2024",,PX0375-000,N/A
TBC,"belantamab mafodotin, bortezomib, dexamethasone","Previously treated multiple myeloma",,Active,"Dec 19, 2024",,PC0379-000,"GlaxoSmithKline Inc."
TBC,teprotumumab,"Thyroid Eye Disease (TED), chronic",,Withdrawn,"Oct 25, 2024",,SR0853-001,"Amgen Canada Inc."
Tecartus,"brexucabtagene autoleucel","Mantle cell lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Dec 18, 2020","Aug 24, 2021",PG0219-000,"Gilead Sciences Canada Inc."
Tecartus,"brexucabtagene autoleucel","Acute lymphoblastic leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Sep 16, 2022","Mar 29, 2023",PG0304-000,"Gilead Sciences Canada, Inc."
Tecentriq,atezolizumab,"Non-small cell lung cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 24, 2022","Sep 1, 2022",PC0269-000,"Hoffmann-La Roche"
Tecentriq,atezolizumab,"Small Cell Lung Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jan 24, 2022","Sep 1, 2022",PC0277-000,"Hoffmann-La Roche Limited"
Tecfidera,"Dimethyl fumarate","Multiple sclerosis, relapsing-remitting","List with criteria/condition",Complete,"Feb 4, 2013","Sep 25, 2013",SR0309-000,"Biogen Idec Canada Inc."
Technivie,"Ombitasvir/ paritaprevir/ ritonavir","Hepatitis C, chronic","List with clinical criteria and/or conditions",Complete,"Sep 4, 2015","Mar 18, 2016",SR0444-000,"AbbVie Corporation"
Tecvayli,teclistamab,"Relapsed or refractory multiple myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Aug 31, 2023","Apr 8, 2024",PC0332-000,"Janssen Inc."
Tegsedi,inotersen,"hereditary transthyretin amyloidosis","Reimburse with clinical criteria and/or conditions",Complete,"Feb 22, 2019","Dec 18, 2019",SR0603-000,"Akcea Therapeutics Inc."
Telzir,"Fosamprenavir calcium","HIV infection","List in a similar manner to other drugs in class",Complete,"Jan 24, 2005","Jun 16, 2005",SR0030-000,"GlaxoSmithKline Inc."
Tepezza,teprotumumab,"Thyroid Eye Disease (TED), active",,Active,"Oct 25, 2024",,SR0853-000,"Amgen Canada Inc."
Tepmetko,tepotinib,"Locally advanced or metastatic non-small cell lung cancer","Do not reimburse",Complete,"Aug 30, 2021","Aug 24, 2022",PC0255-000,"EMD Serono Canada, a division of EMD Inc."
"Teveten Plus","Eprosartan mesylate/ hydrochlorothiazide","Hypertension, Essential","List in a similar manner to other drugs in class",Complete,"Jul 8, 2004","Dec 15, 2004",SR0016-000,"Solvay Pharma Inc."
Tezspire,tezepelumab,Asthma,"Reimburse with clinical criteria and/or conditions",Complete,"Apr 14, 2022","Nov 16, 2022",SR0731-000,"AstraZeneca Canada Inc."
Thelin,"Sitaxsentan sodium","Pulmonary arterial hypertension (WHO class II and III)","Do not list",Complete,"May 5, 2008","Jan 28, 2009",SR0132-000,"Encysive Canada Inc."
Thelin,"Sitaxsentan sodium","Pulmonary arterial hypertension (WHO class II and III)","Do not list",Complete,"Jun 22, 2007","Jan 30, 2008",SR0099-000,"Encysive Canada Inc."
Tibsovo,ivosidenib,"Acute myeloid leukemia (AML)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 19, 2024","Oct 4, 2024",PC0349-000,"Servier Canada Inc"
Tivicay,Dolutegravir,"HIV infection",List,Complete,"Oct 18, 2013","Aug 18, 2014",SR0357-000,"ViiV Healthcare ULC"
Toctino,Alitretinoin,Eczema,"List with clinical criteria and/or conditions",Complete,"May 6, 2011","Oct 24, 2011",SR0232-000,Actelion
Toviaz,"Fesoterodine fumarate","Overactive bladder","List in a similar manner",Complete,"Apr 27, 2012","Oct 18, 2012",SR0277-000,"Pfizer  Canada Inc."
Trajenta,Linagliptin,"Diabetes mellitus, type 2","List with clinical criteria and/or conditions",Complete,"Aug 23, 2011","Feb 15, 2012",SR0244-000,"Boehringer Ingelheim Canada"
Tramacet,"Tramadol hydrochloride /acetaminophen","Acute pain","Do not list",Complete,"Oct 2, 2006","May 17, 2007",SR0079-000,"Janssen-Ortho Inc."
Translarna,ataluren,,,Cancelled,,,SR0607-000,"PTC Therapeutics Canada ULC"
Trecondyv,treosulfan,"Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)","Reimburse with clinical criteria and/or conditions",Complete,"Jul 14, 2023","Feb 28, 2024",PC0324-000,"Medexus Pharmaceuticals Inc."
Trecondyv,treosulfan,"Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0030-000,"Medexus Pharmaceuticals Inc."
"Trelegy Ellipta","fluticasone furoate umeclidinium vilanterol","Chronic obstructive pulmonary disease (COPD)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 1, 2018","Aug 23, 2018",SR0562-000,"GlaxoSmithKline Inc."
"Trelegy Ellipta","fluticasone furoate/umeclidinium bromide/vilanterol trifenatate","Asthma, maintenance","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0025-000,"GlaxoSmithKline Inc."
Trelstar,"Triptorelin pamoate","Cancer, prostate","List in a similar manner to other drugs in class",Complete,"Feb 27, 2006","Jul 20, 2006",SR0051-000,"Watson Laboratories Inc."
Tremfya,guselkumab,"Crohn’s  disease",,Active,"Jan 31, 2025",,SR0882-000,"Janssen Inc."
Tremfya,guselkumab,"Psoriasis, moderate to severe plaque","Reimburse with clinical criteria and/or conditions",Complete,"Aug 25, 2017","Feb 21, 2018",SR0530-000,"Janssen Inc."
Tremfya,guselkumab,"Psoriatic arthritis","Reimburse with clinical criteria and/or conditions",Complete,"May 2, 2022","Nov 17, 2022",SR0733-000,"Janssen Inc."
Tremfya,guselkumab,"Ulcerative colitis",,Active,"Oct 21, 2024",,SR0874-000,"Janssen Inc."
Tresiba,"insulin degludec","Diabetes mellitus, Type 1 & 2","Reimburse with clinical criteria and/or conditions",Complete,"May 31, 2017","Nov 20, 2017",SR0521-000,"Novo Nordisk Canada Inc."
Tridural,"Tramadol hydrochloride",Pain,"Do not list",Complete,"Nov 29, 2007","Apr 17, 2008",SR0117-000,"Labopharm Inc."
Trikafta,"elexacaftor / tezacaftor / ivacaftor and ivacaftor","Cystic fibrosis, F508del CFTR mutation","Reimburse with clinical criteria and/or conditions",Complete,"Jan 22, 2021","Sep 16, 2021",SR0673-000,"Vertex Pharmaceuticals (Canada) Incorporated"
Trikafta,"elexacaftor/tezacaftor/ivacaftor and ivacaftor","Cystic fibrosis, F508del CFTR mutation, 2 years and older","Reimburse with clinical criteria and/or conditions",Complete,"May 10, 2023","Nov 24, 2023",SR0776-000,"Vertex Pharmaceuticals (Canada) Incorporated"
Trikafta,"elexacaftor/tezacaftor/ivacaftor and ivacaftor","Cystic fibrosis, F508del or responsive CFTR mutation,  2 years and older","Reimburse with clinical criteria and/or conditions",Complete,"Mar 5, 2024","Oct 17, 2024",SR0837-000,"Vertex Pharmaceuticals (Canada) Incorporated"
Trikafta,"elexacaftor/tezacaftor/ivacaftor and ivacaftor","Cystic fibrosis, F508del CFTR mutation, 6 years and older","Reimburse with clinical criteria and/or conditions",Complete,"Nov 5, 2021","Jun 17, 2022",SR0710-000,"Vertex Pharmaceuticals (Canada) Inc."
Trintellix,"vortioxetine hydrobromide","Major depressive disorder (MDD), adults.","Reimburse with clinical criteria and/or conditions",Complete,"May 1, 2019","Feb 12, 2020",SR0611-000,"Lundbeck Canada Inc."
Trintellix,Vortioxetine,"Depression, major depressive disorder",,Withdrawn,"Oct 31, 2014",,SR0402-000,"Lundbeck Canada Inc."
Triumeq,"Dolutegravir / abacavir / lamivudine","HIV Infection","List with criteria/condition",Complete,"Jul 31, 2014","Apr 17, 2015",SR0387-000,"ViiV Healthcare"
Trodelvy,"sacituzumab govitecan","Locally advanced or metastatic triple-negative breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jun 30, 2021","Jan 27, 2022",PC0254-000,"Gilead Sciences Canada, Inc."
Trodelvy,"sacituzumab govitecan","HR+, HER2− advanced or metastatic breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Jul 18, 2023","Feb 1, 2024",PC0323-000,"Gilead Sciences Canada, Inc."
Trosec,"Trospium chloride","Bladder, overactive","List with clinical criteria and/or conditions",Complete,"Mar 24, 2006","Aug 24, 2006",SR0055-000,"Oryx Pharmaceuticals Inc."
Trulicity,dulaglutide,"Diabetes mellitus, Type 2","Reimburse with clinical criteria and/or conditions",Complete,"Dec 22, 2015","Jun 16, 2016",SR0462-000,"Eli Lilly Canada Inc."
Truqap,capivasertib,"HR-positive, HER2-negative locally advanced or metastatic breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 14, 2024","Aug 30, 2024",PC0341-000,"AstraZeneca Canada Inc"
Truvada,"Emtricitabine/tenofovir disoproxil fumarate","HIV-1 infection, pre-exposure prophylaxis","Reimburse with clinical criteria and/or conditions",Complete,"Mar 3, 2016","Aug 24, 2016",SR0479-000,"Gilead Sciences Canada Inc."
Truvada,"Emtricitabine/tenofovir disoproxil fumarate","HIV infection","List with clinical criteria and/or conditions",Complete,"Jul 7, 2008","Dec 17, 2008",SF0138-000,"Gilead Sciences Canada Inc."
Truvada,"Emtricitabine/tenofovir disoproxil fumarate","HIV infection","List with clinical criteria and/or conditions",Complete,"May 29, 2006","Oct 25, 2006",SR0063-000,"Gilead Sciences Canada Inc."
"Tudorza Genuair","Aclidinium bromide","Chronic Obstructive Pulmonary Disease","List with criteria/condition",Complete,"Aug 21, 2013","Apr 21, 2014",SR0346-000,"Almirall Canada Ltd."
Tukysa,tucatinib,"Advanced or Metastatic Breast Cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 26, 2021","Nov 17, 2021",PC0243-000,"Seagen Canada Inc."
Twynsta,"Telmisartan/ Amlodipine",Hypertension,List,Complete,"Aug 23, 2011","Dec 16, 2011",SR0245-000,"Boehringer Ingelheim Canada"
Twynsta,"Telmisartan / Amlodipine",Hypertension,,Cancelled,"Jul 9, 2010",,SR0207-000,"Boehringer Ingelheim (Canada) Ltd"
Tysabri,natalizumab,"Multiple Sclerosis, relapsing-remitting",,Withdrawn,"Apr 21, 2021",,SR0687-000,"Biogen Canada, Inc."
Tysabri,Natalizumab,"Multiple Sclerosis, relapsing-remitting","Do not list",Complete,"Oct 26, 2006","Apr 26, 2007",SR0082-000,"Biogen Idec Canada Inc."
Tysabri,Natalizumab,"Multiple Sclerosis, relapsing-remitting","List with clinical criteria and/or conditions",Complete,"May 6, 2008","Feb 25, 2009",SR0133-000,"Biogen Idec Canada Inc."
Tzield,teplizumab,"Delay onset of Stage 3 Type 1 Diabetes",,Active,"Feb 19, 2025",,SR0867-000,"sanofi-aventis Canada Inc."
Uloric,Febuxostat,Gout,"List with clinical criteria and/or conditions",Complete,"Oct 27, 2010","Apr 25, 2011",SR0213-000,"Takeda Canada Inc."
"Ultibro Breezhaler",Indacaterol/glycopyrronium,"Chronic obstructive pulmonary disease","List with criteria/condition",Complete,"Feb 3, 2014","Dec 19, 2014",SR0369-000,"Novartis Pharmaceuticals Canada Inc."
Ultomiris,ravulizumab,"Generalized Myasthenia Gravis","Reimburse with clinical criteria and/or conditions",Complete,"Jun 4, 2024","Dec 17, 2024",SR0855-000,"Alexion Pharma GmbH"
Ultomiris,ravulizumab,"Neuromyelitis optica spectrum disorder (NMOSD)","Reimburse with clinical criteria and/or conditions",Complete,"Aug 29, 2023","Mar 13, 2024",SR0785-000,"Alexion Pharma GmbH"
Ultomiris,ravulizumab,"Atypical hemolytic uremic syndrome","Reimburse with clinical criteria and/or conditions",Complete,"Jun 8, 2022","Feb 27, 2023",SR0740-000,"Alexion Pharma GmBH"
Ultomiris,ravulizumab,"Paroxysmal nocturnal hemoglobinuria","Reimburse with clinical criteria and/or conditions",Complete,"Jul 22, 2021","Feb 11, 2022",SR0700-000,"Alexion Pharma Canada Corp."
Ultomiris,ravulizumab,"AChR antibody-positive generalized Myasthenia Gravis","Do not reimburse",Complete,"Oct 25, 2022","Aug 8, 2023",SR0765-000,"Alexion Pharma GmBH"
Unituxin,dinutuximab,Neuroblastoma,"Reimburse with clinical criteria and/or conditions",Complete,"Nov 23, 2020","Jul 23, 2021",PC0222-000,"United Therapeutics Corp."
Uplizna,inebilizumab,"Neuromyelitis optica spectrum disorders (NMOSD)","Reimburse with clinical criteria and/or conditions",Complete,"Aug 18, 2023","Mar 13, 2024",SR0793-000,"Horizon Therapeutics Canada"
Uplizna,inebilizumab,"Immunoglobulin G4-related disease",,Pending,,,SR0889-000,"Amgen Canada Inc."
Uptravi,Selexipag,"Pulmonary arterial hypertension (WHO class II and III)","Reimburse with clinical criteria and/or conditions",Complete,"Mar 31, 2016","Oct 28, 2016",SR0482-000,"Actelion Pharmaceuticals Canada Inc."
Vabysmo,faricimab,"Diabetic Macular Edema","Reimburse with clinical criteria and/or conditions",Complete,"Mar 24, 2022","Oct 14, 2022",SR0729-000,"Hoffmann-La Roche Canada"
Vabysmo,faricimab,"Retinal vein occlusion","Reimburse with clinical criteria and/or conditions",Active,"Jul 31, 2024","Feb 13, 2025",SR0832-000,"Hoffmann-La Roche Limited"
Vabysmo,faricimab,"Macular degeneration, age-related","Reimburse with clinical criteria and/or conditions",Complete,"Jan 31, 2022","Aug 12, 2022",SR0719-000,"Hoffmann-La Roche Ltd."
Vanflyta,quizartinib,"acute myeloid leukemia (AML)",,Active,"Dec 11, 2024",,PC0359-000,"Daiichi Sankyo Pharma Canada"
Vantas,"Histrelin acetate","Cancer, prostate","Do not list",Complete,"Sep 20, 2006","Apr 26, 2007",SR0078-000,"Paladin Labs Inc."
Vascepa,"icosapent ethyl","Ischemic events in statin-treated patients","Reimburse with clinical criteria and/or conditions",Complete,"Jun 17, 2019","Jul 16, 2020",SR0619-000,"HLS Therapeutics"
Veklury,remdesivir,"COVID-19 in hospitalized patients","Reimburse with clinical criteria and/or conditions",Complete,"Mar 1, 2024","Aug 16, 2024",SR0833-000,"Gilead Sciences Canada, Inc."
Veklury,remdesivir,"COVID-19 in non-hospitalized patients","Reimburse with clinical criteria and/or conditions",Complete,"Mar 1, 2024","Aug 16, 2024",SR0834-000,"Gilead Sciences Canada, Inc"
Velphoro,"sucroferric oxyhydroxide","Hyperphosphatemia, end-stage renal disease","Reimburse with clinical criteria and/or conditions",Complete,"Jun 12, 2018","Jan 2, 2019",SR0571-000,"Vifor Fresenius Medical Care Renal Pharma"
Velsipity,etrasimod,"Ulcerative colitis","Reimburse with clinical criteria and/or conditions",Complete,"Feb 5, 2024","Aug 14, 2024",SR0795-000,"Pfizer Canada ULC"
Veltassa,patiromer,"Hyperkalemia, adults (chronic kidney disease)","Reimburse with clinical criteria and/or conditions",Complete,"Oct 30, 2020","Jun 8, 2021",SR0665-000,"Otsuka Canada Pharmaceuticals Inc."
Vemlidy,"tenofovir alafenamide","Hepatitis B, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Sep 28, 2017","Mar 26, 2018",SR0537-000,"Gilead Sciences Canada, Inc."
Venclexta,venetoclax,"Mantle cell lymphoma (MCL)",,Active,"Feb 20, 2025",,PC0402-00,"AbbVie Corporation"
Venclexta,venetoclax,"Chronic lymphocytic leukemia (CLL)","Reimburse with clinical criteria and/or conditions",Complete,"May 22, 2024","Nov 28, 2024",PC0362-000,"AbbVie Corporation"
Venclexta,venetoclax,"Acute myeloid leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Jan 8, 2021","Aug 20, 2021",PC0238-000,"AbbVie Corporation"
Venclexta,venetoclax,"Acute myeloid leukemia","Do not reimburse",Complete,"Jan 22, 2021","Aug 23, 2021",PC0239-000,"AbbVie Corporation"
Verkazia,cyclosporine,"Severe vernal keratoconjunctivitis, pediatric (≥4 years)","Reimburse with clinical criteria and/or conditions",Complete,"May 22, 2019","Nov 18, 2019",SR0615-000,"Santen Canada Inc."
Verquvo,vericiguat,"Heart failure","Reimburse with clinical criteria and/or conditions",Complete,"Oct 14, 2022","Jun 14, 2023",SR0758-000,"Bayer Inc."
Verzenio,abemaciclib,"Adjuvant treatment of HR-positive, HER2-negative early breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Mar 23, 2022","Sep 29, 2022",PC0282-000,"Eli Lilly Canada Inc. (Eli Lilly)"
Verzenio,abemaciclib,"HR-positive, HER2-negative advanced or metastatic breast cancer",,Active,"Feb 14, 2025",,PC0400-000,"Eli Lilly Canada Inc."
Verzenio,abemaciclib,"Adjuvant treatment of HR-positive, HER2-negative early breast cancer","Reimburse with clinical criteria and/or conditions",Complete,"Feb 9, 2024","Oct 3, 2024",PC0345-000,"Eli Lilly Canada Inc."
Verzenio,abemaciclib,"HR-positive, HER2-negative advanced or metastatic breast cancer",,Active,"Feb 14, 2025",,PC0409-000,"Eli Lilly Canada Inc."
Vesicare,"Solifenacin succinate","Bladder, overactive","List with clinical criteria and/or conditions",Complete,"Jan 5, 2009","Jun 17, 2009",SR0155-000,"Astellas Pharma Canada Inc."
Vesicare,"Solifenacin succinate","Bladder, overactive","Do not list",Complete,"Jul 24, 2006","Jan 24, 2007",SR0070-000,"Astellas Pharma Canada Inc."
VesiFlow,"Solifenacin succinate / tamsulosin hydrochloride","Benign prostatic hyperplasia",,Withdrawn,"Apr 6, 2015",,SR0424-000,"Astellas Pharma Canada, Inc."
VFEND,Voriconazole,"Aspergillosis, Invasive",,Withdrawn,"Aug 24, 2004",,SR0020-000,"Pfizer Canada Inc."
VFEND,Voriconazole,"Aspergillosis, Invasive","List with clinical criteria and/or conditions",Complete,"Oct 25, 2004","Apr 14, 2005",SR0023-000,"Pfizer Canada Inc."
VFEND,Voriconazole,Candidemia,"List with clinical criteria and/or conditions",Complete,"Mar 24, 2006","Oct 25, 2006",SR0056-000,"Pfizer Canada Inc."
Viacoram,"perindopril arginine / amlodipine","Hypertension, essential","Reimburse with clinical criteria and/or conditions",Complete,"May 2, 2016","Oct 26, 2016",SR0490-000,"Servier Canada Inc."
Viberzi,eluxadoline,"Irritable bowel syndrome with diarrhea","Do not reimburse",Complete,"Feb 23, 2018","Aug 24, 2018",SR0560-000,"Allergan Pharma Co."
Victoza,Liraglutide,"Diabetes Mellitus, Type 2",,Withdrawn,"Oct 20, 2016",,SR0505-000,"Novo Nordisk Canada Inc."
Victoza,Liraglutide,"Diabetes mellitus, Type 2","Do not list",Complete,"Nov 29, 2010","Sep 28, 2011",SR0217-000,"Novo Nordisk Canada Inc."
Victoza,liraglutide,"Diabetes Mellitus, Type 2 (pediatric)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0032-000,"Novo Nordisk Canada Inc."
Victrelis,Boceprevir,"Hepatitis C, chronic","List with clinical criteria and/or conditions",Complete,"May 3, 2011","Oct 24, 2011",SR0231-000,"Merck Canada Inc."
Victrelis,Boceprevir,"Hepatitis C, chronic","List with criteria/condition",Complete,"Feb 19, 2013","Jun 13, 2013",SF0312-000,"Merck Canada Inc."
Victrelis,Boceprevir,"Hepatitis C, chronic","List with criteria/condition",Complete,"Dec 21, 2012","Jun 13, 2013",SF0303-000,"Merck Canada Inc."
Viibryd,vilazodone,"Depression, Major depressive disorder","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0006-000,"Allergan Inc."
Vimizim,"Elosulfase alfa","Mucopolysaccharidosis IVA (Morquio A syndrome)","Reimburse with clinical criteria and/or conditions",Complete,"Nov 10, 2015","May 20, 2016",SR0456-000,"BioMarin Pharmaceutical (Canada) Inc."
Vimizim,"Elosulfase alfa","Mucopolysaccharidosis IVA (Morquio A syndrome)","Do not list",Complete,"Aug 5, 2014","Mar 25, 2015",SR0389-000,"BioMarin Pharmaceutical (Canada) Inc."
Vimpat,Lacosamide,"Epilepsy, partial onset seizures","List with clinical criteria and/or conditions",Complete,"Oct 25, 2010","Apr 25, 2011",SR0212-000,"UCB Canada Inc."
Viread,"Tenofovir disoproxil fumarate","HIV infection","List with clinical criteria and/or conditions",Complete,"Aug 11, 2005","Mar 15, 2006",SR0040-000,"Gilead Sciences Canada Inc."
Viread,"Tenofovir disoproxil fumarate","HIV infection",N/A,Complete,"Jul 7, 2008",,SF0139-000,"Gilead Sciences Canada Inc."
Viread,"Tenofovir disoproxil fumarate","Hepatitis B (chronic)","List with clinical criteria and/or conditions",Complete,"Oct 2, 2008","Mar 18, 2009",SR0148-000,"Gilead Sciences Canada Inc."
Viread,"Tenofovir disoproxil fumarate","HIV infection","Do not list",Complete,"Feb 23, 2004","Aug 25, 2004",SR0008-000,"Gilead Sciences Canada Inc."
Visanne,Dienogest,"Pain, pelvic pain associated with endometriosis","List with clinical criteria and/or conditions",Complete,"Oct 18, 2011","Apr 19, 2012",SR0255-000,"Bayer Inc."
Vitrakvi,larotrectinib,"Solid tumours with NTRK gene fusion","Reimburse with clinical criteria and/or conditions",Complete,"Nov 16, 2020","Sep 13, 2021",PC0221-000,"Bayer Inc."
"Vocabria and Cabenuva","cabotegravir sodium cabotegravir-rilpivirine","HIV-1 infection","Reimburse with clinical criteria and/or conditions",Complete,"Aug 19, 2019","Jul 22, 2020",SR0628-000,"ViiV Healthcare ULC"
Volibris,Ambrisentan,"Pulmonary arterial hypertension (WHO class II and III)","List with clinical criteria and/or conditions",Complete,"Jul 9, 2008","Dec 17, 2008",SR0142-000,"GlaxoSmithKline Inc."
Vonvendi,"von Willebrand Factor [recombinant]","von Willebrand disease, adults, treatment and perioperative management","Reimburse with clinical criteria and/or conditions",Complete,"Apr 29, 2020","Mar 17, 2021",ST0639-000,"Shire Pharma Canada ULC, now part of Takeda"
Voranigo,vorasidenib,"Astrocytoma or oligodendroglioma, IDH1 or IDH2 mutation",,Active,"Apr 30, 2025",,PC0407-000,"Servier Canada Inc."
Vosevi,"sofosbuvir velpatasvir voxilaprevir","Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Jul 28, 2017","Jan 23, 2018",SR0529-000,"Gilead Sciences Canada, Inc."
Voydeya,danicopan,"Paroxysmal nocturnal hemoglobinuria (PNH)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 4, 2024","Oct 18, 2024",SR0815-000,"Alexion Pharma GmbH"
VPRIV,"Velaglucerase alfa","Gaucher Disease","List with clinical criteria and/or conditions",Complete,"Oct 28, 2010","Apr 25, 2011",SR0215-000,"Shire Human Genetic Therapies"
Vraylar,cariprazine,"Bipolar Disorder","Do not reimburse",Complete,"Jan 28, 2022","Nov 9, 2022",SR0718-000,"Allergan (an AbbVie company)"
Vraylar,cariprazine,Schizophrenia,"Reimburse with clinical criteria and/or conditions",Complete,"Dec 20, 2023","Aug 15, 2024",SR0827-000,"AbbVie Corporation"
Vraylar,cariprazine,Schizophrenia,"Do not reimburse",Complete,"Oct 29, 2021","Aug 10, 2023",SR0708-000,"Allergan (an AbbVie Company)."
Vyalev,"foslevodopa foscarbidopa","Parkinson’s disease","Reimburse with clinical criteria and/or conditions",Complete,"Nov 23, 2022","Jun 16, 2023",SR0768-000,"AbbVie Canada Inc."
Vyepti,eptinezumab,Migraine,"Reimburse with clinical criteria and/or conditions",Complete,"Jun 8, 2022","Dec 15, 2022",SR0743-000,"Lundbeck Canada Inc."
Vyloy,zolbetuximab,"Gastric or gastroesophageal junction (GEJ) adenocarcinoma","Reimburse with clinical criteria and/or conditions",Active,"Jun 28, 2024","Jan 29, 2025",PC0338-000,"Astellas Pharma Canada, Inc. (APCA)"
Vyndaqel,tafamidis,"Transthyretin-mediated amyloidosis","Reimburse with clinical criteria and/or conditions",Complete,"Dec 14, 2021","Jun 17, 2022",SF0722-000,"Pfizer Canada ULC"
Vyndaqel,tafamidis,"transthyretin-mediated amyloidosis","Reimburse with clinical criteria and/or conditions",Complete,"Jul 4, 2019","Feb 19, 2020",SR0625-000,"Pfizer Canada"
Vyvanse,"Lisdexamfetamine dimesylate","Attention deficit hyperactivity disorder","Do not list",Complete,"Jul 10, 2009","Dec 18, 2009",SR0171-000,"Shire Canada Inc."
Vyvgart,"efgartigimod alfa","Chronic inflammatory demyelinating polyneuropathy",,Pending,,,SR0894-000,"argenx Canada"
Vyvgart,"efgartigimod alfa","Generalized myasthenia gravis (gMG)","Reimburse with clinical criteria and/or conditions",Complete,"May 9, 2023","Dec 14, 2023",SR0782-000,"Argenx Canada Inc."
Vyxeos,"daunorubicin and cytarabine","Acute myeloid leukemia","Reimburse with clinical criteria and/or conditions",Complete,"Jan 22, 2021","Aug 24, 2021",PC0237-000,"Jazz Pharmaceuticals Canada Inc."
Vyzulta,"latanoprostene bunod","Open-angle glaucoma or ocular hypertension","Reimburse with clinical criteria and/or conditions",Complete,"Nov 23, 2018","Jul 24, 2019",SR0590-000,"Bausch Health, Canada Inc."
Wainua,eplontersen,"Polyneuropathy in hereditary transthyretin-mediated amyloidosis","Reimburse with clinical criteria and/or conditions",Complete,"Apr 9, 2024","Oct 21, 2024",SR0826-000,"AstraZeneca Canada Inc."
Wakix,"pitolisant hydrochloride",Narcolepsy,"Do not reimburse",Complete,"Dec 8, 2021","Dec 6, 2022",SR0715-000,"Paladin Labs Inc."
Waymade-Trientine,"trientine hydrochloride","Wilson's Disease","Reimburse with clinical criteria and/or conditions",Complete,"Jul 21, 2021","Feb 8, 2022",SR0696-000,"Waymade PLC"
Wegovy,semaglutide,"Weight management",,Active,"Nov 27, 2024",,SR0841-000,"Novo Nordisk Canada Inc."
Wegovy,semaglutide,"Weight management","Do not reimburse",Complete,"Mar 10, 2022","Sep 16, 2022",SR0725-000,"Novo Nordisk Canada Inc."
Welireg,belzutifan,"von Hippel-Lindau disease-associated tumours","Reimburse with clinical criteria and/or conditions",Complete,"Jan 23, 2023","Sep 1, 2023",PC0309-000,"Merck Canada Inc."
Welireg,belzutifan,"advanced renal cell carcinoma (RCC)",,Active,"Nov 25, 2024",,PC0386-000,"Merck Canada Inc."
Winlevi,clascoterone,"Acne vulgaris","Do not reimburse",Active,"Aug 6, 2024","Feb 6, 2025",SR0863-000,"Sun Pharma Canada Inc."
Winlevi,clascoterone,"Acne vulgaris",,Withdrawn,"Jul 4, 2023",,SR0786-000,"Sun Pharma Canada Inc."
Winrevair,sotatercept,"Pulmonary arterial hypertension (WHO group 1)","Reimburse with clinical criteria and/or conditions",Complete,"Apr 8, 2024","Oct 21, 2024",SR0828-000,"Merck Canada Inc."
Xarelto,Rivaroxaban,"Venous thromboembolism, prevention",N/A,Complete,"Jun 24, 2011",,SF0239-000,"Bayer Inc."
Xarelto,"Rivaroxaban (granules for oral suspension)","Venous Thromboembolic Events","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0022-000,"Bayer Inc"
Xarelto,Rivaroxaban,,"List with clinical criteria and/or conditions",Complete,"Mar 18, 2013","Jul 18, 2013",SF0321-00,"Bayer Inc."
Xarelto,Rivaroxaban,"Venous thromboembolic events, pulmonary embolism","List with criteria/condition",Complete,"May 6, 2013","Mar 26, 2014",SR0327-000,"Bayer Inc."
Xarelto,Rivaroxaban,"Thromboembolism (venous), prevention","List with clinical criteria and/or conditions",Complete,"May 7, 2008","Dec 17, 2008",SR0134-000,"Bayer Inc."
Xarelto,Rivaroxaban,"Atrial fibrillation, stroke prevention","List with clinical criteria and/or conditions",Complete,"Oct 21, 2011","Apr 19, 2012",SR0257-000,"Bayer Inc."
Xarelto,Rivaroxaban,"Deep-vein thrombosis without symptomatic pulmonary embolism",,Complete,"Oct 10, 2012",,SF0295-000,"Bayer Inc."
Xarelto,Rivaroxaban,"Deep-vein thrombosis without symptomatic pulmonary embolism","List with clinical criteria and/or conditions",Complete,"Feb 27, 2012","Aug 16, 2012",SR0271-000,"Bayer Inc."
Xarelto,Rivaroxaban,"Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.","Reimburse with clinical criteria and/or conditions",Complete,"May 24, 2018","Nov 20, 2018",SR0569-000,"Bayer Inc."
Xcopri,cenobamate,"Epilepsy, partial-onset seizures","Reimburse with clinical criteria and/or conditions",Complete,"Feb 7, 2023","Aug 29, 2023",SR0770-000,"Paladin Labs Inc."
Xeljanz,tofacitinib,,,Cancelled,,,SR0575-000,"Pfizer Canada Inc."
Xeljanz,tofacitinib,"Ulcerative colitis","Reimburse with clinical criteria and/or conditions",Complete,"Jun 27, 2018","Feb 27, 2019",SR0572-000,"Pfizer Canada Inc."
Xeljanz,Tofacitinib,"Arthritis, rheumatoid","List with criteria/condition",Complete,"May 5, 2014","Apr 17, 2015",SR0380-000,"Pfizer Canada Inc."
Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins","Spasticity, Post-stroke","Do not list",Complete,"Jun 12, 2009","Dec 16, 2009",SR0193-000,"Merz Pharmaceuticals GmbH"
Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins",Blepharospasm,"List in a similar manner",Complete,"Jun 12, 2009","Dec 16, 2009",SR0168-000,"Merz Pharmaceuticals GmbH"
Xeomin,incobotulinumtoxinA,"Chronic sialorrhea associated with neurological disorders","Reimburse with clinical criteria and/or conditions",Complete,"Feb 26, 2021","Sep 9, 2021",SR0678-000,"Merz Pharmaceuticals GMBH"
Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins","Cervical Dystonia","List in a similar manner",Complete,"Jun 12, 2009","Dec 16, 2009",SR0192-000,"Merz Pharmaceuticals GmbH"
Xermelo,telotristat,"carcinoid syndrome","Do not reimburse",Complete,"Sep 27, 2018","Jun 26, 2019",SR0580-000,"Ipsen Biopharmaceuticals Canada Inc."
Xgeva,"Denosumab  (Drug Plan Submission)","Prevention of skeletal-related events due to bone metastases from breast cancer","List with clinical criteria and/or conditions",Complete,"Jul 31, 2015","Feb 25, 2016",SR0433-000,"Amgen Canada Inc."
Xgeva,"Denosumab (Drug Plan Submission)","Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer","List with clinical criteria and/or conditions",Complete,"Jul 31, 2015","Mar 23, 2016",SR0433-001,"Amgen Canada Inc."
XGEVA,Denosumab,"Prevention of skeletal-related events due to bone metastases from solid tumours","List with clinical criteria and/or conditions",Complete,"Jun 6, 2011","Nov 16, 2011",SR0235-000,"Amgen Canada Inc."
Xiaflex,"Collagenase clostridium histolyticum","Dupuytren’s contracture","List with criteria/condition",Complete,"Aug 30, 2012","Mar 27, 2013",SR0287-000,"Auxilium Pharmaceuticals, Inc. & Actelion Pharmaceuticals Canada Inc."
XigDuo,"dapagliflozin/metformin hydrochloride","Diabetes Mellitus, Type 2","Reimburse with clinical criteria and/or conditions",Complete,"Jan 7, 2016","Jul 20, 2016",SR0468-000,"AstraZeneca Canada Inc."
Xofluza,"baloxavir marboxil",Influenza,"Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0016-000,"Hoffmann-La Roche Limited"
Xolair,Omalizumab,"Chronic idiopathic urticaria","List with clinical criteria and/or conditions",Complete,"Sep 22, 2014","May 7, 2015",SR0398-000,"Novartis Pharmaceuticals Canada Inc."
Xolair,omalizumab,"Chronic rhinosinusitis with nasal polyps","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0026-000,"Novartis Pharmaceuticals Canada Inc."
Xolair,Omalizumab,"Asthma, severe persistent","Do not list",Complete,"Oct 13, 2005","Mar 7, 2006",SR0045-000,"Novartis Pharmaceuticals Canada Inc."
Xolair,Omalizumab,"Asthma, severe persistent",,Cancelled,"Apr 18, 2005",,SR0035-000,"Novartis Pharmaceuticals Canada Inc."
Xolair,"Omalizumab (Drug Plan Submission)","Asthma, severe persistent","Reimburse with clinical criteria and/or conditions",Complete,"Nov 18, 2015","May 18, 2016",SR0457-000,"Novartis Pharmaceuticals Canada Inc."
Xpovio,selinexor,"Multiple myeloma","Reimburse with clinical criteria and/or conditions",Complete,"Jan 14, 2022","Jul 29, 2022",PC0276-000,"FORUS Therapeutics Inc."
Xultophy,"insulin degludec + liraglutide","Diabetes mellitus, Type 2","Reimburse with clinical criteria and/or conditions",Complete,"Jan 30, 2019","Oct 24, 2019",SR0599-000,"Novo Nordisk Canada Inc."
Xydalba,dalbavancin,"Acute bacterial skin and skin structure infections","Reimburse with clinical criteria and/or conditions",Complete,"Apr 11, 2022","Nov 16, 2022",SR0728-000,"Paladin Labs Inc."
Xyrem,"Sodium oxybate",Narcolepsy,"Do not list",Complete,"Jul 9, 2008","Jan 28, 2009",SR0141-000,"Valeant Canada Ltd."
Xyrem,"Sodium oxybate",Narcolepsy,,Withdrawn,"Aug 29, 2007",,SR0107-000,"Valeant Canada Ltd."
Yasmin,"Drospirenone /ethinyl estradiol","Contraceptive, oral",List,Complete,"Jan 20, 2005","Jun 16, 2005",SR0029-000,"Berlex Canada Inc."
Yescarta,"axicabtagene ciloleucel","Relapsed or refractory follicular lymphoma","Reimburse with clinical criteria and/or conditions",Complete,"Apr 13, 2023","Nov 2, 2023",PG0314-000,"Gilead Sciences Canada, Inc."
Yescarta,"axicabtagene ciloleucel","Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL)","Reimburse with clinical criteria and/or conditions",Complete,"Jun 9, 2022","Feb 3, 2023",PG0293-000,"Gilead Sciences Canada Inc."
Zavesca,Miglustat,"Gaucher disease","Do not list",Complete,"May 13, 2004","Nov 24, 2004",SR0012-000,"Actelion Pharmaceuticals Canada Inc."
Zaxine,Rifaximin,"Hepatic encephalopathy","List with criteria/condition",Complete,"Aug 5, 2014","Apr 16, 2015",SR0388-000,"Salix Pharmaceuticals Inc."
Zeldox,"Ziprasidone hydrochloride","Schizophrenia and related psychotic disorders","List with clinical criteria and/or conditions",Complete,"Jan 10, 2008","Aug 14, 2008",SR0124-000,"Pfizer Canada Inc."
Zemaira,"Alpha1-proteinase inhibitor (Human)","Severe Alpha1-proteinase inhibitor deficiency","Reimburse with clinical criteria and/or conditions",Complete,"Oct 1, 2021","Apr 13, 2022",ST0702-000,"CSL Behring Canada, Inc."
Zenhale,Mometasone/formoterol,Asthma,"List with clinical criteria and/or conditions",Complete,"Jun 6, 2012","Dec 19, 2012",SF0281-000,"Merck Canada Inc."
"Zenhale (inhalation aerosol)","Mometasone furoate and formoterol",Asthma,"Do not list",Complete,"Feb 16, 2011","Sep 28, 2011",SR0225-000,"Merck Canada"
Zepatier,Elbasvir/grazoprevir,"Hepatitis C, chronic","Reimburse with clinical criteria and/or conditions",Complete,"Oct 27, 2015","May 19, 2016",SR0454-000,"Merck Canada Inc."
Zeposia,ozanimod,"Ulcerative colitis","Reimburse with clinical criteria and/or conditions",Complete,"Jan 5, 2022","Nov 17, 2022",SR0714-000,"Celgene Inc., a Bristol Myers Squibb Company"
Zeposia,ozanimod,"Multiple Sclerosis, relapsing - remitting","Do not reimburse",Complete,"Aug 25, 2020","Jun 23, 2021",SR0652-000,"Celgene Inc."
Zepzelca,lurbinectedin,"metastatic small cell lung cancer (SCLC)","Do not reimburse",Complete,"Feb 24, 2022","Dec 19, 2022",PC0281-000,"Jazz Pharmaceuticals Canada Inc."
Zevalin,"iIbritumomab tiuxetan","Non-Hodgkin’s Lymphoma (NHL)","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0003-000,"Servier Canada Inc."
Zilbrysq,zilucoplan,"Generalized myasthenia gravis (gMG)","Reimburse with clinical criteria and/or conditions",Active,"Feb 29, 2024","Jan 23, 2025",SR0838-000,"UCB Canada Inc."
Zinbryta,"Daclizumab beta","Multiple Sclerosis, relapsing-remitting","Reimburse with clinical criteria and/or conditions",Complete,"Dec 20, 2016","Jun 20, 2017",SR0508-000,"Biogen Canada Inc."
Zolgensma,"onasemnogene abeparvovec","Spinal muscular atrophy (SMA), pediatrics","Reimburse with clinical criteria and/or conditions",Complete,"Jun 25, 2020","Mar 24, 2021",SG0649-000,"Novartis Pharmaceuticals Canada Inc."
Zolinza,vorinostat,"Cutaneous T-cell lymphoma","Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.","Not filed",,,NS0015-000,"Merck Canada Inc."
Zoryve,roflumilast,"atopic dermatitis",,Received,"May 16, 2025",,SR0887-000,"Arcutis Canada, Inc."
Zoryve,roflumilast,"Plaque psoriasis","Reimburse with clinical criteria and/or conditions",Complete,"Feb 2, 2023","Aug 16, 2023",SR0771-000,"Arcutis Biotherapeutics, Inc."
"Zytram XL","Tramadol hydrochloride","Pain, acute","Do not list",Complete,"Mar 15, 2007","Sep 26, 2007",SR0093-000,"Purdue Pharma"
"Zytram XL","Tramadol hydrochloride","Pain, acute",,Withdrawn,"Nov 3, 2006",,SR0086-000,"Purdue Pharma"